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Abstract
The antibody directed enzyme pro-drug therapy (ADEPT ) is a new anticancer
treatment, where pre-clinical experiments concluded that an intermediate step
involving the inhibition of carboxypeptidase G2 (CPG2 ) from the circulatory
system prior to pro-drug administration is crucial to prevent systemic toxicity
(Bagshawe et al. 1991). The research described in this thesis sought to better
understand the mode of binding of these inhibitors to CPG2 using solution state
nuclear magnetic resonance (NMR) spectroscopy.
A high-yield expression of active and soluble mature CPG2 (in the absence
of the leader peptide) in E. coli suitable for NMR studies and co-crystallisation
screening is reported. We have used this method to routinely produce
milligrams quantities of 1H/13C/15N isotopically-labelled protein suitable for
NMR studies. The second aim of this thesis is interactions; interactions between
CPG2 and selected inhibitors provided by our industrial partner Mologic Ltd.
(Bedford, UK). Di erent structural parts of the inhibitors were identified by
NMR to directly interact with CPG2: the naphthalene and the glutamate
groups. Chemical shift perturbations studies show di erent patterns for CP06
and CP67 inhibitors suggesting that they have di erent binding mechanisms.
Site-directed mutagenesis of residues in P1 pocket of CPG2 reveal no activity
against methotrexate (MTX), suggesting that they are key players in substrate
recognition, while H285A and E200A mutant proteins display similar activity to
wild type CPG2 protein.
Although the NMR data described here for CPG2 were incomplete and thus
did not yield resonance assignment, we show attempts at a "divide-and-conquer"
approach. The CPG2CAT construct shows great promise for downstream NMR
studies as it has favourable solution properties and retains key properties of the
parent protein, namely enzymatic activity and the ability to self associate.
xi
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Introduction
1.1 Discovery of Carboxypeptidase G2 via Anti-
Folate Therapy.
Reduced folates play a pivotal role as co-enzymes in many biochemical
pathways. DNA synthesis is one of the most important pathways reduced
folates are implicated in, and this metabolic pathway can be regulated through
two di erent routes. The first is via DNA precursors, thymidine and purines,
whose synthesis are dependant on folate co-enzymes (Bertino and Hillcoat
1968). The second is by way of DNA methylation, whereby folate co-enzymes
are required in the biosynthesis of methionine (Crider et al. 2012). Methionine
is needed for the synthesis of S-adenosylmethionine (SAM ). SAM is a methyl
group (one-carbon unit) donor operating in most biological methylation
reactions, such as specific sites within the DNA sequence. The DNA
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methylation takes part in controlling gene expression, and anomalies in DNA
methylation have been associated with the development of cancer. As a result,
folic acid is a target molecule for chemotherapy and its depletion has been
accomplished by the use folic acid antagonists, specially
4-amino-N10-methyl-pteroyl-L-glutamate – also known as methotrexate (MTX).
This compound inhbits the dihydrofolate reductase (DHFR) enzyme that is
essential in the biosynthesis of all folate co-enzymes (Osborn and Huennekens
1958). As a consequence, MTX has become one of the most widely used
chemotherapeutic agents today. High-doses of methotrexate (more than 1
mg.m-2 of total body surface area) are also used to e ciently treat human
malignancies and diseases, such as leukaemia and rheumatoid arthritis.
Although high-dose methotrexate carries a low risk for severe treatment-related
toxicity, 2-10% of the patients experience methotrexate-related toxicity that
could hold up further treatment or may be life threatening (Schwartz et al.
2007). Hence work had started on enhancing methotrexate clearance in rescue
therapies.
Depletion of MTX was achieved directly by enzymatic cleavage of the MTX
peptide bond to remove the glutamate moiety. The enzymes capable of such
hydrolysis were named carboxypeptidase G, and various forms have been
isolated throughout the years. Actually, shortly following the exploitation of
methotrexate in anti-cancer therapy, a loss of biological activity (i.e. DHFR
inhibition by MTX) was detected after contact with bacteria. In 1967, a
bacterial enzyme, which catalyses the cleavage of a glutamate moiety from folic
acid derivatives, was isolated (carboxypeptidase G). Figure 1.1 shows the
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products produced from hydrolysis of MTX, 2,4-diamino-N10-methylpteroic acid
(DAMPA) and glutamate, which were less active inhibitors of DHFR (Valerino
et al. 1972). Carboxypeptidase G1 (CPG1 ), extracted from a strain of
Pseudomonas stulteri, was used to lower methotrexate blood concentration
because of its 100-fold greater a nity for methotrexate than carboxypeptidase
G. However, its bacterial source was misplaced (Chabner et al. 1972).
Nonetheless, Minton et al. (1983) managed to isolate carboxypeptidase G2
(CPG2 ) from Pseudomonas sp. Strain RS-16 by cloning the gene into a
pBR322 vector and transforming it in Escherichia coli. The expression method
allowed su cient production of CPG2 to prevent methotrexate toxicity at a
therapeutic level (Sherwood et al. 1985). Compared to its predecessors CPG
and CPG1, CPG2 has a much higher a nity for methotrexate.
Figure 1.1: MTX hydrolysis by CPG2. Cleavage of methotrexate results in the formation
of DAMPA and glutamate: two non-toxic compounds.
1.2 Carboxypeptidase G2 (CPG2).
1.2.1 Structure.
CPG2 is a 415 amino acid zinc-dependant metalloenzyme produced as an
asymmetric homodimer of molecular weight 2◊43,932 Da according to the
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X-ray crystal structure (Rowsell et al. 1997) (Figure 1.2-A,B). Minton et al.
(1984) revealed that the enzyme might have two possible signal peptidase
cleavage sites producing (i) a normal CPG2 protein with an N-terminal Ala
corresponding to position 23 and (ii) a truncated version of CPG2 with an
N-terminal Thr corresponding to position 37 of the primary amino acid
sequence (Lindner et al. 2003). Sequence analysis demonstrated that the signal
peptide preceding the N-terminal alanine, targets the CPG2 to the periplasmic
space of Pseudomonas (Sherwood et al. 1985).
Figure 1.2: Ribbon diagram of CPG2 tetramer and dimer. One CPG2 monomer is
coloured blue, while the other one is coloured in red. A) Front view of the dimer, B) Side-view
of the dimer, C) Front view of the tetramer, D) Side-view of the tetramer. The CPG2 tetramer
shows interactions between the —-strands of CPG2 monomers’ dimerisation domains and helices
of CPG2 monomers’ catalytic domains, while CPG2 dimer shows the dimer interface. PDB:
1CG2, Rowsell et al. (1997).[Pymol Viewer]
4
Chapter 1
The overall structure of the CPG2 monomer consists of two domains: the
metal-binding domain, which likely delivers CPG2 substrates to the two zinc
ions in the active site, and the dimerisation domain (Figure 1.3). The
dimerisation domain, which in inserted in the middle of the metal-binding site
sequence, interacts through hydrogen bonding between two —-strands, one from
each monomer, forming a continuous —-sheet across the whole dimer, as well as
hydrophobic interactions between helices (Rowsell et al. 1997) (Figure 1.2). It is
not clear whether dimerisation domain of CPG2 is necessary for catalysis to
take place. The related homodimeric enzyme PepV from the M20 exopeptidase
family, of which CPG2 is a member, has been shown to be enzymatically active
as a monomer (Jozic et al. 2002). Additionally, the X-ray crystal structure also
showed the presence of tetrameric structures due to interactions between the
catalytic domains of each dimeric proteins (Rowsell et al. 1997) (Figure
1.2-C,D). The question is, then, how biologically relevant these dimeric and
tetrameric structures are; if they are, these oligomeric states would also persist
in solution.
1.2.2 Essential Role of Zinc in Catalysis.
Depending on the number of metal ions, metalloproteins can be divided into
two groups: mononuclear and co-catalytic (i.e. binuclear) enzymes. CPG2
contains two-metal ions bound in its active site, thus it belongs to the binuclear
group (Figure 1.4-A). Zinc 1 is bound to Glu176 and His385, while zinc 2 is
bound to Glu200 and His112. The two zinc ions are bridged by Asp141, and are
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Figure 1.3: X-ray crystallography structure of CPG2. CPG2 monomer consists of two
domains (i) a metal-binding domain, the active site (represented in green) and (ii) a smaller
dimerisation domain (represented in purple). PDB: 1CG2, Rowsell et al. (1997). [Pymol Viewer]
held in a tetrahedral coordination in complex with histidine, glutamic acid and
aspartic acid residues. Although the exact role of these metal ions (called the
catalytic and co-catalytic metal ions respectively) are not fully understood yet,
they display di erences in terms of binding constants, spectroscopic features
and evolutionary origin (Bzymek and Holz 2004; Lowther and Matthews 2002;
Wouters and Husain 2001). Near the active site Glu175 forms a hydrogen bond
to the bridging water molecule, and is thought to function as an acid/base
during catalysis by activating the water molecule, which may be important
during catalytic turnover (Figure 5.1). Analysis of the sequences of the M20
family revealed that enzymes exhibiting carboxypeptidase specificity have all a
glutamate residue (residue Glu175 for CPG2) at the same position, while
proteins with aminopeptidase specificity displayed an aspartic acid residue
(Biagini and Puigserver 2001); it suggested that Glu175 may be important in
substrate recognition too.
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The members of the M20 family are known to be aminoacylases or
exopeptidases, such as CPG2 (Levy and Goldman 1967). Many of these
enzymes have shown potential as therapeutic agents. Succinyldiaminopimelate
desuccinylasase is considered as en excellent target in anti-bacterial therapy
(Bienvenue et al. 2003), while CPG2 is considered as a very promising
therapeutic agent in anti-cancer treatment (see Section 1.3). Also, CPG2 has
very similar structure to aminoapeptidase (AMP) and membrane-bound human
glutamate carboxypeptidase II (GCPII ). Their mechanisms of catalysis were
proposed via the use of X-ray crystallography, site-directed mutagenesis and
computational methods (Klusak et al. 2009, Schurer et al. 2004). The CPG2
metal-binding domain contains structural similarities to the single-domain
aminopeptidase of AAP and GCPII, which is also involved in catalysis. These
proteins contain all eight —-sheets and seven helices, and the active sites of all
proteins superpose incredibly well (Rowsell et al. 1997). Superposition of the
metal-binding sites in Figure 1.4 shows that four out of the five zinc ligands are
conserved in CPG2, compared to AMP and GCPII (Glu200 in CPG2 is changed
for an aspartate residue in AMP and GCPII). The accepted consensus for this
class of enzymes is that the bridging oxygen is provided by a hydroxide anion
rather than a water molecule (crystallography showed the presence of a water
molecule), and the HO- ligand must turn from the bridging position to
coordinate to Zinc 1 only before it can perform a nucleophilic attack on the
carbonyl carbon of the substrate and form an anionic tetrahedral intermediate
(Klusák et al. 2009), and cleavage of the carbon-nitrogen bond and product
formation.
7
Chapter 1
Figure 1.4: Conserved metal-binding domains of CPG2, AMP and GCPII. Active
sites of A) CPG2, B) AMP and C) GCPII in similar orientations to show the conservations
of the zinc ligands. Also shown is the glutamate residue (Glu175 in CPG2, Glu151 in AMP
and Glu424 in GCPII) which is thought to facilitate the nucleophilic attack of the water on
the susbtrate. Adpated from Rowsell et al. (1997) (PDB: 1CG2), Chevrier et al. (1994) (PDB:
1AMP) and Barinka et al. (2004) (PDB: 2OOT). [Pymol Viewer]
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1.2.3 Potential Specific Intermolecular Interactions in
MTX Hydrolysis by CPG2.
Using information extracted from the studies described above for related
enzymes, a binding mode hypothesis was established for the CPG2-MTX
complex by applying molecular docking and molecular dynamics simulation, as
the mechanism of action of CPG2 has not yet been experimentally determined
(Turra et al. 2012). Turra et al. (2012) suggested that MTX was interacting at
very specific positions in the CPG2 catalytic region, which may be at the helm
of substrate recognition and cleavage mechanism (see Figure 5.3 in Chapter 5).
They described the presence of a hydrophilic pocket (P1) near the CPG2 active
site accommodating the large pteroate moiety of MTX required for
enzyme-substrate interaction (Sherwood et al. 1985) (Figure 1.5). The pteridine
moiety of MTX was found to be held via hydrogen bonding interaction between
endo- and exocylic nitrogen atoms of the pteroate and the carbonyl oxygen of
Lys208 and Ser210. On the other hand, the glutamate group was found to point
towards the surface (P2) through the formation of a hydrogen bond with
Arg324. Rowsell et al. (1997) showed that mutation of Arg324 to alanine
resulted in low activity of the CPG2 mutant against MTX, but its exact role
remains unexplained. To this date, no further mutation studies of CPG2 were
performed. Additionally, Turra et al. (2012) also revealed the possibility of an
intermolecular interaction between the amide of MTX and the carbonl oxygen
of Gly360.
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Figure 1.5: Key amino acids in CPG2 in MTX recognition. A schematic view of the
catalytic site is represented, with the di erent amino acids, in the di erent pockets, thought to
directly interact with substrate MTX.
1.3 Biological Implications: ADEPT
CPG2 is currently being exploited in a rescue therapy following high-dose
methotrexate treatment because of its ability to metabolise the highly cytotoxic
methotrexate to two non-toxic metabolites. In this project, we were mainly
interested in the use of CPG2 in a new anticancer treatment: the antibody
directed enzyme pro-drug therapy (ADEPT ). It is well-known that the
e ciency of chemotherapy in cancer is restricted because of its actions on
healthy tissues. This complication can be prevented by restricting the e ects of
the cytotoxic drugs to cancer sites. However, this requires that the cytotoxic
drug to be exclusively produced at tumour sites; and second, however no less
essential, the cytotoxic drug should be retained at tumour sites or loose its
cytotoxic ability on leaving the tumour location. Accordingly the concept of
10
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ADEPT was put forward in the mid-1980s as a method of limiting the action of
cytotoxic drugs to tumour sites, thus amplifying their e ectiveness and
potentially diminishing their unacceptable lethal e ects on normal tissues
(Bagshawe 1987). It was proposed that this could be accomplished in several
steps. In the first step, CPG2 is administered as an immunoconjugate attached
to an antibody directed at tumour-associated antigen (Figure 1.6-Stage 1).
Once it has reached cancer sites, it can enzymatically activate a pro-drug (e.g.
glutamated nitrogen mustard drug) that carries an inactivating component the
glutamate, which is cleavable by CPG2 selectively at cancer sites (Figure
1.6-Stage 3). The benefit of this technique is the ability to deliver a much
higher concentration of active drug to treat cancer due to the higher turnover
rate of the pro-drug by the enzyme. Moreover, it would surmount the problem
of heterogeneity of tumour marker expression within the tumour tissue so that
neighbouring tumour cells that do not express the specific antigen would also be
eradicated through the supposed bystander e ect.
Figure 1.6: Basic principle of ADEPT. ADEPT is a 3 steps concept involving (i) stage
1: immunoconjugate administration; (ii) stage 2: inhibition and clearance of the enzyme at
non-tumour sites; (iii) stage 3: pro-drug administration. Adapted from Bagshawe et al. (1990).
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The choice of the enzyme raised questions of great importance. It was vital
to avoid a human enzyme to prevent the pro-drug from being activated
wherever it was spontaneously located. Bacterial enzymes are known to have
the advantage of improved kinetics with substrate turnover, and a number of
them perform most favourably under physiological conditions. As a
consequence, CPG2 is ideal for use in ADEPT because it has no mammalian
homologue, thus no endogenous enzymes would act on a pro-drug specific for
CPG2, and being a bacterial enzyme, has the advantage of enhanced kinetics
with substrate turnover (Searle et al. 1986). Although non-mammalian enzymes
with no human equivalent have the benefit of singularity, immune response to
CPG2 occurred in patients (Sharma et al. 1992). Understandingly the principle
epitopes involved in antibody interactions were modified to diminish their
immunogenicity (Spencer et al. 2002).
Despite all these improvements to reinforce the prospects of ADEPT
becoming a powerful cancer treatment, pre-clinical experiments concluded that
an intermediate step involving the inhibition of CPG2 from the circulatory
system prior to pro-drug administration was indispensable to prevent systemic
toxicity (Bagshawe et al. 1991). Thus ADEPT requires several specific
constituents: 1) the antibody-enzyme conjugate, 2) the prodrug, and 3) the
clearance of the enzyme (Figure 1.6). It is evident that the interactions and
combination of these various elements need to be investigated. However, it is
necessary to consider them individually first. The goal of this thesis is to study
and characterise CPG2-inhibitors interactions important for enzyme clearance
(Figure 1.6-Stage 2).
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1.3.1 From Thiocarbamate Inhibitors to the
Developement of Peptido-Mimetic Inhibitors.
Early inhibitors were designed to contain the structural features of CPG2
substrates (i.e. MTX). The features that seemed to be crucial include a
–-carboxylated moiety on the L-glutamate residue and a benzene ring close to
the carbonyl carbon of the amide bond as in MTX (Khan et al. 1999; DeAngelis
et al. 1996). Khan et al. (1999) generated thiolate-containing inhibitors based
on a thiocarbamate moiety attached to a benzene ring have also been reported
for CPG2 but were only moderately e ective competitive inhibitors and
displayed toxicity towards human colonic epithelial cancer cell lines (LS174T
cells), possibly allowing their use as inhibitors in ADEPT (Khan et al. 1999)
(Figure 1.7-A). Hence, work had started by Mologic (Bedford, UK) to design
and synthesise the second generation of inhibitors (Figure 1.7-B). They have
designed peptido-mimetic ligands that have a "warhead" that binds and inhibits
the enzyme, and a galactosylated tail that binds to hepatocyte receptors (i.e
asialoglycoprotein receptors) to provide clearance of CPG2 at non-tumorous
locations in a patient. Typically the peptides were developed to bind and
inhibit CPG2 without any significant enzyme modification (i.e. hydrolysis), and
facilitate clearance of the CPG2-inhibitor complex via the liver by binding to
hepatic cells expressing asialoglycoprotein cell-surface receptors, which are
proteins with sialic acid residues removed from glycoproteins and receptors
ensuring rapid clearance of the molecules with subterminal galactose residues.
13
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Figure 1.7: CPG2 inhibitors. A) Thiocarbamate inhibitor synthesised by (Khan et al.
1999), B) New peptido-mimetic inhibitor CP06 produced by Mologic Ltd. (Bedfore, UK).
1.4 Summary.
Due to its therapeutic applications in the treatment of cancer and autoimmune
diseases, CPG2 is of great biomedical interest. The crystallographic data helped
to better inform early rational drug design e orts (Rowsell et al. 1997; Lindner
et al. 2003), but further attempts at co-crystallisation of CPG2 with ligands,
substrates or inhibitors have not been reported and very little progress has been
made since these early studies to establish key features of CPG2 such as the
location of its active site, the presence of additional ligand-binding sites, its
stability, its oligomeric state, and the molecular basis of activity. Thus far, our
current working understanding of the molecular basis of CPG2 activity is
largely based on sequence / structural homology and molecular modelling
(Lindner et al. 2003). Solution state nuclear magnetic resonance (NMR)
spectroscopy is a unique tool for studying protein structure, stability, dynamics,
and ligand binding properties that could inform structure-based drug discovery
and provide a fundamental understanding of CPG2 function (Wuthrich 1986;
Clarkson and Campbell 2003; Stark and Powers 2012).
14
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1.5 Nuclear Magnetic Resonance Spectroscopy.
There are several methods by which one can get structural information about
enzymes. For instance, gel filtration and western-blotting can tell us about the
macroscopic level information of the enzyme. Site-directed mutagenesis can also
be used (see Chapter 5) to study and monitor what kind of changes occurred in
order to draw a conclusion about the structure via the investigation of
substrate-specificity. These studies could lead us closer to the structure, but we
still cannot be sure about the exact three dimensional structure. X-ray
crystallography and NMR spectroscopy are the only established approaches
available to resolve high resolution molecular structures. Although both
methods may complement each other to get a better picture of a given protein
structure, NMR is particularly suited to study of a soluble enzyme and
investigation of enzyme-ligand interactions that are closer to a real functional
environment (i.e. physiological conditions in solution).
The following section provides a very brief description of the NMR basics.
Since NMR spectroscopy is based mostly on the quantum mechanics of nuclear
spin angular momentum, which cannot be visualised by a classical route, for
clarity the classical representation is going to be adopted to describe the NMR
experiments.
15
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1.5.1 Quantum Angular Momentum.
Spectroscopy is a technique that relies on the interaction between matter and
electromagnetic radiation. Electrons possess an intrinsic electron spin angular
momentum known as "spin". Protons and neutrons (and therefore some nuclei)
also possess a spin angular momentum called the nuclear spin angular momentum
I. The spin angular momentum is quantised. If a particle can spin, it has an
angular momentum and therefore has quantised energy levels (1.1).
I = ~
Ò
I(I + 1) (1.1)
where ~=Plank’s constant/2ﬁ
A circulating particle with both charge and spin angular momentum creates a
current and should have an associated magnetic field. The magnetic field
produced by a particle is called its magnetic moment (µ) and is related to the
spin angular momentum via Equation (1.2). The proportionality constant is the
gyromagnetic ratio (“). A positive value of “ means the magnetic moment is
parallel to the spin angular momentum. The value of “ is characteristic of each
nuclei and result in di erent intensity of the magnetic moment and di erences
in their NMR frequencies.
µ = “I (1.2)
In biomolecular NMR spectroscopy, the mainstay nuclei are 1H, 13C and 15N.
Hence, the NMR behaviour is based on the interactions between nuclei with
a nuclear spin quantum number I Ø 1/2. Quantum mechanics tells us that a
16
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nucleus with a nuclear spin quantum number I will split into 2I+1 possible energy
states. In the absence of a magnetic field, the distribution of magnetic moments
of an ensemble of nuclei is isotropic (all possible orientations represented). The
application of a magnetic field removes the degeneracy of the nuclei spin states.
Thus, spin "1/2" nuclei will split into two di erent populations of energy levels,
one parallel and the other one anti-parallel to the external magnetic field (Figure
1.8).
Figure 1.8: Spin polarisation. These schematic shows an isotropic distribution of the spin
polarisation in the absence of an external field (Bo). As soon as the B0 is applied the spin
polarisation become aligned along B0. The magnetic moment will either be aligned with Bo
(for nuclei with “ Ø 0), or anti-parallel to Bo (for nuclei with “ Æ 0).
This splitting is specific to each nucleus, it depends on the chemical
environment and is proportional to the external magnetic field direction. The
distribution among the nuclear spin energy levels is determined (as always) by
the Boltzmann distribution (5.1), where Nupper and Nlower represent the
population number of nuclei in upper and lower energy states, respectively, k is
the Boltzmann constant, and T is the absolute temperature in kelvin (Figure
1.9). This equation reveals that both energy levels are almost equally
populated. As a result, NMR is an insensitive form of spectroscopy. However,
the small excess number of nuclei in the lower energy state is su cient to
17
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measure a net macroscopic magnetisation.
Nupper
N lower
= e≠ ~“B2kT (1.3)
Figure 1.9: The Zeeman e ect. The Zeeman E ect is the name given to the splitting of
the energy levels by B0 for a nuclei with I=1/2.
1.5.2 Free Precession.
When a particle with a magnetic moment is placed in an external magnetic field
(B0), it experiences a torque and precess around the field at a frequency known as
the Larmour Frequency Ê0. The Larmour frequency is identical to the resonance
frequency of the nucleus as shown in Equation (1.4), and depends on the constant
known as the gyromagnetic ratio, “ and the magnetic field applied B0. Each nuclei
possesses a unique “ value.
Ê0 = ≠“B0 (1.4)
The behaviour is comparable to the action of a gyroscope in a gravitational
field. Unlike the gyroscope, the spin energy is quantised and thus the angle and
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frequency of precession are fixed. We previously said that in the magnetic field
B0, the +z component of the magnetic moment of a spin -1/2 particle aligns
parallel to or anti-parallel to the magnetic field direction. In Figure 1.10 the
vector model used to represent electron spins is utilised to represent the x and y
component of nuclear magnetic moment.
Figure 1.10: Free precession. The two spin states of the nucleus are represented as before
(parallel and anti-parallel to B0), but now the Larmour precession is included. Since there is
a slight excess of spin in the ground state (parallel spins to B0), there is a bulk magnetisation
along the z-axis.
In a real sample (imagining all spins to be identical for now), there are
slightly more spins in the "spin up" configuration (lower energy state according
to Boltzmann’s Equation (5.1)). The phases of the individual spins are random.
Thus there is an overall magnetisation along the z direction (i.e. along the static
field B0 direction), but no net magnetisation perpendicular to the field because on
average the the magnetisation distribution at thermal equilibrium is cylindrically
symmetrical around the z-axis (Levitt 2001). Instead of measuring the nuclear
spin magnetisation along the field (i.e. z-axis), NMR spectroscopy measures the
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magnetisation perpendicular to the field. Application of a radio frequency pulse
(RF pulse) along the xy-plane causes the bulk magnetisation to precess about it
at a frequency related to the RF field (Figure 1.11).
The magnetisation precesses in the xy-plane. By varying the length of time
for which the RF field is applied, we can alter the angle through which the
magnetisation is rotated. The most common pulse is the 90¶ excitation pulse. The
e ect of this pulse is to cause the spins to cluster, producing a net magnetisation
along the x-axis in the sample, generating a transverse magnetisation.
Figure 1.11: Radio frequency pulse. The RF pulse is applied perpendicular to the external
field (B0) along the xy-plane.
1.5.3 NMR Signal.
After a 90¶ pulse, the transverse magnetisation will return back to its thermal
equilibrium position along the z-axis. This is due to T1 and T2, known as the
longitudinal and transverse relaxation times respectively. T1 follows the return
to the Boltzmann equilibrium population (i.e. to the initial z direction) of
spin-states through spin-lattice relaxation. Additionally, in an actual sample the
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precise Larmour frequency of spins will vary due to changing local environments
(i.e. neighbouring groups, orientation of the molecule with respect to the axis of
the applied field B0). This means that in the xy-plane some spins precess about
z-axis faster (or slower) than the central radio frequency, as a result the spins
will gradually fan out in the xy-plane and the coherence is eventually lost
(Figure 1.12). This process is called the spin-spin relaxation process, which
removes coherence with a time constant T2. Individual spins with di erent
resonance frequencies due to chemical shift or coupling precess about the
xy-plane at di erent frequencies relative to the RF pulse (i.e. B1). This
precession produces a radio frequency field in the detector coils. Since the NMR
spectrometer detects only the transverse magnetisation, the signal at the coils is
a decay curve with frequency components for each di erent resonance frequency
(Figure 1.12). The decay and oscillation of the transverse magnetisation over
time can be measured and is called the NMR signal or free induction decay
(FID). Using the mathematical technique of Fourier Transformation, this FID
spectrum can be transformed into the frequency spectrum — the usual NMR
spectrum (Figure 1.12).
Figure 1.12: NMR signal. The precession and relaxation of the transverse magnetisation
back to longitudinal magnetisation is represented. The signal is detected as function of time
along the xy-plane (FID). The signal is then Fourier transformed to obtain the NMR spectrum.
1.5.4 Nuclear Shielding.
As seen above, the resonance NMR frequency of a nucleus is given by Equation
(1.4). The local magnetic field experienced by a nucleus in an atom di ers from
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that of a bare nucleus. In an atom, the external field (B0) causes circulation of
electrons within their atomic orbitals. The circular movement of charged particles
such as electrons induces a current and as a result a small magnetic field B’
is established in the opposite direction to the applied field. Subsequently the
nucleus is shielded from the external field applied by the surrounding electrons
and experiences a reduced external field (i.e. B=B0-B’). The field at the nucleus
may be written as (1.5).
B = B0 ≠BÕ = B0(1≠ ‡) (1.5)
where ‡ is the shielding constant
Electronegative atoms (e.g. oxygen) are electron-withdrawing atoms that will
increase the local-field of the neighbouring nucleus. Thus, the nucleus will be
deshielded and appear at higher resonance frequency than expected, downfield in
the spectrum (Figure 1.13). However, the electron movement is more complex in
molecules. Electron currents provided by neighbouring groups (e.g. delocalisation
of electrons in an aromatic group produces a ring-current e ect) can also lead
to shielding or deshielding of nuclei. Thus the resonant frequency of a nucleus
depends also on its local environment. Accordingly, di erent nuclei in a molecule
will resonate at slightly di erent frequencies causing each nucleus to precess at
a di erent Larmour frequency creating di erent resonance frequencies (chemical
shift) in the NMR spectrum.
Thus, the chemical shift will be specific to a functional group (i.e. aliphatic
protons) and enable the identification of secondary structure in proteins. Indeed,
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Figure 1.13: Nuclear shielding. 1D 1H NMR spectrum showing where chemical shifts of
more or less shielded nuclei appear on the spectra, along with how it relates to the magnetic
field generated around the nuclei.
a rapid 1D proton NMR spectrum can help determine whether the protein is
folded and therefore likely to be functional for further analyses. The idea is
that if a protein is well folded, the peaks in the 1D NMR spectrum are sharp
and narrow and cover a large range of chemical shifts, whereas, if the protein is
unfolded or partially folded, the peaks are broader and not as widely dispersed
due to loss of di erent local environments. A spectrum with good dispersion,
i.e. peaks spanning a wide ppm range, is a good indication of a folded protein.
Unfortunately, 1D proton NMR spectra of proteins can get very complicated.
Each peak corresponds to a particular proton in the protein. So that means
CPG2, a protein of ¥ 400 amino acids, will have >400 peaks 1H peaks, many of
them overlapping.
To overcome problems caused by overlap in the proton spectrum, protein
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NMR is usually multidimensional (2D, 3D, or even 4D). The extremely
overlapping 1D NMR spectrum is spread into a carbon or nitrogen dimension.
2D NMR is used to determine which nuclear spins are coupled (through space
or bond) to one another. An example is Heteronuclear Single Quantum
Coherence (HSQC ), an heteronuclear experiment which correlates the chemical
shifts of protons and 15N-nuclei that are directly bound. As a result, the proton
resonances are scattered according to the chemical shifts (discrete spots) of 15N
to which they are coupled.
1.5.5 The Notorious Size-Limitation.
The primary limitation in protein solution NMR is the molecular weight
restriction. Even though one of the largest structures nearly determined by
NMR is an 84 kDa enzyme known as the malate synthase G (Tugarinov et al.
2005), the actual limit for routine studies is in the region of twenty to thirty
kilodaltons (Keeler 2011). Larger proteins yield broad NMR signals that are
eventually non observable. Two main problems occur as the protein size
increases. First, the line width of an NMR signal at half width   ‹ is related to
the transverse relaxation time (T2) as described in Equation (1.6) (Bieri et al.
2011).
 ‹ = 1
ﬁT 2
(1.6)
T2 in most molecules is caused by the external magnetic field variation
modulated by the molecular motion of the protein. The molecular motion can
be defined by the rotational correlation time for the molecule · c, which is the
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average time taken by the protein to end up at an orientation about one radian
from its initial position (assuming it behaves more or less spherically) (Keeler
2011). The rotational correlation time can be estimated using Equation (1.7).
· c =
MV
÷RT
(1.7)
Where M is the molecular mass, V the molecular volume, ÷ the viscosity
and T the temperature (Kay 2005). Thus the tumbling rate is per se
proportional to the molecular size and shape. As a consequence, slower
tumbling rates of huge biomolecules increase transverse relaxation rates, and
broaden NMR signals. This gives rise to the second problem, which is the
superposition of many NMR signals as peak width increases causing ambiguous
assignments. Because of considerable relaxations, peaks can also disappear.
Nevertheless, this limitation is constantly driven back by progress made in
experimental NMR techniques and development of novel strategies for isotopic
labelling of proteins, such as TROSY and perdeuteration respectively.
1.5.6 Transverse Relaxation-Optimised Spectrocopy
(TROSY).
Multidimensional NMR spectroscopy provides much better resolution with fewer
signals cluttering the spectrum. Unfortunately, isotopic labelling and standard
triple-resonance approaches cannot extend application of NMR techniques above
the size limit of thirty kilodaltons (Matthews 2004). The transverse relaxation-
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optimised spectroscopy (TROSY) methods can extend this range to higher mass
(Pervushin et al. 1997).
As the name suggests, it exploits attenuation of the transverse signal
relaxation. Transverse signals are the observable signals in NMR spectrum, but
their relaxation leads to fast exponential signal decay. As mentioned earlier,
transverse relaxation rates are proportional to the molecular weight of a protein.
Relaxation for larger proteins at a high magnetic field strength is dominated by
dipole-dipole relaxation (DD) and chemical shift anisotropy (CSA) mechanisms.
DD relaxation are due to the motion of the nearby magnetic dipole moment (µ)
especially with protons, while CSA arises due to various orientation of the
molecule with respect to the magnetic field B0 (Levitt 2001). In solution NMR
spectroscopy, CSA is averaged out by molecular tumbling, but the latter is
significantly reduced in large proteins. The interference between the two DD
and CSA relaxation mechanisms can be subtractive, resulting in slower
relaxation of the observable transverse signal, which can be carefully retained
and observed in TROSY type experiments. Pervushin et al. (1997)
demonstrated that TROSY produced identical information to a 1H-15N HSQC
(the resulting spectrum is two-dimensional with one axis for 1H and the other
for the 15N), but with much higher resolution for deuterated protein samples
because protons are the highest source of DD relaxation (Pervushin et al. 2000).
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1.6 NMR Spectroscopy in the Determination of
the Binding Interface.
There are times where high-resolution structure determination is not achievable
(i.e. study of large proteins). What follows is a description of the NMR techniques
that can be used to study the molecular changes associated with ligand-binding
interactions at an atomistic level. The e ects of ligand binding can be studied
via two approaches: ligand-based and protein-based methods.
1.6.1 Saturation Transfer: a Ligand-Based Approach.
In ligand-based experiments, isotopic labelling of the target protein is
unnecessary, since only ligand signals are monitored. To study molecular
interactions in solution, the Nuclear Overhauser E ect (NOE) can be exploited.
NOE may be described as the change in intensity of the NMR signal when the
spin transitions of another nucleus are perturbed from their equilibrium
population by radio-frequency saturation (Figure 1.14) (Bieri et al. 2011). This
dipole-dipole relaxation has a 1/r-6 distance dependence, hence only nuclei that
are close in space can experience the NOE e ect.
In the present study, when a ligand binds to a protein, the NOEs undergo
extreme changes leading to the observation of transferred NOE. When a ligand
is bound to the enzyme, it acts as if it is part of a large molecule and adopts the
corresponding NOE behaviour, an intense negative NOE called transferred
NOE. Saturation transfer di erence (STD) NMR is based on the NOE principle
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Figure 1.14: NOE e ect. When an electromagnetic radiation is applied on one resonance of
spin I, a rise (positive NOE) or a drop (negative NOE) in intensity of other NMR signals such
as spin P is observed when spin P is close in space to spin I. Small molecules have positive
NOEs, whereas bulky molecules have negative NOEs due to tumbling times (Williamson 2009).
(Angulo and Nieto 2011). It is used to identify the elements of the ligand that
are in close contact with the protein upon binding. STD-NMR can be described
as a three step approach (Figure 1.15). First, an NMR spectrum without
protein irradiation is recorded, resulting in the normal spectrum of the free
ligand being observed (o -resonance spectrum). Then, a resonance of the
protein, where no ligand signals are present, is irradiated leading to a selective
and e cient intramolecular saturation of the protein by spin di usion. This
saturation transfers the irradiation to the areas of the ligand bound to the
protein. By exchange (free / bound state) that saturation is carried by the
ligand into solution where it is detected (on-resonance spectrum). The delivered
saturation to the individual proton signals of a ligand reflects the proximity of
these to the protein surface. Finally the subtraction of the two spectra
(on-resonance minus o -resonance) results in a di erence spectrum.
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Figure 1.15: Saturation transfer di erence NMR spectroscopy.. First a non-saturated
1D 1H NMR spectrum is recorded, resulting in the spectrum of the free ligand in solution. In
a second step, one resonance of the protein, where no ligand resonance frequencies are present,
is saturated. This leads to saturation of the rest of the protein due spin di usion. Upon
binding of the ligand the saturation is transferred to protons of the ligand that are in close
contact with the protein. By exchange between free and bound states, the saturated ligand is
transferred into solution, where the saturation is detected (on-resonance). The subtraction of
the on-resonance spectrum from the o -resonance spectrum results in the saturation transfer
di erence spectrum, where we can observe directly saturated ligand signals by the protein which
would have experienced a decrease in the intensity of their NMR signal. (Heller and Kessler
2001).
1.6.2 Chemical Shift Perturbation: a Protein-based
Approach.
The major aim of investigating protein interaction with molecules is the
characterisation of the interactions sites on both components. The most
commonly used NMR experiment for mapping ligand interactions of the surface
of the protein is the chemical shift perturbation resulting from complex
formation. Since we will be monitoring the protein NMR resonances, the ligand
29
Chapter 1
can be of any type as long as the NMR resonances of the target protein are
easily detectable. Because chemical shifts are a ected by the changes in the
local electronic environment, binding can be detected by comparing the HSQC
spectra of the protein in the absence and presence of the ligand.
HSQC displays all 1H-15N correlations present within the target protein.
For the most part, these are the backbone residues of all non-proline amino
acids present within the primary sequence of the protein. However, the
sidechains of tryptophan, arginine, lysine, asparagine and glutamine residues,
and also histidine (depending on the protonation state of the imidazole ring),
can also be visible. As a result, the HSQC experiment provides a "fingerprint" of
a protein structure likely to succeed because each protein has a unique pattern
of N-H correlations for each residues. However, it necessitates the production of
recombinant protein with 15N labelling as a minimal prerequisite. For large
proteins, a particular labelling strategy (i.e. perdeuteration) in combination
with the appropriate NMR experiment (i.e TROSY) may be required to
increase sensitivity and resolution in the HSQC spectrum. Still this type of
study usually requires a crystal structure of the target protein, but also an
extensively assigned HSQC, in order to map the chemical shift perturbation
onto the structure and locate the ligand-protein binding site onto a three
dimensional structure of the protein.
Not only can HSQC experiment be used to pinpoint the interaction site of
the ligand in the protein, it can also estimate the kinetic characteristics of the
interaction. The easiest approach to determine the binding constant is to titrate
increasing concentration of the ligand into the protein solution. The kinetics
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of binding can then be classified by the overall chemical shift changes observed
within the HSQC spectrum during the titration. If the protein-ligand complex
dissociation constant is fast on the chemical shift and relaxation rate timescales
(i.e. weak ligand-protein binding), one coalesced peak (two peaks have become
one) at a weighted averaged chemical shift between free and bound protein is
observed throughout the titration (Figure 1.16-A) (Williamson 2013). In cases
of slow exchange (usually associated with "strong" binding) separate signals are
observed for the free and bound forms of the protein (Williamson 2013).
Figure 1.16: Exchange regime. A) In fast exchange, upon titration, the peaks will move
smoothly from the chemical shift resonance of the free protein (blue) to the chemical shift
resonance of the bound protein; B) In slow exchange, the signal of the free protein (blue)
will gradually decrease in intensity as the signal of the bound protein increases close to ligand
saturation (red). Adapted from Williamson (2013).
1.7 Research Aims.
The aim of this work was to further our understanding of the mode of binding of
peptido-mimetic ligands to CPG2 by acquiring structural information of the free
enzyme and inhibitor-enzyme complex. Specifically, we focused on characterising
the di erent molecular interactions, occurring between CPG2 and its di erent
binding inhibitor partners. Using a wide range of biophysical methods, we have
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tried to determine the interactions involved in CPG2-inhibitor complex formation.
The information obtained could then be exploited towards the development of
third-generation inhibitors.
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Materials and Methods
2.1 Materials.
2.1.1 Chemicals and reagents.
All chemicals and reagents were purchased from Sigma-Aldrich Company Ltd.
(Dorset, UK), Fisher Scientific UK Ltd. (Loughborough, UK), Melford
Laboratories Ltd. (Ipswich, UK), New England Biolabs Ltd. (Hitchin, UK),
Promega Corporation (Madison, USA), VWR International Ltd.(Lutterworth,
UK), Life Technologies Ltd. (Paisley, UK), GE Healthcare (Little Chalfont,
UK) unless otherwise stated. Media used for bacterial growth, including
distilled water and glass vessels, was sterilised by autoclave or filtered
beforehand. All other consumables (i.e. tips) were sterilised prior to use.
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2.1.2 Plasmid Constructs and Bacterial Strains.
Plasmids and Escherichia coli strains used in this study are illustrated in Tables
2.1 and 2.2, respectively.
Table 2.1: Plasmid constructs used in this study.
Plasmid Description Reference Source
pET28a Bacterial expression vector with
a T7lac promoter, full length
CPG2 inserts sequence - P06621
(CBPG_PSES6), C-terminal
Histidine tag, Kanr
Novagen Mologic Ltd.
pET151-D-TOPO Bacterial expression vector
with a T7lac promoter, mature
CPG2 insert sequence - P06621
(CBPG_PSES6), N-terminal
Histidine tag with a TEV
cleavage site, Ampr
Invitrogen Invitrogen
pRK793 Bacterial expression vector with
a T7lac promoter, Tobacco Etch
Virus (TEV ) insert sequence
with a N-terminal Histidine tag,
Ampr
Kapust et al. (2001) Challis Group
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2.1.3 Primers.
Table 2.3 lists all the primers used in this study, which were supplied by Sigma
(Dorset, UK), unless stated otherwise. A codon-optimised version of the
full-length CPG2 gene from Pseudomonas sp strain RS16 in the pET28a
plasmid (Novagen) was obtained from Mologic Ltd. and used as a template to
amplify the mature wild-type CPG2 gene in the absence of the signal peptide
(CPG223-415, residues 23-415), as well as the isolated non-contiguous catalytic
domain (CPG2CAT, composed of residues 23-214 and residues 323-415 linked via
a non-native alanine) and dimerisation domain (CPG2DIM, residues 213-322),
using the polymerase chain reaction (PCR). The 5’-sense primers encoded a
CACC site, and the 3’-antisense primers were designed to add a stop codon for
translation termination. The amplified gene segments were ligated into the
pET-151-D-Topo vector (Invitrogen, UK). The rest of the primers were used in
site-directed mutagenesis to change particular base pairs in CPG223-415 gene
sequence to study the e ect of a mutation on protein activity and stability. The
approach used was adapted from the QuikChange® Site-Directed Mutagenesis
Kit purchased from Invitrogen (Agilent Technologies, UK).
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2.1.4 Antibodies.
The monoclonal mouse anti-N-terminal-polyhistidine (dilution 1 in 3000) and
anti-Mouse IgG (Fab specific)-Peroxidase antibody (dilution 1 in 5000) were used
in this study and purchased from Sigma (Dorset, UK).
2.2 Methods.
2.2.1 Cloning and DNA Conservation.
Polymerase Chain Reaction, PCR.
The amplification of DNA was carried out using the specific enzymes for each
PCR according to the manufacturer’s guide. Phusion DNA polymerase (NEB,
UK) was used to amplify truncated CPG2 genes and clone into pET-151-D-Topo
vector (Invitrogen, UK). PCR amplification was usually carried out using a 0.5
µL DNA template (0.52 ng), 10 µL of 5◊Phusion HF Bu er, 1 µL of 10 mM of
dNTPs mix, 2.5 µL of 10 mM forward and reverse primers from table 2.3, 0.5 L
of Phusion DNA polymerase (NEB, UK) and distilled H2O to a final volume of
50 µL. The reaction mixtures were briefly centrifuged at 1,500◊g, before heating
in a A Biometer T3 thermocycler. The general cycling conditions used for PCR
reactions involving amplification and site-directed mutagenesis are described in
Table 2.4.
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Table 2.4: Cycling conditions used for PCR amplification.
Cycle Step Temperature Time Cycles
Initial Denaturation 98¶C 30 s 1
Denaturation 98¶C 5 s
Annealing† 56¶C 10 s 30
Extension 72¶C 45 s
Final Extension 72¶C 10 min 1
4¶C On hold
† For PCR reactions, for primers greater than 20 nucleotides in length
the annealing step was performed at 3¶C above the lowest Tm of the
primer pair. When primers with Tm Ø 72¶C were used, a two-step
thermo-cycling without a separate annealing step was used.
Agarose Gel Electrosphoresis.
The results of most PCR experiments were checked by running a portion of the
amplified reaction mixture in an agarose gel. The required amount of agarose
(1%, w/v) was added to Tris-acetate-EDTA (TAE) bu er (Sanbrook et al. 1989)
and dissolved by heating to boiling using a microwave. Safeview Nucleic Acid
Stain was added (0.1%, w/v) and, once the gel was set, it was submerged in
TAE bu er. DNA samples from PCR reactions were prepared by mixing with
2 µL loading dye. Electrophoresis was carried out at 50 volts for 1.5 hours or
until the dye front was at least half way through the gel. The gel image was
recorded on a gel documentation system. The fragment of interest was excised
from the gel under a UV trans-illuminator using a sharp blade. A QIAprep gel
extraction kit (Qiagen, Germany) was used to remove the agarose from the band
of interest. The DNA concentration was determined using the NanoDrop 2000c
UV-Vis spectrophotometer.
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Ligation of Linear DNA fragments.
PCR product bands 1 and 2 for CPG2CAT construct, composed of two DNA
fragments encoding for residues 23-214 and residues 323-415 respectively were
excised and purified using a QIAquick Gel Extraction Kit after confirmation
by visualisation on an agarose gel (see previous section). These two fragments
were ligated at a nanogram ratio concentration of 3:1 PCR product 1: PCR
product 2 in the presence of 1 U of T4 DNA ligase polymerase (Invitrogen, UK)
according to manufacturer’s instruction in a volume of 20 µL. Reaction mixtures
were incubated at 16¶C overnight. The next day, the polymerase were heat
inactivated at 65°C for 10 minutes before cloning in expression vector pET151-
D-TOPO (Invitrogen, UK) (see next Section).
Cloning procedure.
Amplified PCR products of truncated CPG2 gene were inserted in the E.coli
expression vector pET151-D-TOPO (Invitrogen, UK). The pET Directional
TOPO expression kit utilises a 5-minute cloning strategy to directionally clone
a blunt-end PCR product into a vector with no ligase, post-PCR procedures or
restriction enzymes required. In this system, the PCR product is directionally
cloned by adding four bases to the forward primers CACC (see Table 2.3). The
PCR product is stabilised in the correct orientation when the overhang in the
cloning vector GTGG anneals to the added bases in the 5’ end of the PCR
product. All amplified gene segments were ligated into the pET-151-D-TOPO
vector with an N-terminal tag containing the V5 epitope and a hexahistidine
40
Chapter 2
a nity tag, which could be removed by TEV cleavage. The cloning reaction
mixture was prepared using the reagents described in Table 2.5. The mixture
was mixed gently with the end of a pipette tip and incubated at room
temperature (22-23¶C) for 5 minutes. For optimal results, a 2:1 molar ratio of
PCR product to vector was used. Once the cloning reaction was performed,
chemically competent E.coli strains were transformed with the new pET TOPO
constructs (see Section 2.2.2).
Table 2.5: Cloning reaction mixture.
PCR product 1 µL
Salt solution 1 µL
Sterile water 3 µL
Vector 1 µL
Total volume 6 µL
Site-Directed Mutagenesis.
Site-specific mutation protocol to substitute a specific amino acid in CPG2 23-415
was performed by PCR with use of the QuikChange® Site-Directed Mutagenesis
Kit (Agilent Technologies, UK) and the oligonucleotides listed in Table 2.3, with
the pET151-D-TOPO CPG223-415 plasmid as a template. This method allows
the production of mutants in a rapid three-step procedure involving 1) mutant
strand synthesis with two synthetic oligonucleotide primers (see Table 2.3), both
containing the desired mutation and each complementary to opposite strands
of the vector using temperature cycling where the PCR reaction goes around
the entire vector (see Section 2.2.1), 2) digestion of methylated parent plasmid
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strand by using 1 µL of DPN1 restriction enzyme at 37¶C for an hour in the
PCR mixture to select for mutation-containing synthesised DNA only, and 3)
transformation of 15 µL of the final reaction into 100 µL of DH5– competent cells.
The PCR reaction was performed using the high fidelity Phusion DNA polymerase
to minimise the chances of introducing unwanted mutations in both the gene and
the plasmid DNA backbone. Finally, a colony was picked, the plasmid purified
and sequenced to check for correct mutation and any PCR introduced errors.
PCR Screening of Bacterial Colonies.
After ligation and plating, PCR screening was performed to test for positive
insertion of the gene of interest within the vector. A well isolated colony was
picked and transferred to 50 L of sterile water. Part of the colony was
transferred to 10 mL LB media containing the appropriate antibiotic for
overnight culture and miniprep. 1 µL of the inoculated solution was added to 9
µL of PCR pre-mix. An appropriate volume of PCR pre-mix was set up as
described in Table 2.6.
PCR was preformed according to Section 2.2.1-PCR, and the PCR
products were analysed using a 1% agarose gel (see Section 2.2.1-Agarose Gel
Electrosphoresis).
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Table 2.6: PCR screening of bacterial colonies.
1◊Pre-Mix (µL) 20◊Pre-Mix (µL)
10x Taq bu er (+KCl, -MgCl2) 1 20
MgCl2 (50 mM) 0.3 6
dNTPs 10 mM 0.1 2
Forward primer 0.1 2
Reverse primer 0.1 2
W1 detergent 0.5 10
Taq polymerase 0.1 2
distilled H2O 6.8 136
Glycerol Stocks.
The plasmid constructs produced were stored after transformation in E. coli
strains in glycerol stocks for long-term stability. 800 µL of the overnights
prepared in Section 2.2.1-PCR Screening of Bacterial Colonies were transferred
to 2 mL cryogenic vials with 400 µL 50% (v/v) glycerol solution. The vials were
flash frozen in liquid nitrogen and stored at -80¶C for future use.
Purification of Plasmid DNA.
Plasmid DNA of positive clones were purified from a 5 mL cell culture in LB
(see Section 2.2.1-PCR) using the QIAGEN Mini-Prep Kit (Qiagen, Germany).
This kit employs the alkaline lysis method where the cells are broken open using
an alkaline solution consisting of a detergent sodium dodecyl sulfate (SDS) and
a strong base sodium hydroxide. Through a series of steps involving agitation,
precipitation, centrifugation, and the removal of supernatant, cellular debris is
removed and the plasmid is isolated and purified by its adsorption onto a silica
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matrix, which is driven by the presence of high concentrations of chaotropic salts.
Manufacturers instructions were used and plasmid DNA was recovered in 30 µL
of distilled H2O and stored at -20¶C.
Sequence Analysis of Plasmid DNA.
Purified plasmid DNA was dispatched to GATC (Germany) and sequence analysis
was performed using vector-specific forward and reverse T7 primers synthesised
by GATC to assess the correct orientation of the insert into the vector, presence
of start and stop codons and no mutations were incorporated by PCR errors.
2.2.2 Bacterial Growth and Conservation.
Preparation of Competent Cells.
3 mL of an overnight culture of E.coli in LB was inoculated into 300 mL of
fresh LB broth. The culture was incubated at 37¶C and shaken (180 rpm).
When turbidity was observed, an aliquot was removed and the optical density
(OD) checked at 600 nm, using LB (no cells, no antibiotic) as a blank. The
OD600 was examined every half hour to make sure it was not beyond 0.35. The
culture was cooled by placing the conical flask on ice for twenty minutes,
followed by aliquoting into 50 mL ice-cold falcon tubes. Cells were pelleted by
centrifugation 1500◊g at 4¶C for 10 min. Supernatant was poured o  and
pellets were resuspended in 30 mL of ice-cold 100 mM CaCl2. Pellets were
retrieved by centrifugation at 1500◊g at 4¶C for 10 min. Pellets were
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resuspended in 2 mL of ice-cold 10 mM CaCl2. At this point, the cells were
mixed with glycerol as follows: 300 µL of cells with 50 µL of 50% glycerol
solution into 1.5 mL tubes. These eppendorf tubes were stored at -80¶C until
further use.
Cell Transformation.
Competent cells (50 µL) were transferred with 1 µL of plasmid DNA and
incubated on ice for 30 min. The cells were then heat-shocked for two minutes
at 42¶C, followed by incubation on ice for a further two minutes. LB broth (1
mL) was added to the cell culture and then subjected to shaking (180 rpm)
incubation for 1 hour at 37¶C. 200 µL of the transformation mix was spread
onto LB agar plates containing the appropriate antibiotic (Table 2.7) and
incubated inverted overnight at 37¶C.
Table 2.7: Recommended antibiotic concentrations for rich and minimal media.
Antibiotic Abbreviation Final Concentration (µg/mL)
Kanamycin Kan 50
Ampicillin Amp 100
Chlorampenicol Chl 34
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2.2.3 Preparation of CPG2.
2◊YT medium.
2◊yeast extract and tryptone medium (2◊YT) was used to produce protein used
for ligand based NMR spectroscopy studies. 2◊YT was prepared by adding 16g
of tryptone, 10 g of yeast extract and 5 g of NaCl to 800 mL of distilled H2O.
The pH of the media was adjusted to 7.3 using the pH meter. The volume was
topped up to 1 L using distilled H2O.
Preparation of CPG2.
1 L of 2◊YT with ampicillin was inoculated with 10 mL of the overnight
culture and shaken at 180 rpm and 37¶C until the OD600 of 2 was reached
during the exponential growth phase. Crude pre-induction samples (1 mL) were
removed upon an OD600 of 2 being attained and kept for SDS-PAGE analysis.
Induction of CPG2 expression was achieved with the addition of Isopropyl
—-D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM, and
the culture was transferred to the 15¶C incubator, which is the most favourable
temperature fro expression (see Chapter 3). Crude post-induction samples (1
mL) were removed at 4, 24 and 48 hours post-induction and OD600 readings
were taken. Later they were submitted to sonication. The remaining culture
was transferred evenly to 500 ml centrifuge tubes and centrifuged at 4,300◊g for
20 min at 4¶C. The recovered pellets were then resuspended in 10 ml of Tris
bu er (20 mM Tris, 137 mM NaCl, 1 mg/mL lysosome, 1 mM 4-(2-Aminoethyl)
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benzenesulfonyl fluoride hydrochloride, pH 7.3). If time was an issue, the
pelleted cells by centrifugation at 8,300◊g were stored at -80¶C overnight;
otherwise the cell disruptor was used to lyse the cells.
2.2.4 Preparation of Isotopically Labelled CPG2.
Preparation of Minimal Media.
Minimal media (M9) was used to produce isotopically either singly (15N),
doubly (15N/13C) or triply (2H/15N/13C) labelled protein for enzyme-based
NMR spectroscopy studies. M9 was prepared by adding 200 mL of 5◊M9 salts
(50 mM Na2HPO4, 50 mM K2HPO4, 5 mM Na2SO4), 1 g of 15N-ammonium
chloride, 4 g of 13C-glucose. While stirring to circumvent precipitation, 100 µM
and 2 mM of iron chloride and magnesium sulphate, respectively, were added
drop wise, followed by 10 mL of 100◊BME vitamin solution. The pH of the
solution was adjusted to pH 7.3 and sterile distilled H2O was added to a final
volume of 1 L. Finally, the solution was supplemented with the appropriate
antibiotic for plasmid selection. For perdeuterated (100% deuteration) proteins,
deuterated water was used instead of water.
Traditional IPTG-Induction Expression in M9.
Labelled M9 medium (1 L) inoculated with cells from the glycerol stock (volume
of starter culture corresponds to 10% of the final M9 volume) and shaken at 180
rpm at 37¶C for 24 hours. When the OD600 of the starter culture reached 1, 1L
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of fresh labelled M9 culture was inoculated with the starter culture to obtain an
initial OD600 of 0.1 and was shaken at 180 rpm at 37¶C for growth. As soon as
OD600 ¥ 1, cells were induced with 0.5 mM IPTG and incubated at 15¶C for 20
hours at 180 rpm (optimal conditions).
2.2.5 Protein Expression.
High-cell Density Method and IPTG-Induced Expression.
This expression method, instead of the traditional IPTG-induction expression in
M9, was used to reduce the cost of labelled media. E. coli cells were grown in rich
medium at 37¶C. Once the cell density reached OD600 ¥ 2, the cell culture was
switched to labelled M9 media by gently spinning cells down at 1,500◊g for 5 min.
The pellet was repeatedly washed with M9 to remove rich medium. Cells were re-
suspended into the concentrated volume of minimal medium (2◊). The cells were
cultured for another 1-1.5 h without adding IPTG at 37¶C (OD600 should increase
by 1-2 units). IPTG (0.5 mM) was then added to induce protein expression. Cells
were then incubated at 15¶C for 20 hours, which was the determined optimal
expression time.
Double Colony Selection.
A double colony selection was performed for bacterial expression of triple-labelled
protein in D2O (Murray et al. 2012). For the first colony selection, LB- agar plates
were prepared and the glycerol stock was streaked on to it and left overnight in the
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incubator at 30¶C. The next day, 9 colonies (with the first colony serving as the
negative control) were chosen for expression and a master plate was prepared by
streaking the 9 colonies onto it. 8 colonies were induced with 0.5 mM IPTG and
expressed at 15¶C in LB with 50% D2O and checked for CPG2 level expression
after 24 hours via SDS-PAGE and western blot analysis. The colony with the
thickest expression band for CPG2 was selected from the master plate and used to
prepare 5 mL overnight culture in LB with 100% D2O at 30¶C. This culture was
spread onto an LB-agar plate with 50% D2O and incubated at 37¶C overnight.
A second round of colony selection was repeated, but this time in LB with 100%
D2O. At the end of the procedure, the colony expressing the thickest protein-band
in LB with 100% D2O was selected and used to prepare the final glycerol stock
(800 µL of overnight cell culture of the selected colony from the second master
plate with 400 µL of 50% glycerol), which was stored at -80¶C.
Cell Lysis by Ultrasound Sonication.
Ultrasound sonication was used to disrupt the bacterial cell extracts and lyse cells
(5 mL and above) by high frequency sound. Sonicator probes were pre-chilled on
ice before use. All samples remained on ice throughout the sonication process.
All crude samples (1 mL) and lysed bacterial pellets (10 mL) were subjected to
sonication using 6 cycles of 30 seconds on ice followed by 10 seconds of sonication
using a 5 mm probe, and 4 cycles of 1 minute on ice followed by 1 minute of
sonication using the a 7 mm probe, respectively.
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Cell Lysis by Cell disruption.
A cell disruptor was later used to disrupt cell extracts (10 mL and above) at 30
kPSI. In this method, the pressure drops by transferring the cell extract from
a chamber at high pressure through an orifice into a chamber at low pressure,
ensuring cell lysis. It is fast and e cient but causes significant heating of the
sample. For this reason, the collector was always kept at 4¶C before usage.
2.2.6 Protein Purification.
CPG2 Purification.
Recombinant CPG2 was isolated from cell debris by ultrasound sonication or cell
disruption. Cell pellets from 1 L culture were thawed on ice and resuspended
in 10 mL lysis bu er (20 mM Tris, 137 mM NaCl, no EDTA chelating agent,
lysozyme 1 ug/mL, 1 mM AEBSF, pH 8) and incubated at 4¶C for 30 min. The
cells were lysed and insoluble fraction pelleted by centrifugation (48,000◊g, 20
mins, 4¶C). The soluble fraction was incubated with 10 mM imidazole and Ni-
NTA resin (Novagen, 50% slurry, pre-equilibrated with 10 mM imidazole) for
1 hour. The incubated supernatant-Ni mixture was loaded onto a column and
the flow-through collected as the resin set by gravity. The column was washed
extensively with 10◊bed volumes of Tris bu er (100 mM NaCl, 20 mM Tris,
10 mM imidazole, pH 8). The his-tagged protein was then eluted with 5◊bed
volumes of elution bu er (100 mM NaCl, 20 mM Tris, 250 mM imidazole, pH 8).
The bu er was exchanged against Tris bu er (100 mM NaCl, 20 mM Tris, pH 8)
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using PD-10 columns to desalt samples.
His-TEV Protease Expression and Purification.
The 2◊YT starter culture (10 mL) was inoculated with cells from glycerol stock
and left at 30¶C overnight. This outgrowth was then transferred to a final volume
of 1 L fresh 2◊YT to obtain an initial OD600 of 0.1. The cells were then grown at
37¶C until the OD600 reached ¥ 2, then it was induced with 0.5 mM IPTG and
incubated at 15¶C overnight. Recombinant His-TEV protein was then harvested.
Cell pellets from 1 L culture were thawed on ice and resuspended in 10 mL Tris
lysis bu er (20 mM Tris, 137 mM NaCl, no EDTA — chelating agent, lysozyme
1 µg/mL, 1 mM AEBSF, pH 8) and incubated at 4¶C for 30 min. The cells
were lysed and insoluble fraction pelleted by centrifugation (48,000◊g, 20 min,
4¶C). The soluble fraction was incubated with 10 mM imidazole and Ni-NTA
resin (Novagen, 50% slurry, pre-equilibrated with 10 mM imidazole) for 1 hour.
The incubated supernatant-Ni mixture was loaded onto a column and the flow-
through collected as the resin set by gravity. Column was washed extensively with
10◊bed volume of Tris bu er (100 mM NaCl, 20 mM Tris, 10 mM imidazole, pH
8). The his-tagged protein was then eluted with 5◊bed volume of elution bu er
(Tris bu er, 250 mM imidazole, pH 8) and bu er exchanged against Tris bu er
(100 mM NaCl, 20 mM Tris, pH 8) using PD-10 columns to desalt samples.
51
Chapter 2
His-Tag Removal by Enzymatic Cleavage.
Both desalted and purified his-tagged CPG2 and TEV proteins in Tris bu er (100
mM NaCl, 20 mM Tris, pH 8) were incubated together for 48 hours at 4¶C for
cleavage of the polyhistidine tag.
Purification of the Untagged CPG2.
The overnight CPG2-TEV reaction mixture was incubated with 10 mM imidazole
and Ni-NTA resin (Novagen, 50% slurry, pre-equilibrated with 10 mM imidazole)
for 1 hour. The incubated supernatant-Ni mixture was loaded onto a column and
the flow-through, containing the protein of interest was collected, as the resin
set by gravity. The solution volume was slowly reduced using centrifugal units
of 20 molecular weight cut-o  (Millipore, UK). The unlabelled protein sample
was then lyophilised using the freeze drier and stored at -20¶C for ligand-based
NMR studies, while the labelled protein sample was used straightaway away for
protein-based NMR studies.
2.2.7 Quantification of Protein Concentration.
Protein Concentration Determination using UV-Visible
Spectrophotometer.
60 µL of purified CPG2 was transferred to a Thermo Electron Cuvette and the
absorbance was read at 280 nm against the blank (100 mM NaCl, 20 mM Tris)
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using the UV visible BioMate instrument. The concentration was determined
using Beer-Lambert Law Equation (2.1), where A is the absorbance, ‘ the molar
absorptivity in M-1 cm-1, l the path length in cm and C the concentration in
molar.
A = ‘lC (2.1)
Protein Quantification using BCA Assay.
The bicinchoninic acid (BCA) assay was used for colorimetric detection and
quantitation of total protein (Thermo Scientific Pierce, UK). The
manufacturer’s guidelines were followed to perform the assay. After incubation
at room temperature (i.e. 25¶C) for 2 hours, the absorbance reading of the
sample of interest and the standards at 562 nm were taken using the UV- visible
spectrophotometer. Set at 562 nm, the instrument was zeroed using a cuvette
filled with water. The average absorbance reading for standard I (i.e. blank)
was subtracted from the absorbance reading for each remaining standard and
unknown sample. The standard curve was prepared by plotting the average
blank-corrected absorbance reading for each standard versus their respective
concentrations in µg/mL. Using the standard curve, the gradient was be
calculated and, using Equation (2.2), the protein concentration was established.
Protein Concentration (µg) = Absorbance (562 nm)gradient (2.2)
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2.2.8 Protein Detection.
Protein Solubility Assay.
Sonicated crude samples (1 mL) were centrifuged (5,000◊g) for 5 min to pellet
the insoluble components. The supernatant (soluble fraction) and the pellet (the
insoluble fraction) were retained for SDS-PAGE analysis. 10 mL sonicated lysed
samples were also centrifuged (5,000◊g) for 15 min at 4¶C. The supernatant and
the pellet were retained for further purification.
Optical Density of Culture Samples.
Sample was diluted to yield an OD600 reading between 0.1 and 0.8. Usually a
1:10 dilution of the culture was su cient. The same media used for growth of the
culture was used for zeroing the spectrophotometer and diluting the samples for
taking OD600 readings. The dilution factor and the OD600 reading were recorded
to calculate the actual OD600 of the culture.
Normalising SDS-PAGE Samples.
To accurately compare the amount of protein present between various culture
samples taken at various growth stages, the samples were normalised according to
the cell density (OD600) at the time the samples were taken. Maximum volumes
that can be loaded into the wells of the SDS-PAGE gel were also taken into
account. The volume of samples loaded onto the gels was normalised with respect
to the concentration of cells in the pre-induction sample.
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SDS-PAGE Gels.
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was
used for the separation of proteins based on their molecular weight. All SDS-
PAGE gels were prepared using the standard Laemmli Method (Laemmli 1970).
Table 2.8: SDS-PAGE gels sample bu er and running bu er.
(a) Sample Bu er
SDS 10% w/v
Dithiothreitol 10 mM
Glycerol 20% v/v
Tris-HCl, pH 6.8 0.2 M
Bromophenolblue 0.05% w/v
(b) Running Bu er
Tris-HCl 25 mM
Glycine 200 mM
SDS 0.1% w/v
The percentage acrylamide was selected based on the molecular weight
range of proteins we wished to separate (Table 2.8). A 12% gel was suitable to
separate protein in the 10 kDa-200 kDa range (see Table 2.9).
Tetramethylethylenediamine (TEMED), an essential catalyst for polyacrylamide
gel polymerisation, and ammonium persulfate (APS), an oxidising agent that is
used with TEMED to catalyse the polymerisation of acrylamide, were not
added until the gel was ready to be poured into the gel casting plates.
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Table 2.9: SDS-PAGE gel recipe.
(a) Resolving Gel Solution (12% acrylamide)
12%
H20 10.2 mL
1.5 mM Tris-HCl, pH 8.8 7.5 mL
20% SDS (w/v) 0.15 mL
30% Acrylamide / 0.8% bis-acrylamide (w/v) 12 mL
10% (w/v) ammonium persulfate 0.15 mL 0.15 mL
TEMED 0.02 mL
(b) Stacking Gel Solution (4% acrylamide)
4%
H20 3.075 mL
0.5 mM Tris-HCl, pH 6.8 1.25 mL
20% SDS (w/v) 0.025 mL
30% Acrylamide / 0.8% bis-acrylamide (w/v) 0.67 mL
10% (w/v) ammonium persulfate 0.025 mL
TEMED 0.005 mL
SDS-PAGE Analysis.
The Mini Protean 3 Electrophoresis System (Bio-Rad) was used to perform all
electrophoresis according to the manufacturer’s instructions.
1 mL crude samples and insoluble fractions from sonicated samples were
centrifuged (5,000◊g) for 5 min at 4¶C and the supernatant were discarded.
Pellets were resuspended in 15 µL of PBS bu er and 5 µL Laemmli Bu er.
Sonicated soluble samples (1 mL, 10 mL) were prepared for SDS by adding 5 µL
Laemmli Bu er to 15 µL of sonicated sample. The resulting samples were
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heated at 90¶C on a heating block for 5 min exactly. The sample was
centrifuged (5,000 rpm) and vortexed prior and after heating for 5 min. The
volume sample of SDS were normalised with respect to the concentration of
cells in the pre-induction sample, and ready for SDS-PAGE analysis. SeeBlue®
Plus2 Pre-Stained Standard (Invitrogen, 4-250 kDa) or ColorPlus restained
Protein marker Broad range (NEB, 7-175 kDa) were run on gels as protein
standards. Gels were run at 125 V for approximately 15 min and further at 200
V for 35 min until the front dye had migrated to the end of the gel. Upon
completion, the gel was subjected to Coomassie Blue Staining overnight on a
rocker. Gel was then destained with destaining solution (7% acetic acid, 40%
ethanol) until the bands were clearly visible and scanned (gels were maintained
between 2 plastic sheets) and stored in H2O.
Coomassie Staining.
Upon completion, the gel was subjected to coomassie blue staining overnight on
a rocker. Gels were first immersed in 20 mL of fixing solution [50% (v/v) MeOH,
10% (v/v) acetic acid] for 15 min, then stained in 20 mL coomassie solution
[0.025% (w/v) coomassie blue R250, 10% (v/v) MeOH] for 4 to 12 hours. Gels
were destained in a 10% (v/v) acetic acid solution until the bands were clearly
visible.
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Western Blot.
Gels were electro-blotted onto a 0.45 mm pore size nitrocellulose membrane at
100 V, 35 mA for 60 min using the Mini Trans-Blot® Electrophoretic Transfer
Cell according to the manufacturer’s guide (Bio-Rad).
After the transfer, the membrane was blocked in Tris-Bu ered Saline and
Tween-20 (TBST ) (30 mM Tris-HCl, 140 mM NaCl, 3 mM KCl, 0.1 % Tween-
20, pH 7.4) and 5% milk solution for maximum 1 hour at room temperature
(or overnight at 4¶C), then washed with TBST bu er 3 times for 5 min. The
membrane was inoculated for 1 hour with the primary antibody mouse anti-
polyHistidine, which was diluted in TBST and 5% milk, and then the washing
steps were repeated (3◊5 mins in TBST). The secondary antibody tablet, anti-
mouse anti-polyHistidine-alkaline phosphatase (Sigma), diluted in 10 mL distilled
H2O and used to incubate the blot for 1 hour, followed by 2◊30 min washing steps
with TBST.
Size exclusion size exclusion chromatography analysis.
4 mg/mL of protein solutions (CPG2, CPG2CAT, CPG2CAT’and CPG2DIM) were
prepared in bu er A (20 mM Tris, 100 mM NaCl, pH 8). Gel filtration
chromatography was performed on a HiLoad 16/600 Superdex 75 g GL column
by fast protein liquid chromatography ÄKTAFPLC (GE Healthcare UK Ltd.
Buckinghamshire, UK) at 4°C and at a flow rate of 0.5 mL/min. The column
was equilibrated with two column volumes of bu er A. The detection was
performed by monitoring the column eluate at 280 nm. To determine the
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molecular weight, a parallel column was run with the following molecular weight
markers at 5 mg/mL concentration each: —-amylase (200 kDa), Albumin (66
kDa) and Cytochrome C (12.4 kDa) (see Figure 2.1).
Figure 2.1: Elution and Calibration curve obtained with —-amylase, Albumin and
Cytochrome C protein Standards run on HiLoad 16/600 Superdex 75 g GL column.
A) The graph shows elution profile from HiLoad 16/600 Superdex 75 g GL column for calibration
standards (—-amylase 200 kDa, Albumen 66 kDa, Cytochrome C 12.4 kDa) as absorption in
milli-absorption units (mAU) at 280 nm versus volume in milliliters (mL). An isocratic gradient
of 100% of bu er A (20 mM Tris, 100 mM NaCl, pH 8) was used. B) The calibration curve
graph represents the gel phase distribution coe cient Kav versus the molecular weight (MW).
Kav = (Ve-Vo)/(Vc-Vo), where Ve = elution volume, Vo = column void volume, Vc = geometric
column volume. Straight line is the calibration curve calculated from the data for molecular
weight standards. Using the equation for the line, values for the molecular weights of CPG2,
CPG2CAT, CPG2CAT‘ and CPG2DIM were calculated (see Chapters 2 and 6).
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Protein identification by Means of Tryptic Digest and Nano LC-ESI-
MS/MS.
Excised bands from coomassie stained gel pieces were processed and tryptically
digested using the manufacturer’s recommended protocol on the MassPrep
robotic protein handling system Facility1. The extracted peptides from each
sample were analysed by means of nano LC-ESI-MS/MS using the
NanoAcquity/Ultima Global instrumentation (Waters) using a 30 minutes LC
gradient. All MS and MS/MS data were corrected for mass drift using reference
data collected from the (Glu1)-Fibrinopeptide B (human-F3261 Sigma) sampled
each minute of data collection. A full description of the methodologies employed
is available on request. The data were used to interrogate the E. coli BL21
database (http://www.ebi.ac.uk/integr8) appended with the sequence supplied,
using ProteinLynx Global Server v2.5.1.
Identification of proteins via MaXis II
All his-tagged proteins were analysed for their identity under positive-mode
using liquid chromatography electrospray ionisation ultra-high resolution
quadrupole time-of-flight mass spectrometry (LC-ESI UHR QTOF)2. Samples
at 20 µM protein in 20 µM ammonium bicarbonate where diluted by 1 in 5 in
30% acetonitrile (ACN ) with 0.1% formic acid (FA), and 40 µM aliquots of
these were loaded onto a C4 column with 100% water and 0.1% FA as solvent A
1Dr Suzanne Slade (School of Life Sciences, University of Warwick) performed tryptic digest,
protein identification and analysis by Nano LC-ESI-MS/MS.
2Philip Aston (Department of Chemistry, University of Warwick) performed analysis by
Bruker MaXis II mass spectrometer.
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and 100% ACN with 0.1% FA as solvent B using a 3-step gradient (75% of
solvent A for 16 min, 100% of solvent B for 5 min and 75% of solvent A for 11.5
min) and eluted directly into the Bruker MaXis II mass spectrometer. The
resulting total ion count (TIC) data (summed intensity across the entire range
of masses being detected at every point in the analysis) was extracted and mass
averaged in the region containing the proteins of interest, and deconvoluted
using the Data Anaysis Software (Bruker Daltonik GmbH; Bremen, Germany).
To confirm the identity of expressed proteins, samples were analysed before
TEV digestion (i.e. with the presence of his-tag), by mass spectrometry.
Resulting spectra were averaged (see Table 2.10). Full-length his-tagged
CPG223-415, CPG2CAT and CPG2DIM were identified at the exact molecular
mass predicted ± 1 Dalton, containing the gene sequence. For CPG2 the
[M+H]+ ion was observed at 45477.9 Da (expected molecular ion mass including
the his-tag is 45478.6 Da), for CPG2CAT at 33889.7 Da (expected molecular ion
mass is 33889.4 Da) and for CPG2DIM at 15649.1 Da (expected molecular ion
mass is 15649.7 Da). For his-tagged CPG2CAT’, the [M+H]+ ion was observed
at 22922.9 Da (expected molecular ion mass is 22580.6 Da) with 342.3 Da of
excess mass, which appeared to show post-translational modifications of
phosphogluconoylation of His-tag in E.coli (258 Da), and a combination of
multiple post-translational modifications (i.e. acetylation + 42 Da) at di erent
sites (i.e. di erent amino acid such as Ser, Thr or Lys) could also explain the
remaining 84 Da of excess mass (Cain et al. 2014). The spectra showed some
impurities remaining after the first a nity chromatography, but the highest
intensity peak was the [M+H]+ peak. All CPG223-415 mutants were also
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identified at the exact molecular mass predicted ± 1 Dalton, except for E175A
and E200A, which were at the molecular mass predicted ± 2 Daltons.
Table 2.10: Mass average of all expressed constructs (without TEV protease cleavage) obtained
from LC-ESI UHR QTOF mass spectrometry.
Constructs Calculated Mass
(Da)
Observed Mass
(Da)
Mass Shift (Da)
CPG223-415 45478.6 45477.9 -0.7
CPG2CAT 33889.4 33889.7 +0.3
CPG2CAT’ 22580.6 22922.9 +342.3
CPG2DIM 15649.7 15649.1 -0.6
H112A mutant 45412.6 45411.7 -0.9
H385A mutant 45412.6 45411.8 -0.8
E175A mutant 45420.6 45418.7 -1.9
E200A mutant 45420.6 45418.7 -1.9
D141A mutant 45434.6 45433.7 -0.9
K208A mutant 45421.5 45420.8 -0.7
S210A mutant 45462.6 45461.8 -0.8
T357A mutant 45448.6 45447.7 -0.9
Mass Spectrometry.
A simple protocol for the analysis of intact proteins by matrix-assisted
laser-desorption / ionisation time-of-flight mass spectrometry (MALDI-TOF
MS), utilising a mixture of sinapinic matrix. The degree of isotope
incorporation after labelling (i.e. e.g. 13N/13C/2H labelling), his-tag removal by
TEV protease and sample homogeneity were also rapidly analysed using
MALDI-TOF MS on an Autoflex Speed instrument (Bruker, UK). The protein
samples were bu er exchanged into 20 mM ammonium acetate using Amicon
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Ultra centrifugal filters with a 20 kDa MWCO (Millipore, UK). One microliter
of the protein solution was spotted onto the target MALDI plate and then
overlaid with two microliters of the matrix consisting of a saturated solution of
sinapinic acid or 2-Cyano-3-(4-hydroxyphenyl) acrylic acid (Sigma, UK) in 50%
acetonitrile (Sigma, UK) and 2.5% trifluoroacetic acid (Sigma, UK). The data
was acquired with FLeX Control software and processed using FLeX Analysis
software by Bruker (Coventry, UK).
2.2.9 Protein Folding Assessment.
Bu er Screen.
Initially, three bu er conditions were tested to extend the stability of CPG223-415
and these are summarised in Table 3.3 in Chapter 3. To improve long-term
solubility, stability and sample conditions, we applied the hanging drop method
used in X-ray crystallography (Ducat et al. 2006). The conditions tested were
the pH (5.2, 5.5, 6, 6.5, 7, 7.1, 7.42 7.48, 8.05 and 8.53), the type of salt (NaCl,
NaBr, LiCl, KCl, KSCN, Na2SO4, and Arg and Glu) and salt concentration (50,
100, 150 and 200 mM). Bu er solutions were prepared at 50 mM with sodium
citrate at pH 5, sodium potassium bu er from pH 5 to 7, with Tris bu er from
pH 7.5 to 8.5, with HEPES bu er at pH 7, with MOPS bu er pH 7 and with
PIPES bu er at pH 7. Each bu er solution was pH adjusted after addition
of salt (the final pH of each bu er solution is shown in Table 3.3 in Chapter
3). To determine optimal bu er conditions, the influence of bu er conditions on
concentrated protein sample ( ¥ 23 mg/mL) was determine using the hanging
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drop set up with 24 well-tissue culture plates and and glass cover slips (Ducruix
and Giege 1999). 1 µL aliquots of protein solution and 1 µL of 50 mM reservoir
bu er solution were pipette onto the cover slips. The cover slip was inverted and
sealed onto the wells using para n. The plates were left at room temperature
for vapour di usion to take place. The amount of precipitate were checked after
5 and 11 days by visually examining under the microscope
Spectroscopy Assay for CPG2.
The activity of CPG2 was estimated by measuring its ability to cleave
methotrexate (MTX, which absorbs at 320 nm) into two non-absorbing species
(Figure 2.2). In the assay, a 50 µL aliquot of CPG2 solution (20 mM Tris-HCl
bu er, pH 8) was added to a 1 mL quartz cuvette containing 900 µL of the
assay bu er (0.1 M Tris-HCl, 0.2 mM ZnCl2, pH 7.5) and 50 µL of 0.6 mM
methotrexate solution (0.1 M Tris-HCl, 0.2 mM ZnCl2, pH 7.5) pre-equilibrated
to 37¶C before addition of CPG2. The absorbance at 320 nm was measured
using a Perkin Elmer Lambda 35 UV/VIS Spectrometer with Peltier
temperature control unit for 1 minute, in timesteps of 2 sec, and absorbance
versus time (min) was plotted for each sample. The slope was calculated for the
linear portion of the plots. By default, this is defined as occurring between 0
and 1 min. The value of the slope was adjusted to take into account the dilution
factor for the enzyme solution and the enzyme activity was obtained in
units/mL. One unit is the amount of enzyme required to catalyse the hydrolysis
of 1 µmol MTX per minute at 37¶C. The absorbance of the assay bu er (blank)
was subtracted from all measurements.
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To test a potential inhibitor of CPG2, it was diluted with the assay bu er.
The final concentration of the solution depended on the solubility of the
material in the bu er. The solution was stored at -20¶C. For a standard assay,
assay bu er (900 µL) is pipetted into a cuvette and 0.6 mM MTX solution (100
µL) is added. If an aliquot of a test solution is added to the cuvette, the volume
of assay bu er added is reduced by the corresponding amount.
Figure 2.2: Hydrolysis of MTX measured at 320 nm.
Circular Dichroism (CD).
The protein sample was prepared in 20 mM Tris using between 0.1 and 0.2
mg/mL protein concentration. Measurements were recorded using a J-715
spectrophotometer or a Jacso J-1500 spectropolarimeter (Jasco, UK) using a 0.1
mm pathlength quartz cuvette (Starna, UK) at 25¶C. Spectra were recorded
between 280 and 190 nm, with a bandwidth of 2 mm, a scanning speed of 100
nm/min and 8 number of scans. For every sample, the solvent sample was
recorded and subtracted from the corresponding sample spectrum.
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2.2.10 NMR Experiments.
15N-1H Heteronuclear Single Quantum Correlation (HSQC)
Experiment.
It should be mentioned that CPG223-415, CPG2CAT, CPG2CAT’ and CPG2DIM
without a his-tag were used for NMR studies (See Table 2.3). Each NMR
samples of 180 µL contained approximately 0.4 mM protein dissolved in 20 mM
Tris bu er (pH 7.2) containing 100 mM NaCl. Spectra were collected using 3
mm diameter NMR tubes made for the Bruker MATCH™ System on either a
700 MHz Bruker Avance spectrometer (Bruker, UK), equipped with a
cryoprobe, housed at the University of Warwick or on a 900 MHz Bruker
AVANCE III spectrometer (equipped with a cryoprobe) housed at the Henry
Wellcome Building for NMR (HWB-NMR) at the University of Birmingham,
UK. Two-dimensional 15N-1H heteronuclear single quantum correlation (HSQC)
spectra using hsqcf3gpphsi (Bodenhausen and Ruben 1980; Piotto et al. 1992;
Sklenar et al. 1993) and trosyetf3gpphsi (Czisch and Boelens 1998; Pervushin
et al. 1998; Meissner et al. 1998; Weigelt 1998; Rance et al. 1999; Zhu et al.
1999) were acquired at 298 K, 303 K and 310 K with 2048◊128 data points and
256 scans at 700 MHz and/or 900 MHz. Water suppression was achieved using
3-9-19-pulse sequence with z-gradients (Piotto et al. 1992; Sklenar et al. 1993).
The carrier positions were set to 114.994 ppm for 15N and 4.719 for 1H, the
spectral widths were 14 ppm in the 1H the dimension and 40 ppm in the 15N
dimension. Spectra recorded were referenced to residual water. Data were
processed using TOPSPIN 3.1 by Bruker (Coventry, UK) and analysed using
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NMRFAM-SPARKY (Kneller and Kuntz 1993; Lee et al. 2015).
Saturation-Di erence-Transfer NMR Experiment (STD-NMR
experiment).
Bu er, protein stock and ligand stock solution preparation. A 5 mL bu er
solution (20 mM deuterated-Tris, 0.1 M NaCl, 0.2 mM ZnCl2, pH7.2) in 100%
D2O was prepared. Unlabelled CPG2 protein (see Section 2.2.3) was lyophilised
for STD-NMR experiments and dissolved in the appropriate amount of bu er
solution to make up a 40 µM stock solution when required and a final ligand
stock solution of 5 mM was prepared (ligands were provided by Mologic Ltd,
Bedford).
STD-NMR: set-up. All NMR spectroscopy experiments were performed on
a Bruker Avance 700 MHz instrument equipped with a 5 mm cryoprobe. NMR
samples were prepared in 180 µL of 100% D2O bu er containing 20 mM tris bu er
pH 7.2 (uncorrected for D2O), for the CPG2 samples.
For STD NMR experiments, a pseudo-2D version of the STD NMR sequence
was used for the interleaved acquisition of o - and on-resonance spectra: 1D
STD with spoil and T2 filter using excitation sculpting for water suppression
(stddi esggp.3). O - and on-resonance spectra were acquired separately and
subtracted manually to obtain the STD spectrum. For selective saturation, the
on-resonance frequency was set to -301 Hz (-0.43 ppm) or -700.24 Hz (-1 ppm),
whereas the o -resonance frequency was set to 30,000 Hz (42.8 ppm). Spectra
recorded were referenced to residual water. In all cases, blank experiments (in the
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absence of protein), were performed to test the lack of direct saturation to ligand
protons and select the appropriate on-resonance frequency. Saturation times was
set at 2 s and relaxation delay 3 s. Typically, the number of scans was 8, with 4
dummy scans.
Binding isotherms from STD amplification factors. The concentration of
protein used was 20 µM of CPG2 for ligand binding. Ligands were titrated into
the corresponding protein samples from concentrated stock solutions. Each time
a y µL of ligand was added, also y µL of 40 mM solution of CPG2 was added in
order to keep the concentration of CPG2 constant throughout the titration. In
STD-NMR experiments, at a given ligand concentration, the STD intensity of a
given proton can be considered to be directly proportional to the fraction of
bound ligand (fLB) (Angulo et al. 2010; Viegas et al. 2011).
fLB =
[PL]
[L] =
(Io ≠ Isat)
Io
(2.3)
STD-AF, defined by Mayer and Meyer as the product of fLB by the ligand excess
(EL= [L][P ]). Hence:
STD ≠ AF = (Io ≠ Isat)
Io
◊ [L][P ] (2.4)
Plotting STD-AF values at increasing values of [L] gives rise to a Michaelis-
Menten hyperbolic dose-response as described by equation:
STD ≠ AF[L] = STD ≠ AFmax[L][L] +KD (2.5)
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Where STD≠AFmax is a dimensionless scaling factor representing the maximum
STD amplification factor for the monitored signals. Mathematical fitting yields
to both parameters: KD and STD ≠ AFmax.
For each ligand concentration, STD-AF build-up curves were recorded. To
determine KD values following the standard procedure, the STD-AF values (at
a given saturation time) of a ligand proton were plotted as a function of the
concentration of ligand, and the resulting curve was mathematically fitted to the
dose-response equation (2.5), to yield to KD.
Equilibrium Kinetics of Binding
[P ] + [L]⌦ [PL] (2.6)
Fraction of bound ligand is fLB = [PL][P ]+[L] , but since [L] > [P], we can make the
following approximation:
fLB ¥
[PL]
[L] (2.7)
2.2.11 X-ray Crystallography.
Growth of Protein Crystals.
Precipitants were used to grow proteins crystals by precipitation from aqueous
solutions. There are diverse precipitants, including salts, organic solvents and
polymers (e.g. PEG) and combinations of various types of precipitants can be
used. Other criterion also influence crystal growth, such as precipitant
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concentration, pH and temperature (Boistelle and Astier 1988). In order to find
appropriate conditions for crystallisation of a protein, screening was achieved
over a range of di erent conditions to see when crystals were formed and after
that optimisation of those conditions was usually needed to improve the
crystals.
The procedure of growing crystals usually involves addition of the
precipitants to a aqueous solution of the protein in a concentration just below
what is needed for precipitation. After that, the water is evaporated slowly until
precipitating conditions was reached. The method used for crystallisation was
vapour di usion. This method is based on the technique described by Unge
(1999). A droplet of purified protein solution mixed with a crystallisation
solution is deposited onto a cover glass. The crystallisation solution often
consists of bu er, salt and precipitant. The cover is suspended above a reservoir
of crystallisation solution. Due to concentration gradient, the water from the
drop evaporates towards the reservoir, thus lowering the volume of the drop and
increasing the protein concentration. This will result in supersaturation of the
protein solution and crystals will start to form (Unge 1999). Vapour di usion
can be performed in di erent ways, for example hanging drop and sitting drop,
as shown in Figure 2.3.
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Figure 2.3: Di erent vapour di usion system. A) Hanging drop and B) sitting drop
setups. Adapted from Unge (1999).
Co-Crystallisation.
Protein-ligand interactions can also be studied with X-ray crystallography. For
this, crystals of protein-ligand complexes are needed. There are di erent ways of
achieving this, including soaking and co-crystallisation. These two methods were
used (Hassell et al. 2007).
Soaking: This method implicates transferring the protein crystals into
crystallisation solution that contains the ligand. The ligand can di use through
water channels in the crystal and thereby reach the active site. A requirement
for this method is that the protein crystals are functional for binding ligands.
This can vary for di erent ligands and the soaking process can be a ected by
solubility, size and shape of the ligand.
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Co-crystallisation: The ligand and protein are mixed and crystallised
together. This method is more time-consuming and requires more protein. The
crystal structure can di er with di erent ligands and might not be the same as
for crystals of the protein without ligand, and requires a new screening to
achieve crystals.
Crystal Analysis.
Hanging drop setups were prepared manually using 24-well tissue plates as
described in Chapter 3. However, sitting drop trays were set up using
Honeybee® 963 and Mosquito® LCP3 crystallisation robots to screen 96◊1 mL
trays. For each ligand (CP06 and CP67) three 96-condition crystallisation
screens were used; JCSG+, PACT and Morpheus purchased from Molecular
Dimensions Ltd. (Su olk, UK). Crystallisation screening was performed using
reservoir volumes of 50 µL, and 2 µL sitting drops comprising 1 µL of protein
solution and 1 µL of reservoir solution. The six trays were stored in a constant
temperature room at 18¶C and inspected daily using an Olympus
SZ4045TR-PT microscope.
In both setups, generated crystals were tested with X-rays4. Crystals that
di racted to better than 4 Å resolution were taken to the the Diamond
Synchrotron Source in Oxford. Model building for the crystals, that were tested
so far at the synchrotron, was done by molecular replacement, as we already
3Dr Dean Rea (School of Life Sciences, University of Warwick) set up sitting drop screening
using Mosquito LCP crystallisation robot.
4Dr Karen Ruane (School of Life Sciences, University of Warwick) tested crystals for
di raction, collected the data at Diamond Synchrotron Source in Oxford and solved the
structure.
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had a coordinate set to work with (PDB: 1CG2) (Rowsell et al. 1997).
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Protein Preparation for NMR
Spectroscopy and X-ray
Crystallography Studies
3.1 Introduction.
Due to its wide use in cancer therapy, there has been a massive need for high
yield expression of CPG2. The first goal of this work was development of an
E. coli-based protocol for overexpression of CPG2 in a soluble form. E. coli
was a more attractive alternative to Pseudomonas sp. RS-16, previously used to
produce CPG2 for crystallography studies, as it o ers shorter culturing time, fast
high density cultivation and easier genetic manipulation than Pseudomonas, the
natural CPG2 source (Rowsell et al. 1997). Because Pseudomonas and E. coli
di er greatly in their relative codon-usage, the CPG2 gene from Pseudomonas sp.
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strain RS-16 was codon-optimised and cloned into a pET28a vector for maximum
expression in BL21 (DE3) E. coli strain (Goda et al. 2009). In spite of all these
qualities, expression of CPG2 with E. coli as the host resulted in high yields of
the protein, but in its insoluble form (Goda et al. 2009). Such proteins, forming
dense aggregates (i.e. inclusion bodies), are frequently improperly folded and
thus biologically inactive (Singh and Panda 2005).
In the context of this project, it was vital to express high-yields of CPG2 in
its soluble and active form in order to preserve the integrity of the protein fold
for future structural studies.
3.2 Expression of Codon-Optimised Full
Length CPG2 in E. coli Leads to
Intermittent Activity and Existence of Two
CPG2 Subspecies.
A number of tactics for the redirection of proteins from inclusion bodies to soluble
cytoplasmic fractions are described in the literature. In general, they can be
divided into methods where the expression strategy is modified to obtain soluble
expression and methods where the protein is refolded from inclusion bodies. In
our study, refolding from inclusion bodies, as described previously by Goto and
Kay (2000), was considered undesirable due to lengthy and complex refolding
protocols and the likelihood of poor recovery yields, increasing the expense of
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each sample upon expression in isotopically 13C/15N-enriched minimal media.
Accumulation of denatured protein can be minimised by optimisation of a number
of environmental factors (Sørensen and Mortensen 2005). To increase the levels
of soluble full-length CPG2 in vivo, a range of diverse expression conditions were
initially tested using small-scale cultures.
3.2.1 Testing Di erent E. coli Strains for Higher
Solubility.
Firstly, two E. coli mutant strains of BL21 (DE3), namely the C41 (DE3) and
C43 (DE3) strains known to promote soluble protein expression in previous
studies, were tested at 20¶C using 1 mM IPTG to induce protein expression
(Figure 3.1) (Miroux and Walker 1996). Interestingly, C43 (DE3) cell growth
was limited: the optical density never exceeded OD600 of 0.1 and never entered
the exponential growth phase. However, C43 (DE3) expressed CPG2 (Figure
3.1-A). No enhancement of soluble CPG2 expression was observed and overall
expression in C43 (DE3) was comparable to that observed in BL21 (DE3),
hence BL21 (DE3) was selected as the host (Figure 3.1-B).
76
Chapter 3
S IM
148
98
64
50
36 – CPG2
(a) C41 (DE3).
– CPG2
S I
(b) BL21 (DE3).
Figure 3.1: Expression in di erent E. coli strains. SDS-PAGE gel showing (M) protein
marker, (I) insoluble and (S) soluble fractions after expression of CPG2 using A) C41 (DE3)
and B) BL21 (DE3) with 1 mM IPTG at 20¶C for 4 hours.
3.2.2 E ect of Changes in Temperature, IPTG
Concentration and Induction Duration.
Reduction of the expression temperature and IPTG concentration are also
commonly used approaches to limit in vivo protein aggregation in BL21 (DE3)
(Weickert et al. 1996). However, a sudden decrease in temperature can
negatively a ect, transcription and replication (Shaw and Ingraham 1967).
Hence, it is vital to screen for di erent induction concentrations and expression
durations that would result in higher levels of protein expression at this
temperature.
Thus, a number of IPTG induction concentrations ranging from 0.1 mM to
0.9 mM have been tested as seen in Figure 3.2. Induction for 4 hours expression
(Figure 3.2-A) indicated lower expression of the protein compared to 24 hours
(Figure 3.2-B) and 48 hours expression (Figure 3.2-C). In general, IPTG
concentration had little impact on CPG2 expression level, but the length of
expression duration had a significant impact on the expression level. At
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concentrations above 0.7 mM at the di erent expression durations, we clearly
observed a lower expression of soluble protein, but the protein band in the
soluble fraction had the same intensity when induced at concentration as low as
0.5 mM. Hence the yield, when using BL21 (DE3) as a host, was significantly
improved by the use of low induction temperature (15¶C) and a 24 hours
expression duration in both rich and minimal media (Figure 3.2-B).
W I S W I S W I S
CPG2 –
0.
1
m
M
0.
3
m
M
0.
5
m
M
W I S
0.
7
m
M
W I S
0.
9
m
M
(a) 4 hours expression.
ISI SI SI S
0.
1
m
M
0.
3
m
M
0.
5
m
M
0.
7
m
M
0.
9
m
M
SI
CPG2 –
(b) 24 hours expression.
S I SI SI SI S I
0.
1
m
M
0.
3
m
M
0.
5
m
M
0.
7
m
M
0.
9
m
M
CPG2 –
(c) 48 hours expression.
Figure 3.2: Testing di erent IPTG induction concentration and expression duration
at 15¶C. SDS-PAGE gel showing (W) whole cells, (I) insoluble and (S) soluble fractions
showing expression levels of CPG2 after A) 4, B) 24 and C) 48 hours incubation periods with
0.1, 0.2, 0.5, 0.7 and 0.9 mM IPTG concentrations. SDS-PAGE samples were normalised to
OD600 of 6.
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3.2.3 Presence of Possibly Two CPG2 Isoforms.
Full-length CPG2 was successfully expressed and purified from BL21 (DE3) cells
under control of the T7 lac promoter system, grown from either 2◊YT media for
natural isotopic abundance. The ideal assay to evaluate the quality of the soluble
CPG2 produced was the enzymatic activity based on cleavage of the substrate
MTX (see Section 2.2.9 of Chapter 2).
However, the enzymatic activity of replicate batches of CPG2 preparations
showed high inconsistency (Figure 3.3-A). SDS-PAGE gels indicated the
presence of two bands close to the expected molecular weight of CPG2 (see
bands indicated by arrows in Figure 3.3-C, left panel). In-gel tryptic digestion
and protein identification using mass spectrometry was performed to identify
the band of interest, as it was expected that the two populations corresponded
to CPG2 with and without signal peptide. Results showed that both bands
corresponded to di erent isoforms of full-length CPG2 (Figure 3.3-C, right
panel), although the intensities of the bands were quite di erent. It was thought
that perhaps only one of the proteins was contributing to the enzymatic
activity, which would account for the poor batch-to-batch reproducibility of the
activity assay (Figure 3.3-A). CPG2 contains an N-terminal hydrophobic signal
sequence that directs it to the periplasm of Pseudomonas sp. Strain RS16. The
protein identification using mass spectrometry data1 (Figure 3.3-C, right panel)
suggest that reducing the temperature of induction (and thus expression level)
did not lead to expression of CPG2 in its soluble, periplasmic form in the
1Dr Suzanne Slade (School of Life Sciences, University of Warwick) performed tryptic digest,
protein identification and analysis by Nano LC-ESI-MS/MS.
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mature form containing no signal sequence.
Estimation of the secondary structure content via DichroWeb analysis of
the CPG2 CD spectrum (Figure 3.3-B, see dotted line) yielded 9% –-helical and
47% —-sheet content (Whitmore and Wallace 2004; Whitmore and Wallace
2008). Comparison of these to the values obtained from the crystal structure
(PDB ID: 1CG2; 38% helix, 26% sheet) suggest that the full-length CPG2 is
improperly folded (Rowsell et al. 1997).
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Figure 3.3: Expression of CPG2 in the pet28a vector revealing the presence of
two immature isoforms. A) Activity assays of the purified CPG2 using the same construct
indicating inactivity over time, B) CD spectrum of immature CPG2 and C) SDS-PAGE gel (left
panel) illustrating the presence of two CPG2 isoforms during purification. Mass spectrometry
(right panel) analysis of the two bands of interest (results for bands 1 and 2 are shown
respectively in top and bottom strips) with 47% and 49% similarity to immature (full-length)
CPG2 protein sequence. It should be noted that the signal peptide is present in both bands.
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3.3 Production of Soluble and Active CPG2.
Two approaches were then considered in order to express biologically active
soluble protein using BL21 (DE3) as a host. The first was removal of the
N-terminal signal peptide sequence, which is unlikely to be recognised by E.
coli, to generate soluble cytoplasmic protein. The second was replacement of the
native signal peptide (residues 1-22) with a leader sequence (i.e. pelB) used for
periplasmic localisation in E. coli bacterial strains (Choi and Lee 2004). The
latter usually produces much lower yields since not all expressed protein is
secreted into the periplasm.
Therefore, the first option was prioritised, as it restricts the localisation of
the protein to one compartment of the cell (cytoplasm).
3.3.1 Removal of the Signal Peptide Induces Expression
of a Single, Soluble CPG2 Species.
The pET28a plasmid containing the full-length CPG2 gene was used as a template
to generate a cDNA sequence of CPG2 without the leader sequence (CPG223-415),
which was then subcloned into the pET151-D-TOPO vector (Invitrogen) and
expressed and purified as detailed in Materials and Methods (Figure 3.4).
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Figure 3.4: Agarose gel electrophoresis (2%) of PCR products. The left panel shows
amplification of the gene of interest (without signal peptide, CPG223-415) using pet28a vector
(expected size fragment at 1.3 kb). lane 1 : PCR product (expected size 1.3 kb) and lane L:
1kb DNA ladder (Generuler). Right panel displays colony screening by PCR for gene of interest
using T7 forward and reverse primers. Only colony 6 displayed a positive clone (expected size
fragment at 1.4 kb).
Removal of the signal peptide led to a single-band (Figure 3.5-A, lanes 1-5)
and a 6-fold increase in protein expression yield (Table 3.1).
Table 3.1: Di erence in expression yield between wild-type CPG2 and CPG223-415.
Constructs His-tag Activity Specific Protein Yield†
Terminus U/mL Activity
U/mg
Unlabeled 15N 2H/13C/15N
(2◊YT) (M9) (M9)
(His)6-CPG2 N 32.9 5.6 38.6 nd‡ nd
(His)6-CPG223-415 N 100.26 75.5 251.6 nd 70-109.42
† Yields of purified proteins are in mg/L of culture.
‡ Not determined.
His6-CPG2 was purified and the his-tag was cleaved according to the
protocol described in Section 2.2.6. Because Ni2+ IMAC purification was not
e ective at isolating CPG2 from His6-CPG2, an extra gel filtration purification
step was introduced (Figure 3.5-B). The purified CPG223-415 was then tested for
its ability to catalyse the hydrolysis of MTX. Figure 3.5-C demonstrates that
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CPG223-415 was able to hydrolyse MTX with an enzymatic activity of 100.26
U/mL (Table 3.1), indicating that the recombinant enzyme produced in its
soluble form is biologically active. Circular dichroism measurements of
CPG223-415 in the wavelength range between 190 nm and 280 nm were
performed, and suggest 53% –-helical / 20% —-sheet content after fitting of the
data using DichroWeb (Figure 3.5-D) (Whitmore and Wallace 2004; Whitmore
and Wallace 2008). These values are in better agreement with those predicted
from the crystal structure (i.e. 38% helix, 26% sheet), and suggest that the
presence of the signal peptide was preventing proper folding of the enzyme
(Rowsell et al. 1997).
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(a) Expression and purification. (b) FPLC
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Figure 3.5: Expression and characterisation of CPG223-415. A) Top: SDS-PAGE
gel purification, bottom: western blot, M denotes the protein marker, 1 to 5 are the eluted
sample after nickel chromatography a nity purification, PD10 indicates presence of the protein
after desalting, lane 0 h refers to incubation with His-TEV protein at 0h and the following
lane after 48 h of incubation, lanes FT and E show the his-tag free CPG2 and eluted His-
TEV collected in the flow-through and the eluent respectively after a second round of nickel-
a nity chromatography column. B) Gel filtration chromatography the arrow indicates elution
of untagged protein. C) CPG223-415 enzymatic activity assay against methotrexate substrate.
D) Circular dichroism in the 190-280 nm region for the wild-type CPG2 and CPG223-415.
3.3.2 Purification of CPG223-415 by Gel Filtration
Chromatography.
Elution fractions from IMAC containing CPG223-415 were next applied to PD10
desalting columns (see Section 2.2.6) and further purified by Gel Filtration
Chromatography (see Section 2.2.7). Improved separation of CPG223-415
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proteins was achieved by applying samples that had been concentrated using 30
kDa MWCO concentrators (see Section 2.6.8) to a HiLoad 16/600 Superdex 75
g GL column (separation range 1-120 kDa), under an isocratic gradient of 100%
A (20 mM Tris, 100 mM NaCl, pH 8). As shown in Figure 3.6, the protein
eluted as a double peak at elution volumes of 62.9.4 mL for dimeric CPG223-415
and 52.4 mL for monomeric CPG223-415.
By applying Gel Filtration standards to the column and running at the
same flow rate and with the same bu er (see Section 2.2.7), it was possible to
create a calibration curve of molecular weight against elution volume, assuming
a void volume of 25.0 mL (Figure 2.1). Plotting the relative retention times of
CPG223-415 proteins on this curve gave predicted molecular weights of around 43
kDa and 103 kDa (calculated monomeric peak for CPG223-415 is 42,284 Da), and
therefore CPG223-415 is expected to migrate and exist in monomeric and dimeric
forms (Figure 3.6). Only the eluted fractions corresponding to the monomeric
CPG223-415 peak were collected for NMR spectroscopy.
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Figure 3.6: Calibration curve obtained with Gel Filtration standards on HiLoad 16/600
Superdex 75 g GL column. An isocratic gradient of 100% of bu er A (20 mM Tris, 100
mM NaCl, pH 8) was used. The calibration curve graph represents the gel phase distribution
coe cient Kav versus the molecular weight (MW). Kav = (Ve-Vo)/(Vc-Vo), where Ve = elution
volume, Vo = column void volume, Vc = geometric column volume. Straight line is the
calibration curve calculated from the data for molecular weight standards (see Section 2.2.7
and Figure 2.1). Using the equation for the line, values for the molecular weights of CPG223-415
were calculated and plotted on the graph.
3.4 High-Yield Expression of Isotopically
Labelled Protein for NMR Studies.
2H/13C/15N-enriched protein samples are essential for high-resolution structural
studies of large proteins using NMR. To achieve this, protein expression must be
carried out in M9 media so the investigator has full control over the sources of
carbon, nitrogen and hydrogen utilised by the cell. Expression trials were
carried out for CPG223-415 in M9 media, followed by purification. SDS-PAGE
analyses and estimation of concentration using the BCA assay indicated over
50% reduction in soluble protein yield of CPG223-415 upon switching the
medium from 2◊YT to M9 (Figure 3.7)
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Figure 3.7: Comparison of CPG2 expression in 2◊YT and M9 media. SDS-PAGE
gel showing (M) protein marker, (I) induced CPG2 expression with 0.5 mM IPTG for 18 hours
at 15¶C in left panel 2◊YT medium and right panel M9 medium. The CPG2 protein band is
indicated with a black arrow.
The e ect of incubation temperature on BL21 (DE3) cell growth and
CPG223-415 expression was therefore investigated by analysing the E. coli optical
density after inoculation, as it can be graphically translated into growth curves.
Cell growth in rich medium did not reach the stationary phase and stayed in the
beneficial exponential phase for expression at optical densities as high as 6
(Figure 3.8, solid lines). Conversely, when cells were grown in M9 (Figure 3.8,
dotted lines) stationary phase was reached more rapidly. 2◊YT medium is
abundant in critical nutrients, necessary for the bacteria to multiply quickly
without depleting the host cells of these rudimentary nutrients. As opposed to
2◊YT, M9 is a minimal medium only containing salts and nitrogen, which can
usually be supplemented with labelled carbon and / or amino acids to make a
complete medium for labelled NMR sample preparation. Therefore, cell growth
in M9 correlates to a quicker formation of an unfavourable environment for
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bacteria, due to depletion of lower level of nutrients to start with, which may
explain the lower protein yield. The death phase was not reached in the first 15
hours observed, in either of the media used (Figure 3.8). The latter reveals that
if cells are taken at the stationary phase and moved to a fresher M9 media, they
still have a possibility of reaching the exponential phase.
0 2 4 6 8 10 12 14 16
0
1
2
3
4
5
6
7
8
 M9, 30°C
 M9, 37°C
 2xYT, 30°C
 2xYT, 37°C
O
pt
ic
al
 D
en
si
ty
 (6
00
 n
m
)
Time (hour)
Figure 3.8: Growth curves of cultures post-inoculation with minimal (M9) and rich
2◊YT media at di erent temperatures. Cell growth was tested at di erent incubation
temperatures, 30¶C and 37¶C, with the OD600 of bacterial growth samples being recorded at
one hour intervals. Bacterial cells post-inoculation were able to grow at temperatures as low
as 30¶C and as high as 37¶C in both media, with 37¶C being optimal. 2◊YT growth curves
obtained are consistent with 2◊YT being a nutritionally rich media. On the other hand, as
expected, cell growth in M9 rapidly attained the stationary phase at an OD600 of 3.5.
To reduce the cost of each labelled sample, the results arising from the
e ect of M9 on cell growth (Figure 3.8) and the innovative expression method
described by Sivashanmugam et al. (2009) were used to increase cell density
without interfering with the expression vector (referred to herein as the cell
condensation method). Firstly, a double colony selection was performed (Figure
3.9-A) (Marley et al. 2001). Rich medium (50% D2O) was inoculated with
freshly transformed cells, grown at 37¶C overnight, and spread onto an M9 agar
plate containing 50% D2O. Each colony was checked for expression in 10 mL M9
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with 50% D2O through the usual IPTG-induction method (Figure 3.9-A, left
panel). The colony exhibiting the highest-level CPG223-415 expression was used
for a second round of selection (Figure 3.9-A, left panel, colony 3). Since
high-levels of perdeuterated protein were required, the second round of selection
was conducted in 100% D2O. The colony displaying the highest levels of
CPG223-415 expression under these conditions was picked (Figure 3.9-A, right
panel, colony 13). The colony-to-colony variability in CPG223-415 expression
levels highlights the need to screen colonies at this stage to obtain optimal
expression levels.
After double-colony selection, the cell condensation method was used
(Figure 3.9-B) (Sivashanmugam et al. 2009). The cells were grown to an
OD600=1 in the absence of isotopes in rich medium in order to generate a large
amount of cell mass, then gently spun down and resuspended in a condensed
volume of isotope-enriched minimal media for expression. The degree of
condensation yielding maximal expression di ers depending on the protein
expressed, and must be investigated. Small-scale time-course experiments were
carried out for 1-fold, 2-fold, 4-fold and 8-fold condensations (respectively 100%,
50%, 25% and 12.5% of the initial volume), and CPG223-415 expression was
evaluated using SDS-PAGE and western blots (Figure 3.9-B). Visual inspection
of blots indicated that 2-fold and 4-fold condensation produced optimal yield
and resulted in to a four-fold decrease in the cost of protein samples (as
compared to conventional labelling, e.g. 1-fold) and generated 70-109.42 mg of
labelled protein per litre of bacterial culture (Table 3.1).
89
Chapter 3
(a) Double Colony Selection.
(b) Condensation method.
Figure 3.9: SDS-PAGE gels of double colony selection and condensation method. To
evaluate the amount of CPG223-415 on the western blots, the volumes of samples loaded onto the
gels were normalised with respect to the concentration of the cells in the pre-induction sample
(lane NC and 0 ). A) SDS-PAGE of protein expression of CPG223-415 after first colony (lanes 1-
7 ) and second colony selections (lanes 8-14 ). The black arrow indicates CPG223-415 expression
levels during the double selection method in the di erent colonies and each asterisk indicated
the colony selected after each step. B) E ect of condensation on CPG223-415 expression level.
1x, 2x, 4x and 8x labelled lanes indicate the condensation factor which corresponds to 100 mL,
50 mL, 25 mL, and 12.5 mL relative to the initial volume of rich medium used for cell growth
(100 mL) pre-induction (lane 0 ), post-induction (lanes 16, 18, 20, 22 and 24, IPTG induction
duration hours). These concentrations were investigated for CPG223-415 protein expression
(indicated by an arrow) using Western-Blots (top) and SDS-PAGE analysis (bottom).
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Isotopically labelled CPG223-415 migrated similarly to unlabelled
CPG223-415 on SDS-PAGE gels, thus MALDI-TOF mass spectrometer was used
to examine whether in vivo incorporation of heavy 2H, 13C an 15N labels into
CPG223-415 was acceptable for NMR studies. Figure 3.10-A shows the result of
the mass spectrometer analysis of pure CPG223-415. Assuming 100% label
incorporation, the theoretical molecular weight is 49,193 Da, a 6,809 Da greater
than the theoretical unlabelled protein molecular weight of 42,384 Da (3.10-B).
The main peak observed in Figure 3.10-A was at 49,155.94 Da illustrates the
label enrichment to be >90%, which is suitable for NMR analyses. The absence
of 100% labelling is possibly due to the labile protons in the amide groups of the
protein. The broadness of the peak is primarily due to acquisition of the mass
spectrometer data in linear mode, which is used to keep the protein intact
(impossible using reflector mode). In addition, it also demonstrates that there
was a broad distribution of labelled CPG223-415 with varying degrees of label
incorporation, as expected for protein expressed in labelled media. Mass
spectrometer also showed the presence of higher oligomeric state that required a
gel filtration step (Figure 3.5-B).
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(a) [2H, 13C and 15N]-enriched CPG223-415 preparation.
(b) Unlabelled CPG223-415 preparation.
Figure 3.10: Maldi-TOF mass spectrometer A) labelled and B) unlabelled
CPG223-415. A) Main peak observed at 49155 Da is in close agreement with expected
molecular weight of 48193 Da.B) Main peak observed at 42570 Da is in close agreement with
theoretical molecular weight of 42384 Da. In both cases, the presence of dimer (D) is noticed.
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3.5 Stability of CPG223-415 is Dependent Upon
Bu er Conditions.
While we had successfully expressed CPG223-415 in a soluble form in E. coli, the
resulting protein displayed limited long-term stability (activity deteriorated 24
hours post-purification) and a propensity to aggregate over time in Tris bu er
containing 50 mM NaCl (pH 7.2). To create a stable CPG223-415 sample for NMR
analyses (which must remain in its active, soluble state for days / weeks), a variety
of bu er conditions were tested. Salt concentrations were varied from 50 mM to
500 mM to prevent loss of sensitivity due to increased sample conductivity when
using the cryogenic NMR probe (Kelly et al. 2002). This complicated matters,
as salt concentrations can significantly a ect protein solubility and aggregation.
We were also restricted from use of glycerol, commonly used to increase protein
stability, in the bu er as it can further reduce sensitivity in downstream NMR
measurements due to a reduction in the tumbling time of the protein.
Three bu ers were tested, which were similar apart from the NaCl
concentration Table 3.2.
Table 3.2: Bu er composition for bu ers 1-3. Bu ers 1-3 used to investigate the e ect
of NaCl concentration on activity and fold of CPG223-415.
[NaPi], mM [KH2PO4], mM [KCl], mM [NaCl], mM pH
Bu er 1 10 2 2.7 500 7.2
Bu er 2 (Gomori) 20 - - 50 7.3
Bu er 3 (1◊PBS) 10 1.8 2.7 137 7.3
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As shown in Figure 3.11, the activity of CPG223-415 was significantly a ected
by changes in salt concentration (Table 3.2). The enzyme was not active in bu ers
1 and 2 (500 mM and 50 mM NaCl, respectively), but did show wild-type levels
of activity in bu er 3 (137 mM NaCl) and this activity was maintained over days.
These changes in activity were not due to changes in global enzyme structure,
since CD spectra measured in all three bu ers were largely identical (Figure 3.11-
B) and resulted in very similar secondary structure content as estimated using
DichroWeb (Figure 3.11-C) (Whitmore and Wallace 2004; Whitmore and Wallace
2008).
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Figure 3.11: Characterisation of CPG223-415 in bu ers 1-3, primarily di ering in
their NaCl content. A) Activity assay of CPG223-415 in Bu ers 1-3 (see Table 3.2 for bu er
composition) against its substrate methotrexate. B) Circular dichroism spectra. C) Percentage
of secondary structure of CPG223-415 in the three di erent purification bu ers using DichroWeb
(Whitmore and Wallace 2004; Whitmore and Wallace 2008).
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To investigate whether protein solubility could account for di erences in
the activity, CPG223-415 was solubilised using a low-conductance solution of 20
mM Tris bu er (pH 7.3) containing 50 mM L-arginine and 50 mM L-glutamate
in place of NaCl (Dötsch and Withers 2005). This approach has been used in
the past to prevent protein aggregation, achieve higher soluble protein
concentration and increase protein solubility. These bu er conditions were
initially used to screen for the best NMR conditions. Figure 3.12 shows that
CPG223-415 was active and folded 20 mM Tris bu er (pH 7.3) containing 50 mM
L-arginine and 50 mM L-glutamate. Unfortunately, this bu er did not yield
CPG223-415 stability and solubility at NMR-amenable concentrations
(approximately 0.5 mM) for over 2 days in the magnet at either 25¶C or 37¶C,
which makes it intractable for collection of standard triple resonance
experiments required for sequential assignment of large proteins.
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Figure 3.12: Characterisation of CPG223-415 in 50 mM Arg / 50 mM Glu. A)
Activity assay of CPG223-415 in 50 mM Arg / 50 mM Glu against its substrate methotrexate.
B) CD spectrum.
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The bu er composition was therefore examined more comprehensively
using the approach described by Ducat et al., in which a typical screening
technique used in crystallography studies was applied to determination of
optimal sample conditions for structural NMR studies (Ducat et al. 2006). We
tested 363 bu er conditions using their method, in which 1 µl of approximately
23 mg/mL protein sample was combined with 1 µL of various bu ers. The
precipitation pattern observed for CPG223-415 in crystallisation plates is
described in Table 3.3. In general, precipitation took place at values below pH
6, except when the concentration of NaCl was at or above 200 mM. Above pH
6, CPG223-415 remained soluble in all bu ers for at least 5 days at 18¶C, except
when arginine and glutamate were included in the bu er. The pH range within
which no precipitation was observed over longer timescales was quite limited
(essentially around physiological pH) and greatly depended on the type and
concentration of salt. The analysis of the precipitation pattern clearly indicated
that the arginine / glutamate mixtures were not appropriate in the bu er for
NMR resonance assignment, as we initially believed. Given that bu ers
containing less that 50 mM salt resulted in biologically inactive enzyme, and
that 20 mM Tris bu er containing 100 mM NaCl indicated no precipitation,
CPG223-415 samples were prepared in this bu er for further NMR resonance
assignment.
97
Chapter 3
Ta
bl
e
3.
3:
C
P
G
2
pr
ec
ip
it
at
io
n
m
at
ri
x
to
de
te
rm
in
e
pr
ot
ei
n
so
lu
bi
lit
y
an
d
st
ab
ili
ty
co
nd
it
io
ns
fo
r
N
M
R
st
ud
ie
s
us
in
g
th
e
X
-r
ay
sc
re
en
in
g
m
et
ho
d.
S
od
iu
m
C
it
ra
te
N
a
/
K
P
h
os
p
h
a
te
N
a
/
K
P
h
os
p
h
a
te
N
a
/
K
P
h
os
p
h
a
te
N
a
/
K
P
h
os
p
h
a
te
T
ri
s
T
ri
s
T
ri
s
H
E
P
E
S
M
O
P
S
P
I
P
E
S
(p
H
)
(5
.5
)
(5
.2
)
(6
)
(6
.5
)
(7
.1
)
(7
.4
8)
(8
.0
5)
(8
.5
3)
(7
.4
2)
(7
)
(7
.1
)
50
m
M
N
aC
l
*
*
*
*
*
*
*
*
*
N
aB
r
*
*
*
*
*
*
Li
C
l
*
*
*
*
*
*
*
K
C
l
*
*
*
*
*
*
*
*
K
SC
N
*
*
*
*
*
*
*
*
*
N
a 2
SO
4
*
*
*
*
*
*
*
*
*
A
rg
+
G
lu
*
*
*
*
*
*
*
*
10
0
m
M
N
aC
l
*
*
*
*
*
*
*
N
aB
r
*
*
*
*
*
Li
C
l
*
*
*
*
*
*
K
C
l
*
*
*
*
*
*
*
*
K
SC
N
*
*
*
*
*
*
*
N
a 2
SO
4
*
*
*
*
*
*
*
A
rg
+
G
lu
*
*
*
*
15
0
m
M
A
rg
+
G
lu
*
*
*
*
20
0
m
M
N
aC
l
*
*
*
*
*
*
*
N
aB
r
*
*
*
*
*
Li
C
l
*
*
*
*
*
*
*
K
C
l
*
*
*
*
*
*
*
*
*
K
SC
N
*
*
*
*
*
*
*
*
N
a 2
SO
4
*
*
*
*
*
*
*
*
A
rg
+
G
lu
*
*
*
*
*
*
T
he
as
te
ris
k
in
di
ca
te
s
no
pr
ec
ip
ita
tio
n
of
C
PG
2
in
th
e
co
rr
es
po
nd
in
g
co
nd
iti
on
af
te
r
m
or
e
th
an
el
ev
en
da
ys
.
98
Chapter 3
3.6 Preparation of Co-Crystals for X-ray
Crystallography.
Due to its therapeutic applications in the treatment of cancer and autoimmune
diseases, the three-dimensional structure of CPG2 is of great interest. Early X-
ray crystallography investigation of CPG2 demonstrated that it consists of two
domains, the catalytic domain which delivers the substrates for the two zinc
ions in the active site, and the dimerisation domain (Figure 1.3) (Rowsell et al.
1997). This crystallographic data helped to better inform early rational drug
design e orts (Khan et al. 1999), but further attempts at co-crystallisation of
CPG2 with ligands, substrates or inhibitors have not been reported and very
little progress has been made since these early studies to establish key features of
CPG2. Hence we decided to attempt co-crystallisation of CPG2 with the most
promising inhibitors CP06 and CP67 (see structures in Figures 4.1 and 4.2 of
Chapter 4).
3.6.1 Protein Preparation.
X-ray crystallography requires formation of ordered crystals and much higher
protein concentrations than those required in NMR studies, but one key
di erence is that protein samples for X-ray crystallography do not need isotopic
labelling. So far, our sample preparation did not fail any of the criteria needed
in protein preparation for crystallography. Pure samples of unlabelled
CPG223-415 were obtained successfully (Figure 3.10-B), a high yield of soluble
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protein was produced (Table 3.1), the protein was active (Figure 3.5-C) and
highly stable. The only major di erence was that the protein had to be brought
into a far more concentrated state than in natural circumstances. As noted
earlier, this fact is a rate-limiting step for NMR analyses as well. However, the
rate of concentrating the sample di ers for both techniques, and NMR requires
less concentrating than X-ray crystallography.
Before beginning X-ray trials, the protein had to be prepared with bu er
containing little to no salt. Since X-ray does not restrict from use of glycerol,
commonly used as a cryo-protectant to increase protein stability, we decided to
reduce the salt concentration to 50 mM in the optimised NMR bu er (20 mM
Tris, 100 mM NaCl, 0.2 mM ZnCl2, pH 7.3) and add 20% glycerol. In order
to screen a range of conditions, 200 µL of protein at 10-20 mg/mL, which was
required and was easily achieved using centrifugal concentrators.
3.6.2 Co-Crystallisation Attempts.
Rowsell et al. (1997) were the first to crystallise CPG2 (Rowsell et al. 1997;
Tucker et al. 1996). Hence, we decided to be guided by their final crystallisation
protocol which involved mixing 4 µL of crystallisation bu er solution [200 mM
Tris-HC1 pH 7.2; 12% (w/v) polyethylene glycol 4000, 200 mM zinc acetate, 10%
(v/v) glycerol] with 4 µL of 20.0 mg/m1 protein solution to form a hanging drop
which was allowed to equilibrate with the reservoir solution at room temperature
(Tucker et al. 1996). For co-crystallisation with ligand, 10 molar excess of ligand
was added to the protein sample after concentration.
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A 24-well tissue culture trays was used to set up crystallisation screens
using the handing drop by vapour di usion method (see Section 2.2.11 of
Chapter 2). Firstly, the well was prepared and usually 1 ml of a bu ered
precipitant solution with di erent polyethylene glycol concentrations, pHs and
glycerol content conditions was added (Table 3.4). Then 4 µL of the
concentrated protein sample was pipetted onto a coverslip, followed by 4 µL of
the well solution. The coverslip was then inverted over the well and sealed using
grease. This was then left undisturbed for at least 24 hours to equilibrate at
18¶C.
Table 3.4: First attempt at co-crystallisation: screening using the hanging drop
method. Conditions were guided by Tucker et al. (1996). 7 indicates absence of crystals with
all protein preparations, while 3 indicates formation of crystals. Black checkmark (3): crystals
with CPG223-415, red checkmark (3): crystals with CPG223-415 and glycosylated inhibitor
(CP67), and green checkmark (3): crystals with CPG223-415 and inhibitor (CP06).
10% Glycerol, 200 mM Tris 5% Glycerol, 200 mM Tris
pH 7.0 pH 7.2 pH 7.4 pH 7.0 pH 7.2 pH 7.4
8 % PEG 4000 7 7 7 7 7 7
10 % PEG 4000 7 7 7 7 7 7
12 % PEG 4000 7 7 7 7 7 7
14 % PEG 4000 333 33 3 3 33 333
At the start of the experiment, the precipitant concentration in the drop is
half of that in the well. Equilibration then takes place via the vapour phase.
Given the relatively large volume of the well, its concentration e ectively
remains the same. The drop however loses water vapour to the well until the
precipitant concentration equals that of the well. If conditions are favourable
the protein should become supersaturated and is driven out of solution in the
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form of crystals. Crystallisation was unsuccessful below 14% PEG 4000. All the
crystals produced were tested for di raction (Figure 3.13). Model building2
(where the electron density map is interpreted in terms of a set of atomic
coordinates) was done using molecular replacement, as we already had a
coordinate set to work with from Rowsell et al. (1997). Unfortunately, the
ligands did not co-crystallise with the protein 3.4. This suggests, that the
crystallisation bu er conditions used for co-crystallisation purposes were not
ideal.
(a) CPG223-415 (b) CP06 + CPG223-415 (c) CP67 + CPG223-415
Figure 3.13: Crystal grown using conditions described in table 3.4. Crystals as
observed under a microscope.
A second approach was then used in which a higher protein sample
concentration (20-30 mg/mL) was mixed with with a larger ligand excess (30
and 40◊molar excess), utilising commercially available plates JSCG+, PACT
and Morpheus 96-well plates from Molecular Dynamics (Su olk, UK) to screen
for better bu er conditions for co-crystallisation (see Section 2.2.11 of Chapter
2). Protein began to crystallise as thin needles with 20 w/v PEG 6000, >100
mM NaCl and 0.1 M Tris (pH 7) bu er conditions (Figure 3.14).
2Dr Karen Ruane (School of Life Sciences, University of Warwick) tested crystals for
di raction, collected the data at Diamond Synchrotron Source in Oxford and solved the
structure.
102
Chapter 3
Figure 3.14: Thin needle of protein crystals. This needle grew in 0.2 M NaCl, 0.1 M Tris
and 20% w/v PEG 6000 (pH7) bu er conditions.
Hence further bu er optimisation using 20% w/v PEG 6000 was thought
to potentially generate appropriate co-crystals. A second crystallisation screen
was set-up using the hanging drop by vapour di usion method. The well was
prepared with 1 ml of a bu ered precipitant solution with 20% w/v PEG 6000
concentrations and various ligand-protein sample mixtures were added (Table
3.5). 1 µL of the concentrated protein-ligand sample was pipetted onto a coverslip,
followed by 1 µL of the well solution.
Table 3.5 indicates that CPG223-415 crystallised in the presence of the
glycosylated inhibitor (CP67), but failed in the presence of CP06 inhibitor.
This could potentially be indicative of a weak binding between CP06 inhibitor
and CPG223-415.
Table 3.5: Second trial at co-crystallisation: screening using the hanging drop
method. 7 indicates absence of crystals, while 3 indicates formation of crystals. The ligand
to protein ratio is indicated in the first column.
20% PEG 6000
15% 17.5% 20% 22.5% 25% 27.5%
CP06 ligand, [40]:[1] 7 7 7 7 7 7
CP67 ligand, [30]:[1] 7 7 7 7 3 3
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3.7 Conclusion.
At the start of the project, bacterially-expressed full-length CPG2 enzyme was
highly insoluble. The intention was to redirect the enzyme from inclusion bodies
to cytoplasmic fractions using the E. coli system, and produce soluble and active
CPG2 enzyme for structural studies. This initially involved fine-tuning some
of the expression factors such as changes in the E. coli expression strain and
expression temperature, amongst others.
Di erent E. coli strains were tested for their ability to express CPG2, with a
good yield, in soluble form in the growth media. The C41 (DE3) and BL21 (DE3)
strain showed comparable expression of CPG2 at 20¶C and similar induction
concentration (Figure 3.1). In contrast, the C43 (DE3) strain did not survive
in rich media (cell density OD600 did not exceed 0.1). The yield, when using
BL21 (DE3) as a host, was significantly improved upon use of a low induction
temperature (15¶C) in both rich and minimal media (Figure 3.2). Low IPTG
concentrations were also tested, but had little impact on protein yield. Enzymatic
activity of repeat batches of CPG2 preparation displayed high variability (Figure
3.3-A). SDS-PAGE gels revealed the presence of two bands of di erent density and
thickness that migrate very close together (Figure 3.3-C). CPG2 gene has an N-
terminal leader sequence that points the enzyme to the periplasm of Pseudomonas
sp. Strain RS-16. Mass spectroscopy analysis of these two bands confirmed both
bands were a match to full-length CPG2 protein (Figure 3.3-C, right panel).
Not only did this indicate the production of two di erent isoforms of the same
protein, which could be responsible for the batch-to-batch inconsistency observed
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in activity assays, but the results also suggest that reducing the temperature of
expression did not lead to removal of the signal peptide and susequent soluble
periplasmic CPG2 in E. coli. Thus, the N-terminal signal peptide was removed
in a new construct (CPG223-415). This deletion resulted in the expression of one
single protein with a 6-fold increase in protein yield (Figure 3.5-A and Table 3.1).
CD measurements of full-length CPG2 and CPG223-415 indicated that CPG223-415
secondary structure values were in better conformity with those estimated from
the crystal structure (Figure 3.5-D). The next phase was to overexpress 2H/
13C/15N enriched Pseudomonas protein in E. coli.
Estimation of protein concentration via the BCA assay indicated over 50%
reduction in soluble protein yield of CPG223-415 upon switching the growth
medium from 2◊Y T to M9 with isotopic labels. Because cells containing the
CPG223-415 expression plasmid grew well in rich medium, and poorly in
labelled-minimal medium, methods proposed by Sivashanmugam et al. (2009)
and Marley et al. (2001), which report double-colony selection in increasing
amount of deuterated water and cell-condensation methods, respectively were
ideal approaches to test. Double colony selection revealed variability in
colony-to-colony unevenness in CPG223-415 expression levels and demonstrated
the need to screen colonies for the best protein expression levels (Figure 3.9-A).
Together with the condensation method, we managed to increase expression of
labelled protein and reduce the cost of labelled-protein sample by four-fold, as
compared to conventional labelling (Figure 3.9-B).
Successfully purified soluble CPG223-415 had limited long-term stability
(activity declined 24 hours post-purification) and a propensity to aggregate
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over-time. Consequently, di erent bu er conditions were tested and revealed
that CPG223-415 activity was vastly a ected by changes in salt concentration
(Figure 3.11). The protein required >50 mM NaCl, which is known to increase
sample conductivity and decrease sensitivity in NMR. We tested the low
conductance bu er conditions used by Dötsch and Withers (2005), which
consisted in using 50 mM arginine and glutamine instead of NaCl (Dötsch and
Withers 2005). We were able to collect NMR spectra using this bu er
condition. Unfortunately, the 0.5 mM protein sample started to precipitate
after 2 days in the magnet, making 3D-experiments intractable for backbone
assignment necessitating (3 days each) for this large protein. Thus, a typical
screening technique used by crystallographers was applied to determine optimal
sample conditions for structural NMR studies (Table 3.3). The 363 bu er
conditions screened revealed that at pH values above 6, CPG223-415 remained
soluble in all bu ers for at least 5 days at 18¶C, except when arginine and
glutamate were included in the bu er. However, CPG223-415 remained soluble
for 2 days in the presence of arginine and glutamate, which is consistent with
what we observed previously. After 5 days, precipitation took place at pH
values below 6, except when the concentration of NaCl was at or above 200
mM. Given that bu ers containing less that 50 mM salt resulted in biologically
inactive enzyme, and that 20 mM Tris bu er containing 100 mM NaCl
indicated no precipitation, CPG223-415 samples were prepared in this bu er for
further ligand-protein NMR studies (Chapter 4).
Moreover, expression optimisation of protein preparation and the quest for
stable protein sample made crystal screening for X-ray crystallography all the
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more applicable to this project. Although X-ray crystallography did not call for
labelled protein as required for NMR analyses, it did require higher amounts of
protein. Lowering the salt concentration and adding 20% glycerol made
crystallisation achievable (Figure 3.13).
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Characterisation of Ligand
Binding Properties using NMR
Spectroscopy
4.1 Introduction.
Protein-ligand interactions are implicated in all biological processes. Generally
the a nity can be characterised by the binding constant and / or the standard
free energy. In this project, we were interested in the processes underlying the
mechanism of recognition of CPG2 for its inhibitors, which were provided by
our industrial partner Mologic Ltd. (Bedford, UK). Amongst a plethora of
biophysical techniques, such as isothermal titration calorimetry (ITC), surface
plasmon resonance (SPR), X-ray crystallography, and mass spectrometry (MS),
used to investigate protein-ligand interactions, NMR spectroscopy displays a
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suitable soluble environment for the study of inhibitors targeting soluble
proteins, such as CPG2. Generally, two approaches are utilised to study
protein-inhibitor interactions when NMR spectroscopy is used. These two
approaches are ligand-based and protein-based NMR experiments, in which
NMR parameters of the ligand and the protein, respectively, are monitored an
compared in their free and bound states (Cala et al. 2014). This chapter
describes how NMR spectroscopy, using these two approaches, enabled us to
provide information on the protein-inhibitor binding strength and specificity to
CPG2.
4.2 CPG2 Inhibitors Used for NMR Studies.
Mologic Ltd.1 (Beford, UK) is using CPG2 as part of a fusion-protein with anti-
cancer antibodies, so that it can convert a glutamate-conjugated pro-drug to a
cytotoxic drug selectively on the surface of the tumour.
However, recent clinical trials justified the need for unbound CPG2 to be
cleared from the circulation before administration of the pro-drug to prevent
systemic toxicity in the patient. Hence, Mologic has developed peptide-based
inhibitors that targeted the CPG2 enzyme. These peptides must also carry
sugar residues that enable them to be bound by the asialglycoprotein receptor
of hepatocytes, to ensure e cient clearance of the inhibited CPG2 complex via
the liver. As shown in Figures 4.1 and 4.2, these inhibitors are made of a
1Dr James Schouten and Dr Joannah Towler (Mologic Ltd., Bedford, UK) produced the
CPG2 inhibitors used in this study.
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"warhead", which consists of an aromatic group (shown in black) and a
glutamate moiety (shown in green), attached to a galactosylated tail (shown in
red). The warhead is directly implicated in CPG2 recognition and its inhibition,
whereas the galactosylated tail is present to ensure rapid removal of the
inhibited CPG2 complex from the bloodstream.
Here inhibitors named CP06 and CP39 serve as two potential "warheads",
while CP39 and CP42 are the two galactosylated versions, respectively. CP06
and CP39 di er only by the type of aromatic ring (represented in black in
Figures 4.1 and 4.2 respectively) present in their structure: CP06 has a
naphthalene ring connected to a glutamate moiety, whereas CP39 has an
homophenylalanine that has an additional CH2 group compared to
phenylalanine (for simplification we will refer to it as the benzyl group).
Inhibitors CP67 and CP42 further di er in structure by their galactosylated
tail. CP67 has three serine galactose groups, when CP42 only contains one. To
better understand the mode of binding of these peptide-based ligands, Mologic
is interested in acquiring structural and thermodynamic data for the free
enzyme and ligand-enzyme complex using solution-state nuclear magnetic
resonance spectroscopy (NMR). Moreover, we are interested in the di erences in
the a nity and molecular recognition between the inhibitors and their
glycosylated structures. CP06 and CP67 retained inhibition activity, while one
of the inhibitors (CP39) lost its aptitude to inhibit CPG2 upon galactosylation
(i.e CP42). For the purpose of this project, we wanted to analyse these two
pairs of structures to understand the structural features underlying selective
CPG2 inhibition. Figures 4.1 and 4.2 shows all the di erent inhibitors we
110
Chapter 4
wanted to test. Unfortunately, only the structures displayed in bold were
analysed (i.e. CP06, CP67 and CP42), as CP39 degraded according to the 1D
1H NMR data we recorded.
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4.3 Ligand-Based NMR Experiment:
STD-NMR.
1D-NMR experiments were used to probe the mechanisms of recognition of
these three inhibitors to CPG2 in solution to determine whether the binding
regions of the inhibitor were conserved between the inhibitors and their
matching galactosylated inhibitors. We wanted to know if any particular
functional group was specifically accountable for inhibition. CP06, CP67 and
CP42 inhibitors were hence tested with CPG2 using saturation transfer
di erence (STD) NMR experiment.
To obtain information about the binding specificity at atomistic level,
STD-NMR was used (Cutting et al. 2007). For the purpose of describing the
process, CP06 inhibitor has been used as an example (results for all three
inhibitors are shown in Section 4.3.3). Figure 4.3 reveals the di erent steps
involved in the STD-NMR experiment used for CP06. Spectrum A shows a
1H-NMR spectrum of the free CP06 ligand in solution. STD-NMR relies on the
transfer of saturation from the protein to ligand. Hence, spectrum B in Figure
4.3 corresponds to the spectrum of the same sample recorded with o -resonance
irradiation applied at 38 ppm, far from the on-resonance frequency, and protein
and ligand NMR resonances, so that no NMR signals are modified (Viegas et al.
2011). Spectrum C was recorded with on-resonance irradiation at -0.5 ppm,
where only protein signals are irradiated. Finally, spectrum D shows the
di erence spectrum resulting from the subtraction of the o -resonance and
on-resonance spectra. This spectrum only shows resonances that have
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undergone saturation, namely the protein and the bound ligand resonances.
Because the protein is present at low concentration and has a high molecular
weight, the protein signals will relax too fast to be visible and the result is a
simple 1D 1H spectrum that reveals only the binding nuclei. Moreover,
impurities observed in spectra B are no longer detectable in spectrum D, hence
the impurities contained in the spectrum are e ectively subtracted and
therefore do not give rise to signals in the di erence spectrum.
ppm 2 4 6 8 
A 
C 
D 
B 
Figure 4.3: STD-NMR: 3 step concept. A) Reference 1D 1H NMR spectrum of the CPG2
and CP06 sample mixture. B) Corresponding o -resonance spectrum with irradiation at 38
ppm. C) Corresponding o -resonance spectrum with irradiation at -0.5 ppm. D) Corresponding
STD-NMR spectrum showing that CP06 yields signals and therefore binds to CPG2.
For this work, the protein must be selectively saturated. This is possible
because protein resonances have significant intensity even in the upfield ppm
region from 0 to -1 ppm, where the preponderance of methyl NMR resonances
of folded proteins occur and no ligand signal occurs or above the downfield
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region above 10 ppm, hence outside the spectral window of the low-molecular
weight inhibitors (Wuthrich 1998). Transfer of magnetisation within the
protein, via spin di usion, leads to fast saturation of the entire protein and not
only of the few directly saturated resonances (Kalk and Berendsen 1976).
Furthermore, for the on-resonance experiment to be successful, any direct
irradiation of ligand frequencies needs to be avoided (false-positives). This can
be rapidly checked using a ligand-only sample (in the absence of protein), and
running an STD-NMR experiment. Figure 4.4 reveals that in the absence of the
protein, the ligand is directly saturated at 0 ppm (Figure 4.4-A) and -1 ppm
(Figure 4.4-C), but not at -0.5 ppm ppm (Figure 4.4-B). This reveals the
importance of screening beforehand for the appropriate on-resonance frequency
in order to prevent false-positives. The on-resonance value for the other two
ligands was set at -1 ppm using the same procedure, as -0.5 ppm revealed direct
saturation of the ligand signals.
ppm 2 4 6 8 
A 
C 
B 
Figure 4.4: Testing on-resonance frequencies. To prevent the presence of false-positive
signals due to direct irradiation of ligand protons, di erent on-resonance frequencies at A) 0
ppm, B) -0.5 ppm and C) -1 ppm were investigated using a ligand-only sample. Results showed
that ligand signals were directly saturated at 0 and -1 ppm, only -0.5 ppm displayed the absence
of false-positive signals.
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4.3.1 Use of D2O in Sample Preparation is Essential.
Before measuring the samples in 100% D2O, samples in 90% H2O and
non-deuterated Tris bu er were used. Unfortunately, although the water
suppression pulse program e ciently suppressed water signal around 4.701 ppm,
negative NOE signals were observed in the downfield aromatic region (Figure
4.5-A). Non-binding inhibitors, which should only have contact to "unbound"
water molecules found in solution, can be detected with a positive NOE because
inhibitors that interact with bulk water will experience much faster tumbling
(Ludwig and Guenther 2009). In this case, the negative NOE was originating
from "bound" water molecules, i.e within the binding site of the target protein,
where bound ligand directly interacted with "bound" water molecules via
water-ligand-protein or protein-ligand complexes, whose rotational correlation
time yields to negative cross-relaxation rates, thus negative NOE with water
(Kie er et al. 2011). This pathway of saturation can be overlooked if the ligand
signals were to be detected using the water ligand observation with gradient
spectroscopy (WaterLOGSY) NMR experiment (Dalvit et al. 2001). This e ect
can also be minimised when the samples are measured in 100% D2O and if
protein saturation is performed far from the water signal at 4.701 ppm (Figure
4.5-B). The latter was used as ligands were easily soluble in D2O and the
ligands of interest had NMR signals in the 2 to 8 ppm region of the spectrum,
with very little chance to take part in protein saturation around the water
signal region for STD-NMR experiment (Dalvit et al. 2001).
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Figure 4.5: Bu er conditions for STD-NMR experiments. Two bu ers were tested: A)
a 10% deuterated bu er and B) a 99% deuterated bu er. 10% deuterated bu er showed presence
of negative NOE downfield due to the presence of non-binding inhibitors in solution interacting
with "bound" water molecules at the active site. Hence, for all STD-NMR experiment 99%
deuterated bu er was used.
4.3.2 Saturation Dependence of the STD Intensities.
To investigate the influence of the saturation time on the STD e ect, a set of six
STD-NMR experiments was collected where concentrations of protein and ligand
were fixed at 20 µM and 2 mM respectively. The saturation times were: 0.5 s,
0.75 s, 1 s, 1.25 s, 1.5 s and 2 s.
The time-course of saturation was obtained by plotting the STD
amplification factor against the saturation time. Figure 4.6 shows the
saturation profile for some selected resonances of the CP06 ligand at one ligand
concentration (2 mM). The STD-AF factor of the aromatic protons (H6 and H4
of CP06 and CP67 respectively) were larger than that of the rest protons.
Moreover, one can observe that longer saturation times (i.e 2 s) and high ligand
concentration were required to reach the maximum observable STD e ect. The
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relative STD intensities, which were specified for CP06 in Figure 4.6-A, were
therefore specific for a given saturation time and ligand concentration (2 mM)
and cannot serve as a final value. Moreover, CP67 build up curves in Figure
4.6-B suggested that lower saturation time results in very similar STD-AF
percentage amongst the various protons, prohibiting from experiencing
di erences between these di erent protons. High saturation times allowed a
good di erentiation between the STD-AF of the di erent protons. Hence, a 2 s
irradiation time was used for epitope mapping of the inhibitors.
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A 
C 
B 
Figure 4.6: Saturating time tsat build-up curves. Saturation transfer from CPG2 to
A) CP06, B) CP67 and C) CP42 during STD-NMR experiment at 100:1 ligand to protein
concentration ratio. Build-up curves obtained for di erent protons, protons of the ligand that
are close to the protein, see Figures 4.7, 4.8 and 4.9 for assignment) are represented in di erent
colours and given within each panel.
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4.3.3 Ligand Group Epitope Mapping (GEM).
Figure 4.7 shows the reference at the top 1H-NMR spectrum of CP06 with CPG2
in a 100:1 molar ratio and the corresponding STD NMR spectrum at the bottom.
The STD spectrum indicated that CP06 binds to CPG2, since large signals of the
ligand were observed. In addition, protons of the ligand involved in interactions
with the protein were identified from the STD NMR spectrum because they were
saturated to the highest degree. The di erence signal intensities of the individual
protons were normalised to the integral values of the highest signal of CP06, H3,
set to 100%. Figure 4.7 shows the relative degree of saturation of each individual
proton. The H1, H2, H3, H5 and H6 aromatic protons all have similar STD
intensities between 89% and 100%. On the other hand H8, the only other proton
displaying saturation, had the smallest intensity at 78%. Thus a clear distinction
between protons with a strong contact to the protein, i.e. the aromatic protons,
and the others, was made. Presence of saturation for H8 confirmed that glutamate
is interacting with CPG2 and is presumably required for the CP06 warhead to
be recognised by CPG2.
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Figure 4.7: STD NMR spectrum of mM CP06 in the presence of 20 µM CPG2
recorded at 298 K on a 700 MHz spectrometer. STD intensities relative to the
corresponding reference intensities are shown next to each proton in the ligand (the assignment
of each signal is indicated with an underlined number). The percentages shown on the structure
are the STD epitope map after normalising the largest STD intensity to 100%. The small
underlined numbers on the structure are the atom identification. The pre-saturation time of
STD experiment was 2 s with a total recovery delay of 4 s. CPG2 was irradiated with a
Gaussian shaped pulse at -0.5 ppm. A CMPG T2 filter of 2.5 ms was used to eliminate the
protein background. The reference spectrum was recorded by irradiating at 38 ppm.
Investigation of the CP67 ligand (i.e. the galactosylated CP06 warhead) is
displayed in Figure 4.8, with top spectrum being the reference NMR spectrum
of CP67 with CPG2 in a 100:1 ligand to protein concentration ratio and bottom
spectrum the corresponding STD-NMR spectrum. The STD spectrum
illustrates CP67 binding to CPG2, since large signals of the ligand resonances
were observed. In addition, protons of the ligand which are nearest to proton of
the protein, were again easily identified from the STD NMR spectrum, because
they were saturated to the highest extent. The di erent signal intensities of the
individual protons were best analysed from the integral values of the highest
signal of CP67, H3, set to 100%. Figure 4.8 demonstrated the relative degree of
saturation of each individual protons. The H1, H2, H3, H5 and H6 aromatic
protons all have similar STD intensities between 89% and 100%. On the other
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hand H7, H8 and H9/9’, had the smallest intensities, ranging form 58% to 78%,
whereas the galactosylated tail showed no apparent proximity to the target
protein, leaving it accessible to the hepatocyte receptors for clearance. Thus an
evident distinction between protons with a strong contact to the protein (i.e.
the aromatic protons) and the others, was mapped out. Since none of the
protons from the galactosylated region of the inhibitor seemed to be in close to
CPG2, the protons were not assigned on the 1H-NMR spectrum. The results
supported the hypothesis that the naphthalene ring plays a significant role in
the molecular recognition of the inhibitor by CPG2. Likewise, it corroborates
the requirement of a hydrophobic pocket near the CPG2 active site. With CP67
the glutamate group was again in close proximity to CPG2, as the glutamate
protons were irradiated. Therefore, these results reinforced the idea that
glutamate is evidently required for the inhibitor to be recognised by CPG2.
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Figure 4.8: STD NMR spectrum of mM CP67 in the presence of 20 µM CPG2
recorded at 298 K on a 700 MHz spectrometer. STD intensities relative to the
corresponding reference intensities are shown newt to each proton in the ligand (the assignment
of each signal is indicated with an underlined number). The percentages shown on the structure
are the STD epitope map after normalising the largest STD intensity to 100%. The small
underlined numbers on the structure are the atom identification. The pre-saturation time of
STD experiment was 2 s with a total recovery delay of 4 s. CPG2 was irradiated with a
Gaussian shaped pulse at -1 ppm. A CMPG T2 filter of 2.5 ms was used to eliminate the
protein background. The reference spectrum was recorded by irradiating at 38 ppm.
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Results for CP42 are given in Figure 4.9, with top spectrum being the
reference 1H-NMR spectrum of CP42 with CPG2 in a 100:1 molar ratio, and
bottom spectrum the corresponding STD-NMR spectrum. The STD spectrum
indicates that CP42 binds to CPG2, since large signals of the ligand can be
observed. In addition, protons of the ligand which are closest to CPG2 can be
once more easily identified from the STD-NMR spectrum, because they are
saturated to the maximum degree. The di erence signal intensities of the
individual protons are best analysed from the integral values of the highest
signal of CP42, H8, set to 100%. Figure 4.9 displays the relative degree of
saturation of each individual proton. This time H10 displays the lowest STD
intensity. On the other hand H7, H8, H9, display a saturation intensities
ranging from 69% to 100%. Thus a clear distinction between protons with a
strong contact to the protein, i.e. the protons found in the galactosylated
region, and the others, found in the glutamate / benzyl region can me made.
Although, the benzyl ring is in close proximity to the CPG2 binding site, the
absence of saturated glutamate protons suggests that the glutamate is not
interacting with CPG2. This shows that the type of aromatic ring used and the
variation in galactosylation may play an important role in the molecular
recognition of the inhibitor by CPG2, as CP42 contains a di erent aromatic
ring and galactosylation than its predecessors, CP06 and CP67, which uses a
naphthalene ring and three galactoses.
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Figure 4.9: STD NMR spectrum of mM CP42 in the presence of 20 µM CPG2
recorded at 298 K on a 700 MHz spectrometer. STD intensities relative to the
corresponding reference intensities are shown newt to each proton in the ligand (the assignment
of each signal is indicated with an underlined number). The percentages shown on the
structure are the STD epitope map after normalising the largest STD intensity to 100%. The
small underlined numbers on the structure are the atom identification (the assignment of the
galactosylated group was not made, as it did not lead to any NOE saturation). The pre-
saturation time of STD experiment was 2 s with a total recovery delay of 4 s. CPG2 was
irradiated with a Gaussian shaped pulse at -1 ppm. A CMPG T2 filter of 2.5 ms was used to
eliminate the protein background. The reference spectrum was recorded by irradiating at 38
ppm.
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4.3.4 Better Assessment of the Absolute Magnitude of the
Saturation E ect.
STD-NMR data can be related to KD because spectra only contains signals from
the bound ligands and, therefore, report information about the protein-ligand
a nity. As with all the procedures used to study ligand-protein interactions, a
titration with ligand is conducted to plot the response as a function of the initial
ligand concentration.
The concentration of CPG2 protein used was 20 µM and ligands were
titrated onto the corresponding protein samples from concentrated stock
solutions (Figure 4.10). Each time y µL of ligand was added, y µL of 40 µM
solution of CPG2 was added in order to keep the concentration of CPG2
constant throughout the titration. For titration and saturation time
experiments, the STD amplification factor (STD-AF) was used (Heller and
Kessler 2001; Angulo and Nieto 2011). This factor allowed a better visualisation
of the complete extent of the saturation e ect. The STD-AF is the fractional
saturation of a given proton multiplied by the excess of the ligand over the
protein. In e ect, STD-AF is the relative intensity of the STD signal compared
to that of a signal of the protein, i.e. STD-AF of 13 means that the STD signal
has an intensity 13 times higher to that of a CPG2 proton. It provides an easy
measure to quantify the amplification of the protein information observed in the
STD signals of the ligand. Evidently, the STD-AF can be higher than 1 only if
the residence time of a ligand is significantly shorter than the saturation time
and if the concentration is much higher than that of the protein (Angulo and
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Nieto 2011). Hence the STD-AF was always normalised to the signal displaying
the highest STD-AF value.
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Figure 4.10: STD-NMR titration experiments of CPG2 by inhibitors. Titration
using A) CP06, B) CP67 and C) CP42 inhibitors. The protein to ligand concentration ratios
are displayed on the left, on top of each STD spectra. As titration progressed, the extent of
saturation was increasing for the signals that were close to CPG2 surface.
128
Chapter 4
The equation (Io-Isat)/Io is the fractional STD e ect expressing the signal
intensity in the STD spectrum as a fraction of the intensity of an unsaturated
reference spectrum. Undoubtedly, the fraction of ligands which are saturated is
continuously reduced when the ligand excess is increased (Goldflam et al. 2012).
By multiplication of the ligand excess with the fractional STD e ect the STD-AF
is obtained, as described by Equation (4.1).
STD ≠ AF = (Io ≠ Isat)
Io
◊ [L][P ] (4.1)
In this equation, Io is the intensity of one signal in the o -resonance NMR
spectrum, Isat is the intensity of one signal in the on-resonance NMR spectrum,
and Io-Isat represents the intensity of one signal in the STD-NMR spectrum.
Figures 4.11, 4.12 and 4.13 show the binding isotherms obtained by
plotting the STD-AF values of each proton that resulted in an NOE against the
ligand concentration. For each proton, STD-AF build up curves were recorded
(Angulo and Nieto 2011). The binding isotherms of CP06 protons, H7, H8 and
H9/9’ curves did not converge at high ligand concentrations, suggesting that the
glutamate moiety weakly bound to CPG2, although they were in close
proximity to it. For CP67, we see an identical pattern, where only protons 1 to
10 located in the "warhead" domain were directly involved in binding to CPG2.
On the other hand for CP42, the second glycosylated inhibitor, only the
aromatic protons showed NOEs. Since the curves did not converge at high
concentration, it indicated these protons are only weakly binding to CPG2,
which is in close agreement with the IC50 observed by Mologic.
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Plotting these values at increasing values of ligand concentrations yields to
a Michaelis-Menten hyperbolic dose-response curves described by Equation (4.2)
(Angulo and Nieto 2011).
STD ≠ AF [L] = STD ≠ AFmax ◊ [L]([L] +KD) (4.2)
where STD-AFmax is a dimensionless scaling factor representing the maximum
STD amplification factor for the monitored signals. For each ligand
concentration, an STD-spectrum was recorded. A plot of the STD-AF against
ligand concentration was then used to measure the dissociation constant of the
protein-ligand complex (Angulo and Nieto 2011).
STD amplification factor titration curves from some of the ligand protons
are presented in Figures 4.11, 4.12 and 4.13). CP06 H1 to H6 protons binding
isotherms fitted nicely to the Michaelis-Menten Equation (4.2), whereas H8 and
H9 did not converge 4.12. This was indicative of very weak binding from H8 and
H9, but suggested close interaction of these glutamate protons to CPG2.
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CP67 H1 to H6 protons binding isotherms also fitted to Michaelis-Menten
equation, with very similar curves to that of CP06 aromatic protons (Figure 4.12).
This suggested, again, that the naphthalene was required for CPG2 recognition,
binding and possibly inhibition. Maximum STD-AF for H7 to H10 was reached
very rapidly, indicating very strong binding from the glutamate group. This
also implied that the glutamate moiety was indispensable for recognition and
binding to CPG2. As opposed to CP06, protons that experienced saturation,
all demonstrated high a nity to CPG2. These findings validated the inhibitory
constants observed for CP67 and CP06 using the octet RED system (Figure 4.1).
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As shown in Figure 4.13, CP42 binding isotherms suggested very weak
binding to CPG2 as STD-AF saturation was not reached, not even at 80:1
ligand to protein concentration ratio. This substantiated the absence of
inhibition reported by Mologic using the octet RED system (Figure 4.2).
Figure 4.13: Binding isotherms fits for CP42. The STD-AF growth curve of each CP42
protons exhibiting saturation (dots), and the fit to Equation (4.2) (red line).
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The apparent equilibrium constants (KD) of each protons that yielded
STD-NMR signals are listed in Table 4.1. All individual protons from the
aromatic region had high a nity to CPG2; however, the magnitude of the
a nities observed was di erent. The glutamate group in the "warhead" was in
close proximity to CPG2, but displayed very weak a nity to CPG2 suggesting
the importance of it for CPG2 recognition. The equivalent galactosylated ligand
displayed very di erent tendencies. Indeed, CP67 glutamate protons showed
very high a nity to CPG2 (ranging from 75 to 174 µM), whereas CP42
displayed very weak binding. The binding a nities of the same ligands
determined by the octet RED system by Mologic were universally stronger
(smaller KD) (Figures 4.1 and 4.1). The octet RED system (ForteBio, USA) is
an instrument that specialises in measuring the a nity of small molecule
binding to a therapeutic target. The purified CPG2 was immobilised onto an
amine reactive biosensor and assayed against the inhibitors of interest. The
lower KD values could be attributed to the presence of a protein layer on the
biosensor and the use of bovine serum albumin (BSA) as a blocking agent to
prevent non-specific binding events. Meanwhile, the higher KD values observed
with STD-NMR are possibly due to NMR methods giving an averaged picture
of the ligand in its bound and free states (Fielding et al. 2005).
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Table 4.1: Apparent binding constants. The KD values obtained from each individual
curves fits, presented in Figures 4.11, 4.12 and 4.13, are unveiled next to their respective protons.
The mean value was calculated as 437 µM, 227 µM and in the millimolar range for CP6, CP67
and CP42, respectively. The standard deviations are 374 µM and 94 µM, for CP6 and CP67
respectively.
Ligand Proton number KD (mM)
CP06 H1 0.339
H2 0.450
H3 1.326
H4 0.456
H5 0.234
H6 0.325
H7 0.199
H8 very high
H9 very high
CP67 H1 0.330
H2 0.254
H3 0.289
H4 0.251
H5 0.346
H6 0.333
H7 0.140
H8 0.174
H9 0.107
H9’ 0.075
H10 0.203
CP42 H7 24.674
H8 very high
H9 2.277
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4.4 Protein-detected NMR experiments.
Most of the protein-based methods rely on chemical shift perturbations as
barometer for intermolecular binding, monitoring the changes in the NMR
spectrum of the protein upon ligand binding. This technique was first applied
to study structure–activity relationships obtained from NMR by Shuker et al.
(1996)). Drug-design has known exceptional progress since the likelihood of
identifying and characterising potential weak binding molecules at the surface of
drug-targets using heteronuclear NMR experiments.
4.4.1 1H-15N-HSQC of Free CPG2.
Typically ligand binding studies involve uniform isotopic labelling of the protein
as protein signals are monitored using heteronuclear NMR experiments. To
overcome problems associated with higher molecular weight proteins, isotope
labelling and deuteration were used.
Here, we managed to remove protons to 45-50% in a random fashion in
order to reduce external relaxation contributions. 226 µM of his-tagged CPG2
(approximately 4 mg per NMR sample) in 10 mM phosphate bu er at pH 8 was
used for NMR analyses. 1H-15N-HSQC is the most common experiment and
displays all 1H-15N correlations. This spectrum is a fingerprint of the folded
protein and is usually the first heteronuclear experiment carried out on proteins.
From it, it could be judged whether other experiments are likely to succeed
because each protein has a unique pattern of N-H correlations for each residues
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(see Section 1.6.2 in Chapter 1). As so, it can also be used as a tool to optimise
the NMR sample conditions (temperature, pH, etc). Spectra were acquired at
three di erent temperatures: 25¶C (with 64 scans), 30¶C (128 scans) and 37¶C
(256 scans) (Figure 4.14). It was assumed that increasing the temperature
would reduce the rotational correlation time and improve the spectrum (Figure
4.14-B and C). Unfortunately, the protein started to precipitate at 30¶C and
37¶C. It was decided that 25¶C was the optimal temperature at which to run
NMR experiments. Secondly, the dispersion of signals in the spectrum A of the
protein is far beyond the envelope of signals seen in the spectrum B, where
clustered peaks are observed around 7.5 and 9 ppm. This clearly reflects that
nuclei in spectrum A are in many distinct environments and suggests proper
folding of the protein. 236 of the 420 possible peaks were observable in this
sample (e.g. 60%, Figure 4.14-A). While we had successfully expressed
CPG223-415 in a soluble, active form in E. coli, the resulting protein displayed
limited long-term stability (activity deteriorated 24 hours post-purification) and
a propensity to aggregate over time in Tris bu er containing 50 mM NaCl (pH
7.2) as seen in Chapter 3.
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Figure 4.14: Three CPG2 1H-15N-HSQCs at di erent temperatures and number
of scans. A) CPG2 1H-15N-HSQC (4 mg/180 µL) at 25¶C, 3 hours. B) CPG2 1H-15N-
HSQC (4 mg/180 µL) at 30¶C, 1 day. C) CPG2 1H-15N-HSQC (4 mg/180 µL) at 37¶C, 1 day
(precipitation).
139
Chapter 4
4.4.2 TROSY-NMR Characterisation of 42 kDa
CPG223-415 at Two Fields and Two Temperatures.
After successful production of high-yields of soluble, active and isotopically
labelled CPG223-415 that was stable at 18¶C for at least five days as described in
Chapter 3, we wished to evaluate the potential of solution NMR spectroscopy to
study the structure, substrate / ligand-binding, catalytic mechanism and
dynamics of this protein in solution. NMR has not been used to study CPG2
previously, and allows study of this enzyme in solution without the need to
generate crystals. The molecular weight of CPG223-415 (42 kDa) and its
dynamic nature (L-shaped protein) makes NMR assignment and subsequent
structural investigation of the full-length enzyme an ambitious goal. Thus we
applied TROSY (transverse relaxation-optimised spectroscopy) based
techniques to measurements of 2H/15N/13C-labelled CPG223-415. TROSY,
pioneered by Wüthrich, decreases the fast T2-mediated decay of amide-proton
NMR signals, by exploiting constructive use of the two e ects that determine
transverse relaxation in large proteins: dipole-dipole coupling (DD) between
two spins and chemical shift anisotropy (CSA) of the two spins (Pervushin et al.
1997; Zhu et al. 1999). This relaxation interference minimises line-broadening
due to limited molecular tumbling in large proteins and can result in significant
improvements in resolution and sensitivity (Ollerenshaw et al. 2003; Wuthrich
1998). To further minimise loss of sensitivity due to increased sample
conductivity when using the cryogenic NMR probe, data were then acquired for
CPG223-415 dissolved in the low-conductance bu er solution (20 mM Tris, pH
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7.3 and 50 mM L-arginine, 50 mM L-glutamate) after cleavage of the his-tag.
1H-15N-TROSY-HSQC spectra were measured at two field strengths (700
and 900 MHz2) and two temperatures (25¶C and 37¶C) and the results are
shown in Figure 4.15. At both temperatures, we observed the expected
improvement in linewidths at 900 MHz when using TROSY-based methods (the
TROSY e ect has been shown to yield the narrowest line widths at 900 MHz),
but a substantial reduction in the number of peaks observed as annotated in
Figure 4.15 (Keeler 2011). At both field strengths, increasing the temperature
to 37¶C yielded a noticeable improvement in peak width and spectral overlap
(Figures 4.15-B, D) and a significant increase in the number of peaks observed.
This was unsurprising since peak width, and thus the resolution and
signal-to-noise ratio, can be significantly improved by varying the acquisition
temperature, which a ects the tumbling time and relaxation properties of large
proteins (Keeler 2011). However, sustained exposure to 37¶C temperatures lead
to aggregation of the enzyme after two days in the low-conductance bu er
solution. Acquisition at 25¶C (700 MHz) reduced aggregation, and yielded a
spectrum containing 318 of the 420 theoretical HSQC peaks (or 76%) expected
from the primary sequence of CPG223-415 (Figure 4.15-A).
2Dr Sara Whittaker (School of Cancer Sciences, University of Birmingham) collected the
NMR data using the 900 MHz Bruker Instrument.
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Using these optimised parameters, we acquired a 1H-15N TROSY-HSQC
spectrum of 1H/15N/13C-labelled CPG223-415 solubilised in 20 mM Tris bu er
(pH 7.3) containing 100 mM NaCl (Figure 4.16). Although this bu er contained
NaCl concentrations that may lead to sensitivity loss when using the cryogenic
NMR probe, it yielded protein samples with the highest stability while retaining
activity. No loss of sensitivity was observed in this bu er at 25¶C when
compared to the equivalent spectrum acquired in bu er containing 50 mM
L-arginine, 50 mM L-glutamate (Figure 4.15-A), suggesting that the cryoprobe
was not negatively impacted by the presence of 100 mM NaCl (Kelly et al.
2002). Quite the opposite was observed as this spectrum displayed improved
signal to noise, narrower linewidths, and an increase in the number of
observable peaks (342 peaks, or 81% of the expected peaks) as compared to the
equivalent spectrum acquired in the Arg/Glu-containing bu er.
Figure 4.16: 1H-15N TROSY-HSQC spectrum of 1H/15N/13C-labelled CPG223-415.
1H-15N TROSY-HSQC spectrum acquired for 1H/15N/13C-labelled CPG223-415 solubilised in
20 mM Tris (pH 7.3) containing 100 mM NaCl. The spectrum was acquired at 25¶C and 700
MHz, and yielded 353 resolved peaks.
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4.4.3 Unravelling Binding by Using Simple HSQC NMR
Experiments.
In these protein-detected experiments, ligand binding is observed via chemical
shift changes in the 1H-15N HSQC spectrum of the protein induced by the binding
of the ligand. In this section, we decided to focus on the first set of inhibitors
CP06 and CP67, the warhead and its galactosylated alternative that showed
inhibitory activity. Despite the large number of expected resonances and some
overcrowded regions in the spectrum, a large number of peaks were resolved,
thereby producing a large number of potential probes within the protein upon
addition of CP06 and CP67. To our knowledge, the NMR assignment of CPG2
have not been elucidated, thus preventing the localisation of the amide resonances
in the CPG2 3D X-ray structure. However, we expected these correlation peaks
to provide a su ciently large illustration, enabling characterisation of the kinetic
events taking place at the protein surfaces in the presence of these two ligands by
titrating increasing concentration of ligand into the CPG2 solution (see Section
1.6.2 in Chapter 1).
Several interaction experiments with di erent ligand concentrations were
performed to obtain a KD. A mixture of approximately 0.45 mM CPG2 protein
sample with increasing CP06 ligand concentration samples were prepared to
probe the binding events (Figure 4.17).
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1[h!]
Figure 4.17: 1H-15N-HSQC spectra of CPG2 acquired in the presence of CP6
ligand. Titration were carried out with 1:1, 3:1, 5:1, 10:1 and 20:1 ligand to protein
concentration ratio. The spectra shows changes in the protein signals upon additions of the
CP06.
Most of the 1H-15N peaks in Figure 4.17 were not a ected by the presence
of ligand (peak F), and only a small set of isolated peaks moved (peaks A to
E). Their behaviour were thoughtfully investigated in Figure 4.18. To start with,
the ligand binding kinetics are likely in the fast exchange regime on the NMR
chemical shift timescale (Williamson 2013). All the peaks moved smoothly from
the free protein chemical sift (blue) to the chemical shift of the bound protein
(red). However, di erent behaviours in chemical shift changes were observed.
Chemical shifts of peak A and C displayed the same shape throughout ligand
titration suggesting that they were in fast exchange rate; chemical shifts of peaks
D and E became broader upon ligand titration, but sharpened up again close
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to saturation, suggesting they were at the limit of the very fast exchange rate
(Figure 4.18). Chemical shift changes for peaks B and E displayed a linear shift
in the 1H-15N correlation peak upon titration, while chemical shift changes for
peaks D and C were not linear which was indicative of an intermediate formed
during the titration demonstrating a conformational change in the bound protein
(Figure 4.18-D and C).
Figure 4.18: Close-up of 1H-15N HSQC spectra of CPG2 acquired in the presence
of CP06 ligand. Titration were carried out with 1:1, 3:1, 5:1, 10:1 and 20:1 ligand to protein
concentration ratio. The figure shows some of the significant chemical shift changes upon
additions of the CP06.
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Multiple binding curves were determined by titrating each ligand into
separate samples of 1H/15N/13C-labelled CPG2 and acquiring 1H-15N HSQC
spectra at as many as 5 di erent ligand to protein concentration ratios ranging
from 1:1 - 20:1. Chemical shift changes in both 1H and 15N dimensions were
logged and fitted by non-linear regression analysis to Equation (4.3) (Fielding
2007; Sudmeier et al. 1980).
 obs =  max =
(KD + [L]0 + [P ]0)≠
Ò
(KD + [L]0 + [P ]0)2 ≠ (4[P ]0[L]0)
2[P ]0
(4.3)
The measured KD values are shown in Figure 4.19. These HSQC titration
derived KD (41 to 493 µM) compared favourably with that derived from the
STD-NMR titration experiments (169 to 1326 µM) and octet RED system (88.5
µM).
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Figure 4.19: CP06 curve fits. Fits for all significant chemical shift di erences using Equation
(4.3) are shown. The KD value obtained from each individual curve fit is displayed next to the
respective curve.
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HSQC titration experiments were also repeated with CP67 as a ligand, the
galactocsylated derivative of the CP06 inhibitor, as shown in Figure 4.20. Upon
addition of CP67, changes in 1H-15N chemical shift correlations were observed
indicating local changes in environment caused by CPG2-CP67 complex
formation. Some peaks were still visible and displayed no chemical shift changes
(Figure 4.20-A,B and C), indicating that these resonances were not a ected by
CP67 binding. This implied that these residues may be located further away
from the CP67 binding site, as there were only limited chemical shift changes.
NMR spectra also indicated small chemical shift changes (Figure 4.20-D).
Additionally, a great number of peaks disappeared as soon as the CP67 was
titrated in (Figure 4.20-E) and other peaks started to shift (Figure 4.20-F).
Some NMR peaks probably broaden beyond detection by binding to CP67,
which may quench internal motion of the protein. But the great number of
anomalous peak broadening upon titration suggested that these protein residues
may have been directly involved in CP67 recognition and binding. Moreover,
binding of CP67 to CPG2 dramatically changed the global molecular tumbling
motion of the protein due to the lack of any visible narrow NMR resonances.
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Figure 4.20: 1H-15N HSQC spectra of CPG2 acquired in the presence of CP67
ligand. Titrations were carried out with 1:1, 3:1, 5:1, 10:1 and 20:1 ligand to protein
concentration ratio. The spectra shows some changes (i.e broadening) in the protein signals
upon additions of the CP67.
Other 1H-15N correlation appear at higher CP67 concentrations (Figure
4.21-E). This indicates that in the presence of the galactosylated tail, this
protein residue was in slow exchange on the chemical exchange rate as the free
signal does gradually decrease in intensity as the bound signal increases after
addition of an excess of CP67 ligand as shown in Figure 4.21 (Williamson 2013).
On the other hand, Peak F in Figure 4.21 displayed an intermediate motion
because during the titration the NMR signal for this residue seemed to broaden
and form a doublet, but as soon as the protein was saturated with CP67, the
peak disappeared. Because of signals broadening during ligand titration, it was
not possible to extract the KD for CP67.
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Figure 4.21: Close-up of 1H-15N HSQC spectra of CPG2 acquired in the presence
of CP67 ligand. Titration were carried out with 1:1, 3:1, 5:1, 10:1 and 20:1 ligand to protein
concentration ratio. The figure shows some of the significant chemical shift changes upon
additions of the CP67.
4.5 Conclusion
This chapter describes how relevant ligand-protein interactions can be studied
without chemical shift assignment of the 2D 1H-15N HSQC spectrum of CPG2.
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The e ects resulting from the binding of a ligand can be categorised into two
groups: the global e ects and the local e ects (Heller and Kessler 2001). The
former are size-dependant and therefore are suited to the observation of the
ligand. In general, upon binding to a macromolecule, the apparent molecular
weight will change dramatically the size by several orders of magnitude. Those
changes can be studied using NMR experiments, such as the DOSY experiment
(Goldflam et al. 2012). It will reveal binding, but cannot provide structural
information about the inhibitors or the binding process. On the other hand, the
global e ects of binding that are restricted to the binding region can be
monitored on both CPG2 and the inhibitors, using STD-NMR and chemical
shift perturbation methods (Heller and Kessler 2001).
The inhibitors provided and produced by Mologic, shown in bold in Figures
4.1 and 4.2, were used in a ligand-based approach via the STD-NMR
experiment. The initial idea was to investigate the reason why CP06 and CP39
upon galactosylation, retained or lost inhibition strength. Unfortunately, 1D 1H
NMR of CP39 showed degradation. Hence, we were left with inhibitors CP06,
CP67 and CP42 for further analysis. Analysis of the three inhibitors showed
that the glutamate moiety is indeed essential for CPG2 recognition and / or
binding, as protons of the glutamate group in CP06 (Figure 4.7) and CP67
(Figure 4.8) showed saturation, while none of the glutamate protons in CP42
seemed to be in close proximity to CPG2 (Figure 4.9). However, the CP06 and
C067 glutamate H7, H8, H9/9’ protons that were revealed to be close to CPG2
did not show very high binding constants (Table 4.1). H7, H8 and H9 protons of
CP42 (found in the benzyl group, between the galactosylated and glutamate
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groups) were the only protons to display any closeness to CPG2 (Figure 4.9),
but KD values for these protons were very high suggesting very weak binding to
CPG2 in accordance with the RED octet values (Figure 4.2). The change in the
aromatic ring type seemed to have an e ect on the inhibitory e ect of these
ligands. Indeed, CP06 and CP67 inhibitors revealed that the naphthalene ring
present in these inhibitors may play a significant role in molecular recognition
by CPG2 (Figures 4.7 and 4.8). The protons of the naphthalene ring showed
very micromolar range KD on average below 0.5 mM for CP06 and below 0.35
mM for CP67, except for proton for CPO6-H6 proton (Table 4.1). CP06-H6
proton displayed an unusually high binding KD constant in the millimolar range
compared to its neighbouring protons. This is probably due to tight binding of
the ring to CPG2 a ecting the final KD. The interesting aspect involving CP67
analysis was that none of the protons of the galactosylated moiety revealed
proximity to CPG2 protein. This results indicated that, firstly, the
galactosylated moiety was available for the hepatocytes receptors to bind to for
blood clearance, and secondly, the galactosylated moiety did not interfere with
the rest of the CP67 compound involved in CPG2 recognition and / or binding.
As a result, CP06 and CP67 were taken forward for chemical shift perturbation
investigation using 1H-15N HSQC experiments titration.
Usually protein-based method is used to enable to resolve the ligand
binding footsteps on the target protein. However, NMR structural studies of
large proteins such as CPG2 face distinct challenges as it su ers from
line-broadening, frequency degeneracy (i.e. resonances that have overlapping
frequencies) and spectral crowding, which is confinement of a large number of
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NMR signals within a given spectral region due to a large number of residues as
we observe in Figure 4.14. For optimal data collection, adequate perdeuteration
(Chapter 3) and TROSY was used (Pervushin et al. 1998). By combining a
suitable labelling strategy with the appropriate pulse sequence, we were able to
generate an acceptable 1H-15N TROSY-HSQC spectrum. Before assigning the
signals observed the NMR spectra to the nulcei in CPG2, we decided to use a
very simple method to study binding to protein: chemical shift perturbation. In
addition to exposing potential binding sites, it can present detailed a nity
information.
1H-15N TROSY-HSQC were acquired as increased concentration of CP06
and CP67 respectively were titrated in CPG2. The two ligand did not behave
similarly upon titration. CP06 displayed linear chemical shift perturabtion and
CP67 exhibited large line-broadening as ligand concentration was increased.
CP67 displayed very fast exchange rate on the NMR time scale as resonances
were averaged for the free and bound species of CPG2 (Figure 4.18) (Bryant
1983). In some cases, shifts were not in a straight line, which was indicative of
an intermediate conformation formed during the titration displaying a
conformational transition in the bound protein (Williamson 2013). Fitting the
chemical shift perturbations to a 1:1 binding model using Equation (4.3)
produced the best fits to the data and allowed calculation of the binding KD
constants for the few residues that suggested interaction between CPG2 and
CPO6. All KD values yielded to micromolar range values between 40-493 µM
(Figure 4.19). These values were very similar to the binding constants observed
with STD-NMR for CP06, where KD were ranging below 0.5 mM.
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Unfortunately, considering the pairing of line broadening with spectral crowding
upon titration as observed in Figure 4.20, KD could not be obtained for CP67
even when it was showing chemical shifts (Figure 4.21-F).
To conclude, it is evident from the STD-NMR data and chemical shift
perturbation data for CP06 and CP67 that residues are a ected by the
inhibitors binding that could be explained by direct interaction between CPG2
and the di erent structural parts of the inhibitors identified via STD-NMR
experiments: the aromatic ring and the glutamate moiety. However, further
work is required to confirm the scope of these ligand-induced e ects and
techniques. In the future, the determination of the solution structure of CPG2
could further characterise the binding sites, and conformational e ects of these
inhibitors in order to design more potent drugs.
155
Chapter 5
Site-directed Mutagenesis of
Positions Within or Close to the
Regions of CPG2 Directly
Related to Substrate Binding
5.1 Introduction.
The X-ray crystallographic structure of CPG2 has been determined (Rowsell
et al. 1997). It contains a co-catalytic domain and a dimerisation domain.
Analysis of the co-catalytic Zn(II) active site of CPG2 reveals a distinctive
similarity to the active site of Aeromonas proteolytica aminopeptidase AAP.
CPG2 contains two metal ions bound in its active site with a
(µ-aqua)(µ-carboxylato) dizinc(II) core as shown in Figure 5.1 (Remaut et al.
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2001). The coordination geometry of each Zn(II) ion is tetrahedral, with Zn1
being liganded by a carboxylate oxygen of Glu176 and an imidazole nitrogen of
His385. Similarly, Zn2 is coordinated by –-carboxylate oxygen of Glu200 and
imidazole nitrogen His112. These residues at the active site co-ordinates each of
the metal atoms separately and allow conservation of a Zn1 to Zn2 distance of
3.3 Å. The Asp141 residue co-ordinates both zinc ions at once while, near the
co-catalytic Zn(II) active site of CPG2 residues, a glutamate residue (Glu175)
forms a hydrogen bond to the zinc bridging water molecule (Rowsell et al.
1997). Glu175 probably functions as a general acid / base during catalysis by
making the water molecule reactive, in a similar manner to Glu151 in AAP
(Bzymek and Holz 2004).
Glu175
Glu176
His385
His112
Glu200
Asp141
Zn1
Zn2
H2O
Figure 5.1: Zinc binding domain. View of CPG2 catalytic site based on the X-ray
crystallographic structure by rowsell1997 (PDB: 1CG2). The site is shown in a ball and stick
representation. Zinc ions are represented as purple spheres and the water molecule as a grey
spheres. The residues involved in catalysis are also displayed. [Pymol Viewer]
In ADEPT, the pro-drug is converted from an inactive form to a cytotoxic
agent by CPG2. As the mechanism of action of CPG2 has not been elucidated
yet, the spectrum of inhibitors which are used in medicine is limited. The usual
features that seem to be crucial include an –-carboxylated moiety on the L-
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glutamate residue and a benzyl ring close to the carbonyl carbon of the amide
bond (Khan et al. 1999; DeAngelis et al. 1996). Thiolate-containing inhibitors
based on a thiocarbamate moiety attached to a benzene ring have also been
reported for CPG2 but were only moderately e ective competitive inhibitors and
displayed toxicity towards human colonic epithelial cancer cell lines (LS174T
cells), possibly allowing their use as inhibitors in ADEPT (Khan et al. 1999). As
described in Chapter 4, Mologic has since developed peptide-based ligands that
targeted the CPG2 enzyme. These peptides must also carry sugar residues that
enable them to be bound by the asialglycoprotein receptor of hepatocytes, to
ensure e cient clearance of the inhibited CPG2 complex via the liver. As shown
previously in Chapter 4, these inhibitors are made of a warhead, which consists of
an aromatic group and a glutamate moiety, attached to a galactosylated tail (see
Figures 4.1 and 4.2 on pages 112 and 113 respectively). The warhead is directly
implicated in CPG2 recognition and its inhibition, whereas the galactosylated
tail is present to ensure rapid removal of the inhibited CPG2 complex from the
bloodstream.
The overall structure of CPG2 is very similar to the structures of
corresponding domains in the related enzymes aminoacylpeptidase (AAP) and
membrane-bound human glutamate carboxypeptidase II (GCPII) (Lindner
et al. 2003). Their mechanisms of catalysis were proposed via the use of
computational methods (Klusák et al. 2009; Schürer et al. 2004). Using
information extracted from these studies, a binding mode hypothesis was
established for the CPG2-MTX complex by applying molecular docking and
molecular dynamics simulation (Turra et al. 2012). Turra et al. (2012)
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established that MTX was interacting at a very specific position in the CPG2
catalytic region, which may direct the substrate recognition and cleavage
mechanism (Figure 5.2) (Turra et al. 2012). CPG2 seemed to accommodate
MTX in the active site by adjusting the N-terminal pteroate moiety of MTX in
an adjacent pocket (P1). The pteridine group looked to remain secure via
hydrogen bonding interaction involving nitrogen atoms from pteridine and the
carbonyl oxygen from Ser210, Lys208 and Thr357. The glutamate side-chain
pointed towards the protein surface and appeared to be hydrogen bonded to
Arg324 and Gly360 residue, which are located in another pocket adjacent to the
active site (P2). Rowsell et al. (1997) showed that the Arg324 mutation to
alanine resulted in a mutant CPG2 with very low activity towards
methotrexate. Arg324 is obviously playing an important part in catalysis but its
exact role still remains unknown. None of the other residues thought to be
involved in substrate recognition was studies by site-directed mutagenesis yet.
P2
P1
Catalytic 
Site
Figure 5.2: Two possible pockets in the CPG2 active site. The protein external surface
of interior cavities and pockets in the active site are shown based one the X-ray crystallographic
structure by Rowsell et al. (1997) (PDB: 1CG2). The catalytic site’s molecular surface is
coloured in pink and the two possible P1 and P2 pockets are displayed in red and yellow,
respectively. The residues possibly involved in substrate molecular recognition are also shown.
[Pymol Viewer]
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Despite the above-stated e orts, the reaction mechanism of CPG2 is not
fully understood and, to date, no co-crystallised complex has been published.
This work sought to further complement the structural results obtained from
CPG2 X-ray crystal structure, and computational simulations of CPG2-MTX
complex, using site-directed mutagenesis studies to focus on the e ects of more
comprehensive residue mutation in both P1 and P2 pockets, and also the catalytic
site of CPG2, against MTX and competitive inhibitors produced by Mologic
(see Figures 4.1 and 4.2 on pages 112 and 113) using the well-established CPG2
spectrophotometric assay (Bhatia et al. 2000).
5.2 Site-Directed Mutagenesis, Expression and
Purification of CPG2 Mutants.
Mutagenesis was used to report the site of functional importance for MTX (and
its competitive inhibitors) binding. This study was aimed at describing the
contribution of the di erent residues introduced above, and previously proposed
in therotical studies to MTX substrate recognition and / or binding. Figure 5.3
shows the di erent residues possibly participating in substrate recognition and
catalysis. The intention was to mutate all the residues shown in Figure 5.3 to
alanine, a small uncharged amino acid, to establish whether the side-chains of
these various residues played a critical role in CPG2 bioactivity. The residues
taken forward for the study were H112, H385, E175, E176, E200, D141, K208,
S210, T357 and G360.
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Figure 5.3: Residues mutated to alanine in the active site. Top panel shows the di erent
residues within CPG2 proposed to make up binding sitemapped onto the x-ray crystallographic
structure by Rowsell et al. (1997) (PDB: 1CG2). Bottom panel is a close-up of the region
possibly involved in MTX catalysis. In pink are shown the residues involved in catalysis, in red
the residues possibly interacting with the pteridine moiety of MTX and in yellow the residue
that may be in contact with the glutamate group of MTX. [Pymol Viewer]
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Site-directed mutagenesis1 were performed using the QuickChange
site-directed mutagenesis kit (Stratagene, La Jolia, CA) according to
manufacturers instruction. The oligonucleotide primers used to introduce the
alanine mutation at each residue position into the pet151-CPG223-415 plasmid
are shown in Table 2.3 on page 37. The presence of the mutation was verified by
DNA sequencing (GATC, UK). Successful mutations were carried out for
H112A, H385A, E175A, E200A, D141A, K208A, S210A and T357A. E176A and
G380A mutations were not obtained, as transformation of plasmids
pet151-E176A and pet151-G380A into E. coli were not e ective.
All mutant constructs were expressed and purified using the same
purification protocol used to produce unlabelled CPG223-415 in order to avoid
additional optimisation steps for purification (Section 3.3). The mutants were
stored in 20 mM Tris (pH 7.3) containing 100 mM NaCl and 20% glycerol, at
-20¶C until future use. Figure 5.4 shows typical purification steps and
characterisation by MALDI-TOF carried out for each mutant. The second
round of nickel a nity chromatography (Figure 5.4-A, lane FT) produced a
very pure mutant protein sample, as confirmed by MALDI-TOF (Figure 5.4-B)
for T357A. This removed the need for an extra purification step using
size-exclusion chromatography. MALDI-TOF of the T357A mutant showed a
monomeric peak at 41,683.91 Da (theoretical mass is 42,296.1 Da) (Figure
5.4-B). Three additional small peaks were also observed due to MALDI matrix
ions causing interference.
1Mutagenesis was performed by Carla Brackstone (Department of Chemistry, University of
Warwick), while I designed the experimental side (design of primers, etc) and analysed the
data.
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Figure 5.4: Typical purification of a mutant construct. A) Coomassie-stained SDS-
PAGE gel (top) and anti-His western blot (bottom) summarising purification and cleavage of
the His-tag from T357A. Lanes 1-5 show elution of the protein from a Ni-NTA a nity column,
followed by desalting of the protein using a PD10 column, and cleavage of the His-tag from
CPG2 using TEV protease. Cleavage was approximately 50% complete after 48 hours, at which
point a second round of nickel a nity chromatography was used to collect the untagged T357A
in the flow through (FT) and first elution fraction (E). A protein marker (M) is shown for
reference. B) The MALDI-TOF mass spectrum of unlabelled T357A. Monomeric and dimeric
species were observed in the mass spectrum (calculated size: 42,296.1 Da).
The same procedure was successfully applied for purification of H112A,
H385A, E175A, E200A, D141A, K208A and S210A mutants (Figure 5.5). For
MALDI-TOF analyses, a positive ion linear mode method was used to collect
the mass spectra. In this mode, MALDI produces positive ions, usually in the
formsof (M+H)+. The technique can also produce multiply charged ions,
usually up to +3, as well as dimers, trimers, etc. Figure 5.5 shows that dimeric
species are observed in the mass spectra of mutants H385A, E175A, E200A,
K208A and S210A, although none of the SDS-PAGE gels, nor western blots,
suggested the presence of higher order oligomeric state for any of these mutants.
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Figure 5.5: Purification of mutants. The same purification protocol used for T357A
mutant shown in figure 5.4 was applied for the rest of the CPG2 mutants. The coomassie-
stained SDS-PAGE gel purification is shown as an inset to the MALDI-TOF mass spectrum.
Lanes 1-5 show elution of the protein from a Ni-NTA a nity column. A protein marker (M) is
shown for reference. Both monomeric and dimeric species were observed in the mass spectrum
of mutants H385A (calculated size without His-tag: 42,260 Da), E175A (calculated size without
His-tag: 42268.1 Da), E200A (calculated size without His-tag: 42268.1 Da), K208A (calculated
size without His-tag: 42269 Da) and S210A (calculated size without His-tag: 42310.1 Da).
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To check whether these various point mutations had an impact on the
expression levels of the mutant proteins compared to wild-type CPG2, relative
quantification of gene expression was achieved by comparison of the expression
level of the protein of interest with that of wild-type CPG2. Cell density for
each sample was normalised to an OD600 of 6 to allow comparison. Figure 5.6
shows that the H112A mutant had the lowest expression level, followed by
K208A and S210A mutants. On the other hand, H385A displayed the highest
level of expression amongst all mutants. The protein yields (per litre of culture)
for each mutant were calculated via BCA assay. The yield of all purified
mutants protein was reduced in comparison to wild type expression levels (251.6
mg, Table 3.1 on page 82). H112A, D141A and K208A mutants had the lowest
yields with 23.4 mg, 15.1 mg and 63 mg respectively, while H385A and E200A
mutants displayed the highest expression yields with 153.1 mg and 125.2 mg
respectively. In general, lower yield of purified mutant proteins could be
attributed to the instability of the mutant proteins.
Figure 5.6: Coomassie-stained SDS-PAGE gel comparison of expression levels of
wild type and its point mutant proteins. All point mutant plasmids were transferred
in E. coli BL21 DE3 bacterial strain, where the recombinant mutant proteins were tested for
expression before (U ) and after (I ) induction with 0.5 mM IPTG. The top band in each lane
corresponds to the band of interest, and is absent from uninduced (U ) lanes, except for K208A
and S210A mutants where leaky expression was noticeable. Collected samples were normalised
to an OD600 of 6 for comparison. The protein yields (per litre of culture) for H112A, H385A,
E175A, E200A, D141A, K208A, S210A and T357A were 23.4 mg, 153.1 mg, 74.9 mg, 125.8 mg,
15.1 mg, 63.1 mg, 114.8 mg and 112.1 mg, respectively. The final concentration was determined
using the BCA assay.
165
Chapter 5
5.3 Investigation of Mutant Proteins Secondary
Structure Using Circular Dichroism.
5.3.1 Secondary Structure Di erences.
The CD spectra of the mutants produced were measured in the far-UV region
in order to determine whether any important changes in secondary structure
were observable in comparison to the native wild-type protein (Figure 5.7-A)
(Greenfield 2006). CD measurements were performed at pH 7.3 in 20 mM Tris
bu er. Far-UV CD spectra of the proteins at 25¶C have a similar shape, with a
negative maximum at 209 nm and positive maximum at approximately 190 nm,
and similar intensities. The CD data at 25¶C were fitted using the CDSSTR
algorithm at DichroWeb and the percentage secondary structure content were
estimated and are shown in Figure 5.7-B (Whitmore and Wallace 2008). The
data showed very similar population-weighted combinations of each contributing
secondary structure types, –-helix, —-sheet, turn and random coil, since these
single amino acid mutants have overlapping spectra. This finding indicated that
the mutant proteins have very similar secondary structure content to wild-type
protein.
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A 
B 
Figure 5.7: Circular dichroism. A) Far-UV CD spectra collected between 190-240 nm for
wild-type CPG2 and all mutants (0.1 mg.mL-1) solubilised in 20 mM Tris bu er containing 100
mM NaCl and 0.2 mM ZnCl2. B) Percentage of secondary structure for wild-type CPG2 and
all mutants using DichroWeb (Whitmore and Wallace 2004). Circular dichroism measurements
were recorded using a Jasco J-1500 spectrophotometer with 0.1 mm cylindrical cell. Each
spectrum was accumulated at least 8 times at room temperature.
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5.3.2 Thermal Stability.
Thermal stability of the wild type and mutant proteins was studied by monitoring
the loss in secondary structure as a function of temperature by CD measurements.
A wavelength of 220 nm was chosen to monitor –-helical features of the proteins
structure. The CD signal at that wavelength was then recorded continuously as
the temperature was raised from 20¶C up to 90¶C using a Peltier unit.
The results are collected in Figure 5.8 as scattered plots fitted (in red) to
the sigmoidal boltzmann Equation (5.1) when possible.
y = A2 +
(A1 ≠ A2)
1 + e
x≠x0
dx
(5.1)
where A1 is the initial ellipticity value at 220 nm, A2 is the final ellipticity value
at 220 nm, x0 is the Tm at which temperature is halfway between the initial and
the final ellipticity value at 220 nm, dx describes the steepness of the curve.
All proteins aggregated or precipitated quickly after they were melted at
90¶C, making unfolding irreversible. Melting temperatures for H385A, E200A,
D141A, K208A, S210A and T357A mutants ranged from 53.24 to 64.28¶C, which
are very close to the wild-type protein Tm of 60.43¶C. H112A showed the lowest
Tm value of 28.23¶C, while E175A showed the highest Tm value of 71.45¶C. This
implied that the E175A mutation conferred increased stability to the protein. On
the other hand, H112A mutation decreased protein stability as it unfolded at a
lower temperature.
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The unfolding mechanism for many globular proteins is essentially a
two-state process, where only the folded and unfolded states are reasonably
populated at equilibrium (Pace et al. 1999; Waldner et al. 1999). This was
observed for wild-type, H385A, E175A, E200A, D141A, K208A, S210A and
T357A mutant proteins where proteins from a folded state, at lower
temperatures, continued onto an unfolded state as temperature was increased.
The presence of a sigmoidal curve is usually considered as a strong indication of
the occurrence of a two-state denaturation process (Privalov and Khechinashvili
1974; Privalov 1997). The cooperativity of the unfolding reaction is measured
qualitatively by the width and shape of the unfolding transition (Consalvi et al.
2000). A rapid and highly cooperative unfolding reaction was observed for
H385A, S210A, K208A and T357A (Figure 5.8-H385A, S210A, K208A and
T357A). In the X-ray crystal structure, these residues are located in the
dimerisation and catalytic domains of CPG2. The data suggest that these
proteins exist initially as a compact well-folded structure. The mutation of
these residues from the dimerisation and catalytic domains seemed to also
increase the rate of unfolding, which suggested that both domains may unfold
as a single, larger cooperative unit compared to wild-type (Vermeer and Norde
2000). It inferred that the H385A, S210A, K208A and T357 mutants may
increase the stability of the domain they are respectively located in, and / or
the neighbouring domain. Secondly, a very gradual, non-cooperative melting
reaction was observed for E175A, E200A, D141A and wild-type proteins (Figure
5.8-E175A, E200A, D141A and WT), all of which are located in the catalytic
domain. This suggested that the proteins existed initially as a very flexible,
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folded protein, which is consistent with the presence of the two di erent
domains (i.e catalytic and dimerisation domains) in the protein. The mutation
of these residues in the very flexible region of the catalytic site may have not
significantly changed the cooperative unfolding behaviour of the two domains
within the protein, compared to wild-type. However, H112A (located in the
catalytic domain) displayed a peculiar behaviour compared to the other mutant
and wild-type proteins (Figure 5.8-H112A). The H112A melting curve showed a
double sigmoidal curve, as if the H112A mutant protein could not unfold in a
single transition, but in two transitions. This may indicate that the catalytic
and dimerisation domains of H112A unfolded independently, with one of the
domains unfolding rapidly at low temperatures (around 30¶C) compared to the
other domain, where a slow unfolding transition was observed at higher
temperature (Vermeer and Norde 2000). It may also suggest that mutation of
residue H112 in the catalytic site had a bigger impact on the cooperative
unfolding behaviour of the two CPG2 domains than the mutation of residues
E175, E200 and D141, also located within the catalytic site, had. As a result
H112A melting curve could only be fitted using the double Boltzmann equation
in order to obtain the Tm of the first unfolding domain.
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5.4 Use of CPG2 Spectrophotometric Assay to
Study the E ects of Residue Mutation on
Substrate Binding.
Finally a spectrophotometric assay was used to measure the catalytic activity of
the mutant proteins, by monitoring the rate of degradation of MTX at 320 nm.
Figure 5.9 shows the results. We expected that the mutations disturbing the
catalytic site would inevitably result in inactive forms of CPG2, whereas the
mutations involving P1 pocket would result in reduced activity of CPG2.
H112A, E175A and D141A mutant proteins (found in the catalytic domain)
revealed very low activities against MTX. However, H385A and E200A showed
measurable activity. Although the activity is reduced compared to wild-type
CPG2, it was noteworthy. H385A and E200A showed activities of 50.87 and
63.70 U/mg, respectively. Residue H385 co-ordinates zinc 1, whereas amino acid
E200 co-ordinates zinc 2 (Figure 5.1). H112A mutant protein resulted in
inactivity, while its counterpart H385A co-ordinating zinc 1 appeared active
(Figure 5.3). H112A mutant protein was less active at low temperature than
H385A mutant protein, which could explain activity di erences. The same
comparison between E200A and E176 could not be made as the pet151-E176A
plasmid would not transform into BL21 DE3 E .coli strain. There were possibly
other residues in the region that have compensated for the absence of residues
H385 and E200. Mutants K208A, S210A and T357A also had very low-activity
against MTX. It implied that these residues, residing in P1 pocket, are possibly
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involved in substrate recognition.
Figure 5.9: Enzymatic activity assays of each mutant and wild-type proteins. A)
Enzymatic activity measurements for all mutants as measured using the methotrexate cleavage
assay.B) Enzymatic activity measurements for boiled protein was included as a negative control
in the same assay. The calculated specific activity values from these assays were CPG2: 96.7
U/mg, H112A: 3.91 U/mg, H385A: 50.87 U/mg, E175A: 2.40 U/mg, E200A: 63.70 U/mg,
D141A: 1.75 U/mg, K208A: 3.93 U/mg, S210A: 1.46 U/mg and T357A: 1.42 U/mg.
The next step was to analyse the sensitivity of mutants that remained active
after mutation to CP06 and CP65 inhibitors (Figure 4.1 on page 112). To test
a potential inhibitor of CPG2, it was diluted with the assay bu er. The final
concentration of the solution depended on the solubility of the material in the
bu er. Both H385A and E200A mutant proteins were active against MTX, and
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inhibited by CP06 and CP67 (Figure 5.10). This suggested that CP06 and CP67
bind to the CPG2 active site, preventing MTX from binding and being degraded
by CPG2. This data also indicated that H385 and E200 residues can be replaced
by an alanine residue and still behave very similarly to wild type CPG2 protein.
Figure 5.10: Competitive enzymatic activity assays of H385A and E200A mutant
proteins. A) Competitive enzymatic activity measurements for H385A mutant using CP06 and
CP67 inhibitors as measured using the methotrexate cleavage assay. B) Competitive enzymatic
activity measurements for E200A mutant using CP06 and CP67 inhibitors as measured using
the methotrexate cleavage assay.
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5.5 Conclusion.
The main question concerned whether the selected residues for site-directed
mutation revealed the potential binding site of MTX and their inhibitors on
CPG2. First, all constructs were easily made, transformed in E. coli BL21 DE3,
expressed and purified for characterisation, except for E176A and G360A
(Figures 5.4 and 5.5). As a result, P2 pocket’s implication in substrate
recognition could not be clarified.
Characterisation of the proteins expressed revealed the presence of dimers
in the MALDI-TOF spectra for H385A, E175A, E200, K208 and S210A mutant
proteins. This was also observable with the wild-type protein (Figure 3.10-B,
page 92). This suggested that the mutation of these residues did not a ect the
capacity for the protein to dimerise.
Moreover, the e ect of a mutation on the secondary structure of a protein
can be studied by CD spectroscopy in the "far-UV" spectral region (190-240
nm) (Whitmore and Wallace 2004). Unfortunately, CD analysis did not present
considerable discrepancies in the far-UV region (Figure 5.7). Therefore, it was
decided to study stability of the protein using CD thermal melts (Figure 5.8).
For most proteins secondary structure is lost upon unfolding and the far-UV
CD spectra of a folded and unfolded protein are therefore unique. Thus, the
thermal stability of each mutant and wild-type proteins was investigated by
measuring the intensity of the CD signal at a fixed wavelength (e.g. 220 nm for
the –-helical region) as a function of temperature. Melting temperatures for
H385A, E200A, D141A, K208A, S210A and T357A mutants ranged from 53.24
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to 64.28, which are very close to the wild-type protein Tm of 60.43¶C.
Additionally, the shape of the sigmoidal curve allowed to understand more
about the unfolding process of each protein. H385A, E175A, E200A, D141A,
K208A, S210A, T357A and wild-type proteins were in a folded state at lower
temperatures which continued onto an unfolded state as temperature was
increased. This implied that the unfolding process for these proteins was
essentially a two-state denaturation process. The cooperativity of the unfolding
reaction was measured qualitatively by the width and shape of the fitted
sigmoidal curve (Figure 5.8). A rapid and highly cooperative unfolding reaction
was observed for H385A, S210A, K208A and T357A. It suggested that the
protein existed initially as a compact, well-folded structure. Secondly, a very
gradual, non-cooperative melting reaction, was observed for E175A, E200A,
D141A and wild-type proteins indicating that the proteins existed initially as a
very flexible, folded protein, which is consistent with the presence of the two
di erent domains (i.e catalytic and dimerisation domains) in the protein.
Amongst, all these proteins only H385A, E200 and wild-type demonstrated
activity against MTX substrate (Figure 5.9). H385 showed the lowest activity of
50.87 U/mg, whereas both wild-type and E200A presented activities of 96.70
and 63.70 U/mg, respectively. The greater specific activity levels may be also
associated with higher flexibility observed within the folded wild-type and
E200A proteins. However, the melting data showed significant di erence in Tm
with H112A and E175A construct. H112A showed the lowest Tm value of
28.23¶C, while E175A showed the highest Tm value of 71.45¶C. H112A mutant
protein also showed a di erent tendency. The H112A melting curve showed a
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double sigmoidal curve, as if H112A protein could not unfold in a single
transition, but in two transitions. This is also consistent with the presence of
two di erent domains within the protein and suggested the unfolding of one of
the domains in preference to the other. Since H112 residue is found in the
catalytic domain, it may imply that the catalytic domain was the first to unfold
and its secondary structure became more unstable upon mutation. These data
were supported by the low expression level observed showed in Figure 5.6 and
the absence of activity against MTX observed in Figure 5.9.
To conclude, only two mutations within the catalytic site, H385A and
E200A showed activity against MTX and were inhibited by CP06 and CP67.
This suggested that not only CP06 and CP67 were competitive CPG2
inhibitors, but that H385 and E200 residues did not play an important part in
the MTX recognition process because replacement of both residues by alanine
still generated active proteins. However, inhibition of H385A and E200A
mutant protein was achieved by CP06 and CP67. Since theses residues are
co-ordinated to both zinc ions, these data indicated that the protein may have
compensated for their absence some other way. H385A showed better stability
than wild-type, whereas E200A showed higher flexibility than the wild-type
CPG2 according to CD thermal melts analysis. All other mutants showed loss
of activity. E175A, E200A and D141A mutants had reduced activity against
methotrexate implying that they were crucial for catalysis to occur, as they
co-ordinate to the metal centres. However, there is no clear explanation as to
why H112A resulted in inactivity, when its counterpart H385A co-ordinating
zinc 1 appeared active (Figure 5.3). Although residues in P2 pocket could not
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be analysed, K208A, S210A and T357A mutations from P1 pocket manifested
no activity against MTX, validating their involvement in substrate recognition.
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Characterisation of Engineered
Individual Domains of CPG2
6.1 Introduction.
We have seen in previous chapters that one of the most important tools for
probing physiological processes, mainly controlled by intermolecular recognition
mechanisms involving protein-ligand interactions, is solution state NMR
spectroscopy through protein-based and ligand-based experiments.
In protein-based methods, chemical shift is the easiest variable to monitor in
order to locate the ligand binding site. The major disadvantages of protein-based
methods are the experimental time, and the need for isotopically-labelled protein
with good solution properties soluble at high concentration. Chapter 3 describes
methods used to overcome these challenges. Unfortunately, these methods are
179
Chapter 6
restricted to proteins with relatively low molecular masses (below 30 kDa) to
avoid di cult labelling strategies and full resonance assignment. In order to
explore the structure of CPG2 in solution upon binding of its inhibitors, the
NMR resonances must be assigned to specific nuclei of the protein. As the size of
the protein increases, the assignment process becomes progressively problematic
because of amplified spectral overlap in the already poorly resolved NMR spectra.
E orts at more exhaustive labelling (15N/13C/2H) were unable to overcome this
issue; hence a “divide-and-conquer” approach where individual domains of the
full-length enzyme were cloned, expressed and purified was used to reduce the
molecular-weight to a range more amenable for NMR studies.
6.2 Di erent Domains of CPG2.
According to the crystal structure (PDB ID: 1CG2), CPG2 consists of distinct
protein domains associated with di erent functions, namely a dimerisation
domain inserted between two non-contiguous regions of the catalytic domain
(Rowsell et al. 1997). Rowsell et al. (1997) suggested that the catalytic domain
is likely to contain the binding site as it provides the substrate with two zinc
ions in the active site required for cleavage. Considering this molecular domain
organisation, we decided to dissect the protein into three smaller fragments
suitable for NMR structural studies: the 12.73 kDa dimerisation domain
fragment (CPG2DIM, residues 213-322); the full 30.95 kDa catalytic domain
fragment (CPG2CAT, composed of residues 23-214 and residues 323-415 linked
via a non-native alanine); and the largest 21.27 kDa contiguous region of the
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catalytic domain (CPG2CAT’, composed of residues 23-198) (Figure 6.1).
Figure 6.1: Di erent domains of CPG2. Left panel: coloured in purple is the catalytic
domain and in orange is the dimerisation domain of CPG2. Right panel, the largest contiguous
region of the catalytic domain coloured in purple is shown. PDB: 1CG2, (Rowsell et al. 1997).
6.3 Cloning and Expression of the Individual
Domains.
6.3.1 Preparation of Plasmid DNA Constructs.
The pET151-D-topo plasmid containing the CPG223-415 gene was used as a
template to generate cDNA sequences of the di erent constructs (CPG2DIM,
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CPG2CAT and CPG2CAT’), which were then sub-cloned into pET151-D-TOPO
vector (Invitrogen, UK) with an N-terminal tag containing the V5 epitope and a
hexahistidine a nity tag, which could be removed by TEV cleavage. The
CPG2DIM and CPG2CAT’ constructs were easily generated, while the CPG2CAT
(made of two non-contiguous regions of the catalytic domains) required two
regions of the gene to be amplified and ligated through the presence of an extra
non-native amino acid, alanine (Figure 6.2).
Figure 6.2: Construction of His-tagged recombinant proteins. Schematic diagram
shows primary structure (N- and C-termini of protein) and functional domains (signal peptide:
amino-acids 1-23, catalytic domain: amino-acids 23-214 and 323-415, and dimerisation domain:
amino-acids 213-322) of CPG2 as described previously.
It was unknown whether the absence of the dimerisation / catalytic domains,
or the addition of an extra alanine residue between the two non-contiguous regions
of the catalytic domain, would have an impact on the fold of the di erent domains
generated (Figure 6.1). All the constructs were successfully prepared, confirmed
via multiple analyses of PCR products performed on 1-2% agarose gels and DNA
sequencing by (GATC, Germany) as described in Figure 6.3.
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Figure 6.3: 1-2% agarose gel electrophoresis of PCR products. A) PCR products
from pet151-CPG223-415 plasmid using the appropriate pair of primers for each construct as
described in Table 2.3 of Chapter 2. Lane 1: amplification of the CPG2DIM gene (expected
band: 330 bp). Lane 2: amplification of the gene encoding the N-term region of the CPG2CAT’
domain (expected band: 528 bp). Lane 3: amplification of the largest sequence of CPG2CAT
gene (expected band: 576 bp). All PCR products were confirmed by sequencing. Lane 4:
amplification of the gene encoding the N-term region of the CPG2CAT domain (expected band:
282 bp). B) Lanes 2-3: Positive PCR products (indicated with a purple arrow) resulting from
the ligation of the largest and smallest genes composing CPG2CAT gene sequence. C) Cloning
confirmation of the gene of interest into pET151 vector by colony PCR using T7 forward and
reverse primers. Lanes 3-4: positive PCR products for pet151-CPG2DIM (expected band: 592
bp, indicated with an orange arrow, left panel). Lanes 8 and 10: positive PCR products for
pet151-CPG2CAT’ (expected band: 790 bp, indicated with a black arrow, left panel). Lanes
19, 20 and 24: positive PCR product for pet151-CPG2CAT (expected band: 1120 bp, indicated
with a purple arrow, right panel).
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6.3.2 E ect of Changes in Temperature and IPTG
Concentration on Expression.
To investigate whether these domains were able to fold and function
independently of each other, each of the above three constructs was expressed
with uniform labelling in E. coli. Induction temperatures and IPTG
concentrations were varied to optimise the expression levels in rich media.
Figure 6.4 shows that optimal expression was achieved at 25¶C for all three
proteins. Changes in IPTG concentration had little impact on expression levels
of CPG2CAT and CPG2DIM at 25¶C (Figures 6.4-A,C). However, upon visual
inspection of the SDS-PAGE gel, expression levels of CPG2CAT’ improved when
0.7 mM IPTG was added (Figure 6.4-B). Hence, to keep the expression protocol
identical across all constructs, for simplicity, protein expression was induced
with 0.7 mM IPTG induction at 25¶C for 18 hours.
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Figure 6.4: E ects of IPTG concentration and temperature changes on expression.
Total expression levels of A) CPG2CAT, B) CPG2CAT’ and C) CPG2DIM at 37¶C, 25¶C and
15¶C with 0.3 mM, 0.7 mM and 0.9 mM IPTG (expression band of the corresponding protein
of interest is indicated with a black arrow).
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6.4 Preparation of Isolated CPG2 Domains
Narrows Down Requirements for Activity.
To streamline expression of multiple proteins in parallel, the optimal expression
conditions in rich media were directly applied to expression of CPG2 fragments
in labelled minimal media. The condensation method (see in Section 2.2.5 of
Chapter 2) was also applied, but without the use of double colony selection. As
shown in Figure 6.5 all three constructs were purified using the same
purification protocol used for CPG223-415 in order to avoid additional
optimisation steps for purification (Section 3.2). The activity of each labelled
construct was then assessed using the methotrexate-based activity assay and
the activities are provided in Table 6.1.
Figure 6.5: Characterisation of CPG2CAT, CPG2CAT’ and CPG2DIM. A): SDS-
PAGE purification gels. (M ) denotes the molecular weight marker, lanes (1) to (5) show
protein samples eluted after purification by Ni-IMAC chromatography. B): Size-exclusion
chromatography for (from left to right) [U-2H,13C,15N] CPG2CAT, [U-15N] CPG2CAT’ and [U-
15N] CPG2DIM constructs respectively (the black arrow indicates elution of monomeric untagged
protein). C): Enzymatic activity assay against the substrate methotrexate.
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As expected, CPG2DIM yielded low activity (compared to CPG223-415)
(Table 6.1). CPG2CAT yielded activity was 62% of that observed for CPG223-415,
suggesting that linking these two polypeptide chains and adding an extra amino
acid (alanine) did not disrupt the domain structure so critically that all
function was lost (Table 6.1). Removal of residues 323-415 from the catalytic
domain, to create the CPG2CAT’ protein, lead to a further reduction in catalytic
activity indicating that the C-terminal region of the catalytic domain is
implicated in substrate recognition / activity.
Table 6.1: Di erence in expression yield between CPG223-415 and its
individually expressed domains.
Constructs His-tag Activity Specific Protein Yield†
Terminus U/mL Activity
U/mg
Unlabeled 15N 2H/13C/15N
(2◊YT) (M9) (M9)
CPG223-415 N 100.3 75.5 251.6 nd‡ 70-109.42
CPG2CAT N 62.8 42.7 91.4 65.8 95.2
CPG2CAT’ N 8.2 3.7 nd 21.6 nd
CPG2DIM N 1.5 2.9 48.8 5 nd
† Yields of purified proteins are in mg/L of culture.
‡ Not determined.
At the high concentrations required for NMR analyses, it was crucial to
eliminate any ambiguity originated by the presence of dimers. Gel-filtration
suggest the presence of higher oligomeric states for CPG223-415 (Figure 3.3-B)
and CPG2CAT (Figure 6.5-B), but no dimers (or higher order oligomers) were
observed for CPG2DIM, which was thought to form the dimer interface in
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CPG223-415 (Figure 6.6-B). This is likely due to the low concentration of purified
CPG2DIM (Table 6.1). For the constructs that did form oligomers, gel filtration
chromatography was used to isolate the monomeric form of these proteins
(Figure 6.5-B).
(a) Purified CPG2CAT.
(b) Purified CPG2DIM.
Figure 6.6: MALDI-TOF spectra of the isotopically labelled proteins. A) [U-2H,
13C, 15N]-labelled CPG2CAT (theoretical monomeric size: 35,275 Da). B) [U-15N]-labelled
CPG2DIM construct (theoretical monomeric size: 12,932 Da). M, D, and T denote the presence
of monomer, dimer and trimer respectively.
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6.4.1 Purification of CPG2CAT, CPG2CAT’ CPG2DIM by
Gel Filtration Chromatography.
Elution fractions from IMAC containing CPG2CAT, CPG2CAT’ CPG2DIM were
next applied to PD10 desalting columns (see Section 2.2.6) and further purified
by Gel Filtration Chromatography (see Section 2.2.7). Improved separation of
CPG2CAT, CPG2CAT’ CPG2DIM proteins was achieved by applying samples that
had been concentrated using 10 kDa MWCO (and 5 kDa MWCO for CPG2DIM)
concentrators (see Section 2.6.8) to a HiLoad 16/600 Superdex 75 g GL column
(separation range 1-120 kDa), under an isocratic gradient of 100% A (20 mM
Tris, 100 mM NaCl, pH 8). As shown in Figures 6.5-B and 6.7, CPG2CAT eluted
as a double peak at elution volumes of 65.99 mL for dimeric CPG2CAT and 57.15
mL for monomeric CPG2CAT. CPG2CAT’ and CPG2DIM eluted as single peaks at
elution volumes of 71.17 mL and 76.56 mL respectively (Figure 6.5-B).
By applying Gel Filtration standards to the column and running at the
same flow rate and with the same bu er (see Section 2.2.7), it was possible to
create a calibration curve of molecular weight against elution volume, assuming
a void volume of 25.0 mL. Plotting the relative retention times of CPG2CAT
protein on this curve gave predicted molecular weights of around 34 kDa and 70
kDa (calculated monomeric peak for CPG2CAT is 30,736 Da), and therefore
CPG2CAT is expected to migrate and exist as a monomer and a dimer, as a
consequence it seem to retain CPG223-415 protein’s capacity to dimerise.
However, plotting the relative retention times of CPG2CAT’ and CPG2DIM
proteins on this curve gave predicted molecular weights of around 22 kDa and
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14 kDa respectively (calculated monomeric peak for CPG2CAT’ is 19428.10 Da
and calculated monomeric peak for CPG2DIM is 12497.100Da), and therefore
CPG2CAT’ and CPG2DIM are expected to migrate and exist as monomeric
species, therefore both fail to exist as dimers. This implies that the shortest
region of the catalytic domain may be involved in the dimerisation process.
Figure 6.7: Calibration curve obtained with Gel Filtration standards on HiLoad 16/600
Superdex 75 g GL column. An isocratic gradient of 100% of bu er A (20 mM Tris, 100 mM
NaCl, pH 8) was used. The calibration curve graph represents the gel phase distribution
coe cient Kav versus the molecular weight (MW). Kav = (Ve-Vo)/(Vc-Vo), where Ve =
elution volume, Vo = column void volume, Vc = geometric column volume. Straight line
is the calibration curve calculated from the data for molecular weight standards (see Section
2.2.7 and Figure 2.1). Using the equation for the line, values for the molecular weights of
CPG2CAT, CPG2CAT’, CPG2DIM were calculated. Molecular weights of CPG223-415 are plotted
for comparison.
190
Chapter 6
6.5 Preparation of Isolated CPG2 Domains
Leads to Greatly Improved NMR Spectra.
Two dimensional 1H-15N HSQC NMR spectra were then acquired for all three
protein constructs in Tris bu er (20 mM Tris, 100 mM NaCl, pH 7.3) to explore
their suitability for further structural characterisation, and the spectra are
shown in Figure 6.8. The 110-residue protein derived from the CPG2
dimerisation domain (CPG2DIM), did not yield a well-dispersed 1H-15N HSQC
spectrum, with most of the backbone amide 1H chemical shifts falling between
7.7 and 8.4 ppm (Figure 6.8-C). These results indicate that the dimerisation
domain is highly unstructured in isolation and likely required the presence of
the catalytic domain to fold correctly. The largest improvement in peak width
was observed for the 176-residue CPG2CAT’ protein, which produced a
well-dispersed 1H-15N HSQC spectrum suggesting a well-folded protein (Figure
6.8-B). However, given the low activity observed for this construct (3.7 U/mg,
Table 6.1), it is unlikely to be carried forward for structural investigation in the
future.
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(a) [U-13/15N]-labelled CPG2CAT.
(b) [U-1/H15N/13C]-labelled CPG2CAT.
(c) [U-15N]-labelled CPG2DIM
Figure 6.8: 1H-15N HSQC spectra of the di erent domains.. Approximately 0.8 mM
of A) CPG2CAT, B) CPG2CAT’ and C) CPG2DIM in 20 mM Tris and 100 mM NaCl pH
7.2 at 25¶C on 700 MHz using trosyetf3gpsi and hsqcetf3gpsi pulse sequences for CPG2CAT,
CPG2CAT’ and CPG2DIM, respectively.
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Significantly improved chemical shift dispersion was observed for the
CPG2CAT protein (Figure 6.8-A) suggesting that the non-contiguous catalytic
domain is able to fold in the absence of the dimerisation domain. However, an
overlay of the CPG2CAT HSQC spectrum with the corresponding spectrum of
CPG223-415 indicated that many of the chemical shifts have changed upon
removal of the dimerisation domain, likely because of the absence of contacts
between these domains (Figure 6.9). Nevertheless, comparison of the peaks in
the CPG2CAT HSQC spectrum to those in the corresponding spectrum of
CPG223-415 did show some improvement in line width and variable intensity
suggesting improved solution behaviour for this smaller construct while
retaining activity against methotrexate (Figure 6.5-C and Table 6.1).
Figure 6.9: 1H-15N HSQC spectra comparison of CPG2CAT and CPG223-415.
Overlay of CPG223-415 (in blue) with CPG2CAT (light-green) spectra. Used 1 mM sample
protein in 20 mM Tris and 100 mM NaCl, pH 7.2 at 25¶C using trosyetf3gpsi pulse sequence
(700 MHz).
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Since we were quite interested in the CPG2CAT construct, we decided to do
a rapid secondary structure determination to analyse how di erent the folding
properties of the engineered catalytic domain were compared to the structure of
the catalytic domain within the full-length CPG2 protein. We used CD to
analyse how ligating these two non-contiguous primary sequences to form the
catalytic domain a ected the final conformation for the catalytic domain
generated. DichroWeb, an online tool, was used to predict the secondary
structure from the data obtained via circular dichroism (Whitmore and Wallace
2004; Whitmore and Wallace 2008).
Figure 6.10: CD spectra of CPG2CAT. According to DichroWeb the secondary structure
content was 79% –-helix, 11% —-strand and 10% random coil (Whitmore and Wallace 2004;
Whitmore and Wallace 2008).
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6.6 Conclusion
A “divide-and-conquer” approach was utilised to study smaller domains of
CPG223-415 with solution properties (e.g. faster tumbling, slower relaxation)
more amenable to NMR measurements. Considering the molecular domain
organisation of CPG2, we chose to divide the protein into three smaller
fragments: the dimerisation domain fragment (CPG2DIM residues 213-322); the
full catalytic domain fragment (CPG2CAT composed of residues 23-214 and
residues 323-415 linked via a non-native alanine); and the largest contiguous
region of the catalytic domain (CPG2CAT’ composed of residues 23-198)
(Figures 6.1 and 6.2). CPG2DIM did not yield a well-dispersed 1H-15N HSQC
spectrum suggesting that the dimerisation domain is highly unstructured in
isolation and likely requires the presence of the catalytic domain to fold
correctly (Figure 6.8-C). The methotrexate-based activity assay also revealed
that CPG2CAT generated a low activity, one comparable to full-length CPG2.
On the other hand, as anticipated, CPG2CAT was active, but less active that
CPG223-415 suggesting than the dimerisation domain plays a role in catalysis
(Table 6.1). Plus, significantly improved chemical shift dispersion was observed
for the CPG2CAT protein suggesting that the non-contiguous catalytic domain is
able to fold in the absence of the dimerisation domain (Figures 6.8-A).
In an attempt to get a better-resolved spectra, we also tested a smaller
construct, CPG2CAT’. The 176-residue CPG2CAT’ showed the largest step-up in
peak width and the protein produced a well-dispersed 1H-15N HSQC spectrum
suggesting a well-folded protein (Figure 6.8-B). However, given the low activity
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observed for this construct (3.7 U/mg), it will not be carried forward for structural
investigation in the future (Table 6.1). Most importantly, the results revealed
the implication of the C-terminal region of the catalytic domain in substrate
recognition / activity.
196
Chapter 7
Discussion and Perspectives
The three-dimensional structure of CPG2 is of great interest due to its
therapeutic applications in the treatment of cancer and auto-immune diseases.
Early X-ray crystallography investigation of CPG2 (Rowsell et al. 1997)
demonstrated that it consists of two domains, the catalytic domain which
delivers the substrates for the two zinc ions in the active site, and the
dimerisation domain which is thought to stabilise the dimeric form of the
enzyme (Figure 1.3). This crystallographic data helped to better inform early
rational drug design e orts (Rowsell et al. 1997; Khan et al. 1999), but further
attempts at co-crystallisation of CPG2 with ligands, substrates or inhibitors
have not been reported and very little progress has been made since these early
studies to establish key features of CPG2 such as the location of its active site,
the presence of additional ligand-binding sites, its stability, its oligomeric state,
and the molecular basis of activity. Thus far, our current working understanding
of the molecular basis of CPG2 activity is largely based on sequence / structural
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homology and molecular modelling (Lindner et al. 2003). Solution state nuclear
magnetic resonance (NMR) spectroscopy is a unique tool for studying protein
structure, stability, dynamics, and ligand binding properties that could inform
structure-based drug discovery and provide a fundamental understanding of
CPG2 function (Wuthrich 1986; Stark and Powers 2012; Clarkson and Campbell
2003). The work presented in this thesis sought to gain further understanding of
the thermodynamic and structural aspects of the mode of binding of the
inhibitors Mologic Ltd. (Bedford, UK) has developed to target CPG2 enzyme,
but also the key features of CPG2, its stability and molecular basis of activity.
This chapter brings together the work pursued in order to address these
questions, and outlines how the results of the work have advanced our knowledge.
7.1 First Reported Method for High-Yield
Expression of Active and Soluble Mature
CPG223-415.
Chapter 3 describes the first reported method for high-yield expression of active
and soluble mature CPG2 (in the absence of the leader peptide) and its
individual catalytic and dimerisation domains in E. coli. We have used this
method to routinely produce milligrams quantities of 15N and 1H/13C/15N
isotopically-labelled protein suitable for NMR studies. Using a range of
biophysical methods, the impact of solution conditions such as ionic strength,
temperature and pH on the fold and stability of CPG2 was demonstrated, as
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well as its activity against one of its primary substrates, methotrexate.
Conditions were obtained (20 mM Tris, 0.1 M NaCl, pH 7.3) that enabled
preparation of concentrated and stable CPG2 samples suitable for NMR studies.
7.2 The Aromatic Ring and Glutamate Groups
are Essential Key Features in CPG2
Inhibitors.
Several attempts have been made to design potent inhibitors for CPG2. The first
active inhibitors N-benzoylglutamate (Levy and Goldman 1967), which showed
moderate inhibition activities against CPG2, and then thiocarbamate inhibitors
(Khan et al. 1999), which unfortunately were found to be toxic against LS174T
cells.
Recently a series of new inhibitors were synthesised by Mologic (Bedford,
UK) highlighting important structural aspects present in substrates such as
MTX for CPG2 enzyme (Turra et al. 2012). These were tested for their CPG2
inhibitory activity by Mologic using the octet RED system, which allows a nity
analysis of biomolecular interactions. A series of peptide clearing agents
consisting of a binding molecule which specifically targets and inhibits CPG2
activity at non-tumourous locations were analysed, where the most potent
inhibitors were CP06 and CP39 with an IC50 of 88.5 µM and 61 µM (Figures
4.1 and 4.2 respectively). The CP06 and CP39 inhibitors were also
galactosylated to allow and expedite clearance of the inhibited CPG2 enzyme
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via the liver by binding to the asialoglyco-protein receptor expressed by hepatic
cells (Figures 4.1—CP67 and 4.2—CP42, respectively). However, only CP67
(galactosylated CP06) showed significant inhibition with an IC50 of 93 µM.
We wished to investigate the reason why CP06 and CP39 retained or lost
inhibition strength upon galactosylation. The major structural di erences
between these two inhibitors are the galactosylated moiety and the type of
aromatic ring used. CP39 having degraded, we were left with with CP06, CP42
and CP67 for further investigations. The results revealed that glutamate is
essential for recognition and / or binding as protons of the glutamate group
showed saturation while none of the CP42 seemed to be close to the CPG2
binding site. This data could explain the absence of inhibition observed for
CP42 using the octet RED system and the very high KD values for aromatic
protons exhibiting saturation. Furthermore, although inhibitory properties can
be improved by replacing the naphthalene ring (CP06) with a benzyl ring
(CP39), the change in the aromatic ring type together with the galactosylated
group seemed to have an e ect on the inhibitory response of these ligands. As a
matter of fact, CP06 and CP67 inhibitors revealed that the naphthalene ring
may play a significant role in molecular recognition by CPG2 (Figures 4.7 and
4.8, and Table 4.1). Despite the benzyl ring of CP42 showing proximity to
CPG2 (Figures 4.9), the extracted CP42 KD from the STD-NMR titration
experiments revealed weaker binding than that of the naphthalene ring in CP67
(Table 4.1). A distinct di erence between CP67 and CP42 is the galactosylation
type and the length of the linker separating the galactosylated end and the
binding molecule inhibiting CPG2 (Figure 4.2—CP42). The galactose groups
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may be too close in space to the "warhead" in CP42. This absence of
conformational flexibility may a ect the adaptability of the ligand-binding site,
and this may explain the absence of saturation of the glutamate and aromatic
groups, and therefore the lack of inhibitory activity of CP42 towards CPG2.
The absence and presence of saturation for the glutamate group and benzyl
ring, respectively, suggest that CP42 does not e ciently sit within the CPG2
active-site, but that its benzyl ring still forms weak interactions with the CPG2
active site.
Site-directed mutagenesis of the hydrophobic pocket which was assumed to
receive the aromatic moiety according to the X-ray crystallography structure
and computational simulations showed that residues K209, S210 and T357
within the pocket P1 are essential for substrate recognition MTX (Chapter 6).
Mutation of these polar (K208 and S210) and aromatic (T357) amino acid by
alanine in CPG2 seem to have abolished electrostatic and / or ﬁ-ﬁ stacking
interactions respectively with the pteridine ring of MTX, and further supports
the importance of the aromatic moiety for CPG2 substrate recognition.
Furthermore, none of the protons of the galactosylated domain in CP67
revealed proximity to CPG2 protein. This result indicated that, firstly, the
galactosylated moiety was available for the hepatocyte receptors to bind to for
blood clearance of the complex, and secondly the galactosylated moiety did not
interfere with the CP67 domain responsible for its inhibitory activity and CPG2
recognition.
1H-15H HSQC data was used to determine the binding a nity of CP06 and
CP67 to CPG2. In general, 1H-15H HSQC is used to locate the binding site of
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the ligands on the target protein. However, 1H-15H HSQC spectrum assignment
of a large protein like CPG2 was not feasible due to line-broadening of the NMR
signals, spectral crowding and frequency degeneracy as a result of a large
number of expected NMR signals (theoretically 400 peaks for CPG223-415).
Hence prior to focusing on assigning cross-correlation peaks observed in the
1H-15H HSQC spectrum to each CPG2 nuclei, a very simple method was used to
study the binding a nity of the inhibitors to CPG2: chemical shift
perturbation (Chapter 4). By monitoring the chemical shift changes during the
titration for CP06, one type of exchange regime was observed for the
CP06-CPG2 complex when comparing the chemical shift of uncomplexed and
complexed CPG2 signals. Continuous linear chemical shift changes were
observed for some resonances, while other resonances displayed a non-linear
chemical shift changes characteristic of a conformational transition in the
ligand-bound CPG2 (Williamson 2013) (Figure 4.18). The calculation of the
binding constants (KD) for the few residues displaying chemical changes yielded
to micromolar range values between 40-493 µM (Figure 4.19), very similar to
binding constants derived from STD-NMR data for CP06 where the majority
KD were below 500 µM (Table 4.1). On the other hand, we observed an
intermediate exchange regime for the CP67-CPG2 complex as resonances with
the most pronounced chemical shift perturbation broadened and disappeared at
various locations within the 1H-15H HSQC spectra upon titration. As a result,
binding KD constant could not be obtained for CP67 (Figure 4.21-F). Severe
line-broadening, and the cross-peaks’ shape and pattern, in the HSQC spectrum
suggested an increased e ect of CP67 on the CPG2 chemical shifts, in
202
Chapter 7
comparison to CP06, which could be interpreted as a further change in the
tumbling rate of CPG2 upon binding of CP67 to CPG2. Since assignment of
the 42 kDa CPG2 enzyme was not completed, co-crystallisation screening was
also conducted for X-ray crystallography to locate the inhibitors binding site
(Chapter 3). The screening yielded crystals that are awaiting analysis.
7.3 Insight into CPG2 Substrate Recognition.
CPG2 is an interesting protein to study due to its implication in anti-cancer
and autoimmune therapies. Despite the X-ray crystal structure of CPG2 being
determined by Rowsell et al. (1997) and its overall structural similarities with
related AAP and GCPII proteins (Lindner et al. 2003), which had their
mechanisms of catalysis proposed via the computational methods, the MTX
binding mode hypothesis was mainly established by computational studies and
homology structure studies (Turra et al. 2012). Turra et al. (2012) suggested
that residues Ser210, Lys208 and Thr357 (located in pocket P1) may be
involved in hydrogen bonding with the nitrogen atoms of the pteridine moiety of
MTX, and residues Arg324 and and Gly360 located in another adjacent pocket
(P2) appeared to be hydrogen bonded to glutamate. Rowsell et al. (1997)
showed that mutation of amino acid Arg324 to alanine had lower activity
against MTX degradation. However, the implication of the other residues
mentioned above were never proven experimentally, and the reaction mechanism
of CPG2 remains non-elucidated. Hence, the work was sought to complement
the information obtained via X-ray crystallography and computational
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simulation of the CPG2-MTX complex using site-directed mutagenesis. Chapter
5 was aimed at characterising the contribution of the di erent residues in the
catalytic site and substrate recognition are introduced in Figure 5.3.
This is the first time that 8 mutants of CPG2 have been expressed, and tested
for activity against MTX. Only two mutations withing the active site, H385A and
E200A, showed activity against MTX and inhibitory activity in the presence of
CP06 and CP67 (Figure 7.1). This suggested that CP06 and CP67 were e ectively
competitive CPG2 inhibitors. Since these residues are zinc co-ligands, the data
indicated that the mutant proteins may have compensated for their absence some
other way. H385A protein showed an activity of 82.93 U/mL, whereas both
wild-type and E200A proteins presented higher activities against MTX (96.7 and
63.70 U/mg respectively). The greater activity levels could be attributed to
higher flexibility observed within the wild-type and E200A proteins by CD melts.
On the other hand E175A and D141A mutant proteins showed residual activity,
although they exist as very flexible folded proteins. This suggest that these
protein residues which are zinc co-ligands may be directly involved in tuning the
electrophilicity of the zinc ions and its reactivity (Ataie et al. 2008), explaining
the low activities observed against MTX. K208A, S210A and T357A mutant
proteins also showed residual activity against MTX suggesting direct implication
in substrate recognition of P1, which could hold in the pteridine moiety of MTX
but also the aromatic ring present in all three inhibitors investigated in the thesis.
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Figure 7.1: Summary of the mutations and their respective activities mapped onto
the X-ray crystal structure of CPG2. The image shows the di erent residues, and their
activity against MTX mapped onto the CPG2 binding site in the X-ray crystal structure (PDB:
1CG2, Rowsell et al. (1997). Mutations coloured in red showed no activty, while mutations
coloured in green demonstrated activity against MTX. [Pymol Viewer]
7.4 A "Divide-and-Conquer" Approach.
As opposed to crystallography, NMR could provide key information on the
ligand-binding characteristics of CPG2, which is of high importance in
applications using this enzyme (such as ADEPT). NMR can also be used to
obtain information on conformational dynamics, which may have held back
crystallographic approaches to ligand-binding studies thus far. Solution NMR
studies must overcome a further limitation in that there is an upper limit for
the molecular weight of proteins that can be readily analysed using this method,
with few structural studies reported in the literature for proteins larger than
thirty kilodaltons (Fernández and Wider 2003). Large, slowly tumbling proteins
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in solution lead to a loss of resolution due to spectral crowding as well as broad
NMR signals that are ultimately unobservable (Nietlispach et al. 1996).
Although the NMR data described here for CPG223-415 were incomplete and
thus did not yield resonance assignment, work is ongoing to use our optimised
expression protocol and preliminary structural understanding to identify
conditions that yield a full complement of 3D NMR data to facilitate
assignment.
Hence a "divide-and-conquer" approach was used to study the smaller
domains of CPG223-415 with solution properties (e.g. faster tumbling, slower
relaxation) more applicable to NMR measurements. CPG2DIM did not yield a
well-dispersed 1H-15N HSQC spectrum suggesting that the dimerisation domain
is highly unstructured in isolation and likely requires the presence of the
catalytic domain to fold correctly (Figure 6.8-C). It is the first time that the
ability of the catalytic domain in CPG2 to fold independently without the
dimerisation domain is reported and the components necessary for activity has
been narrowed down. Specifically, the CPG2CAT construct shows great promise
for downstream NMR studies as it has favourable solution properties and
retains key properties of the parent protein, namely enzymatic activity and the
ability to self associate. Although the largest contiguous region of the catalytic
domain (CPG2CAT’ composed of residues 23-198) showed the largest step-up in
peak width and a well-dispersed 1H-15N HSQC spectrum, it showed low activity.
The results revealed that the C-terminal region of the catalytic domain is
implicated in substrate recognition and activity.
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7.5 Future Directions.
The first reported method for high-yield expression of active and soluble mature
CPG2 (in the absence of the leader peptide) and its individual catalytic and
dimerisation domains in E. coli was described. Such a method is of key
importance for future structural, functional and binding studies involving this
enzyme, which was hampered by di culties in obtaining large yields of the
protein as well as labelling of the protein. The NMR techniques useful to the
investigation of di erent recognition processes have been successfully applied. In
particular a versatile protocol based on STD-NMR and chemical shift
perturbation experiments for the screening of putative inhibitors, towards the
rational design and optimisation of novel CPG2 inhibitors have been provided.
Moreover some more insights on the study of CPG2 binding requirements via
site-directed mutagenesis and screening of putative inhibitors have been
presented. This work establishes the support for future work.
To reinforce the NMR study conducted during this project, surface
plasmon resonance (SPR) (Johnsson et al. 1991), isothermal titration
calorimetry (ITC ) (Ciulli et al. 2006; Torres et al. 2010), ligand-observed
mass-spectrometry analysis (Chen et al. 2015) could also be employed. In SPR
studies, proteins are immobilised on a metal laminated plate and ligands flow
past. When a ligand binds to a protein, SPR spectroscopy quantifies using an
optical device the changes in refractive and reflective properties of the metal
surface, which are correlated to the mass of the ligand and the mass of the
protein. The appreciable benefit of this technique is that only small amounts of
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protein is required (unlike for NMR and ITC) and a nity can be acquired from
the recorded SPR spectrum representing a constant flow system, where ligand
saturate the protein and then wash o , and hence, kon and ko  can be
determined. SPR tolerates screening of several hundreds of compounds in a few
days using the same SPR plate, and is well suited for prioritising subsequent
X-ray co-crystallisation studies. This screening method could eventually be used
to rapidly screen for potent inhibitors from the second generation of ligands
produced in the near future by industrial.
In order to design specific inhibitors, structural information on substrate
recognition with atomic resolution and on the catalytic mechanism is required.
The advantage of crystallography is the more detailed info in well-defined parts
of the molecule, and the absence of size limitation, which restricts solution
NMR to molecule below ¥ 30 kDa. The next step in understanding the
catalytic properties of CPG2 should be the establishment of a model describing
the reaction mechanism of substrate hydrolysis by CPG2. This will necessitate
the investigation of residue Gly360 located in P1 pocket that was not achieved,
and analysis of potential co-crystals generated during this study (Chapter 3).
Hence, solving the X-ray structures of the di erent mutant proteins could
enable structural comparison of the substrate binding cavity, and possibly give
insight in the CPG2 catalytic mechanism, which could further explain the
activity of these mutant proteins, or lack of, against MTX.
Additionally, the CPG223-415 construct was crystallised without di culty in
this project and exhibited very similar structure to the full-length CPG2
published by Rowsell et al. (1997). Unfortunately, attempts at co-crystallisation
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of CPG223-415 and its inhibitors, (i.e. CP06 and CP67 (Chapter 3) indicate that
the protein packed in crystals may retain biological activity creating a challenge
for the co-crystallisation process. In this case, we could potentially use inactive
enzyme for co-crystallisation in order to dissect the molecular reaction
mechanisms (i.e. an inactive CPG223-415 mutant created for the purpose of this
project).
The previous rationale could be also adopted for protein-ligand studies using
NMR spectroscopy. The inactive CPG223-415 construct, CPG2CAT’ of 20 kDa size
and amenable for NMR studies (Chapter 6), could be used for determination
of CPG223-415-inhibitors complexes. Using a relatively standard triple-resonance
NMR experiments for standard backbone assignments of CPG2CAT’, and chemical
shift perturbations utilising HSQC titrations of [U-15N,13C]-enriched CPG2CAT’
by CPO6 and/or CP67 ligands, the resulting changes in the chemical shifts of the
protein could be monitored, assigned to a specific protein residue and mapped
onto the X-ray structure of the full length CPG2 by Rowsell et al. (1997) to
localise the inhibitor binding site.
Furthermore, it was unambiguous from the outset that there would be
several obstacles to overcome in order to use CPG2 in ADEPT. It was
recognised that if foreign enzymes and those of bacterial origin, such as CPG2,
presented the necessary specificity of action (Chapter 1), there would be an
immunogenicity issue that would have to be discussed (Bagshawe 1989).
Immunogenecity is the capability for a an entity, with an antigen and an
eptitope, to induce a cell-mediated answer in the human body. To reduce
immunogenicity in CPG2, a T-cell modification approach based on the HLA
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binding, a prerequisite for T-cell stimulation, could remove antigenic eptitopes
of CPG2 in order to weaken a durable and high-a nity immune response.
Several immunogenic regions have been located using T-cell proliferation studies
and in silico analysis (Chester et al. 2005). However, changes in amino acid
sequence in enzyme can immediately lead to loss of catalytic activity. An
imperative condition is that the modifications introduced do not interfere with
structure, function or stability. In this thesis, the development of a less
immunogenic CPG2CAT protein (Chapter 6), was successfully demonstrated to
be enzymatically active without the presence of the dimer subunit of CPG2.
This shorter enzymatically active construct could be used as a foundation to
produce less immunogenic CPG2 enzymes. Therefore, further work is necessary
to reduce the immunogenicity barrier by further removal of the remaining
problematic epitopes in CPG2CAT protein to make ADEPT safer for patients.
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Study of Synthetic Peptides
Mimicking —3-Loop Antibody
Binding Site in hCG and LH
Proteins by NMR Spectroscopy
A.1 Introduction.
Cancer treatments are more likely to work successfully if cancer is detected
early. Today, most of the cancers are detected by biopsies, a painful procedure.
An immunoassay provides a safer and non-invasive procedure. Tumour markers
are molecules appearing in blood or tissues that are associated with cancer
(Darwish 2006). The immunoassay approach allows quantification of a wide
range of compounds including these biomarkers, which are indicators of cancer
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prognosis. The aim of this side-project was to investigate the solution structure
of polypeptides derived from a sequential epitope known as the —3-loop, which
is present in all members of the glycoprotein hormone family. This chapter
describes the di erent NMR experiments used to identify potential secondary
structures within these small peptides and the obstacles associated with peptide
analysis by NMR.
A.1.1 Structure Dependence in 8G5 Antibody Binding of
hCG—66-80 Epitope.
Human chorionic gonadotropin (hCG) is used as a biomarker in pregnancy
testing and diagnosis of hCG-secreting cancers, where tests are carried out as
immunoassays. However, the hormones human chorionic gonadotropin (hCG),
luteinizing hormone (LH), follicle-stimulating hormone (FSH), and
thyroid-stimulating hormone (TSH) from the glycoprotein family consist of an
identical –-subunit coupled to an hormone specific —-subunit. The –-subunit of
the four hormones of the glycoprotein family are interchangeable and each is 92
amino acid residues in length. Despite also featuring substantial sequence
homology, —-subunit contain the hormone-binding regions and influence the
activity of each hormone (Pierce 1971). As a result, the —-subunit is targeted in
all hCG immunoassays. Because of similarities in sequence and structure, the
demand for specific immunoassays that are able to discriminate between these
di erent proteins of the glycoprotein hormone family is required. Moreover,
hCG is present in a wide-range of variants, diverging both in glycosylation state
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and fragment sizes (O’Connor et al. 1994; Elliott et al. 1997; Birken et al. 1988).
Hence, reliable hCG immunoassay should be able to detect all forms of hCG
generated in cancer to the same extent. However, recent studies showed that
care should be taken with sandwich assays, such as the sandwich ELISA assay.
In a two-site immunoassay, hCG is sandwiched between two antibodies binding
to di erent hCG epiptopes, which could generate an increased number of
false-negative results due to the doubled contingency of one of the antibodies
not recognising certain hCG variants produced in later stages of cancer because
of the absence of one of the indispensable epitopes (Gri ey et al. 2013). Hence,
focus has been on an immunoassay built around a well-known single hCG
epitope site: the —3-loop from the —-hCG subunit shown in Figure A.1.
Figure A.1: Crystal structure of hCG. The full-length (left panel) and a close-up (right
panel) of the hCG—3-loop as obtained from PDB ID: 1HRP (Lapthorn et al. 1994).
Gregor et al. presented binding a nity measurements demonstrating that
8G5 (—3-loop monoclonal antibody) was capable of distinguishing between
hCG—3-loop (hCG—66-80) and the closely related LH —3-loop (LH—86-100). The
—3-loop in hCG and LH di er only by one one amino-acid; asparagine (Asn/N)
in hCG and aspartate (Asp/D) in LH at position 77 and 87 respectively.
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Postulating that the —3-loop contains self-contained secondary structural
characteristics, Gregor et al. have synthesised hCG—66-80 as a synthetic peptide
(SIRLPGCPRGVNPVV) and used point mutations in a range of peptide arrays
to study whether a substitution at position 77, occupied by asparagine in
hCG—, had an impact —3-loop-8G5 binding. The results from screening assays
in Figure A.2 showed that the peptide mimicking the hCG—3-loop (shown in
red) had a higher a nity for 8G5 antibody than the peptide derived from
LH—86-100 (shown in green). Only one other peptide sequence containing
histidine at position 77 (shown in blue), demonstrated binding to 8G5 antibody
(60% that of hCG).
Figure A.2: Binding results from Pepscan - Mab 8G5. Binding result of the
range of peptides arrays with a substitution at position 77, occupied by Asn in hCG—.
SIRLPGCPRGVDPVV peptide equates to the —3-loop present in LH. SIRLPGCPRGVHPVV
peptide is the only sequence, other than hCG—3-loop, exhibiting a nity to 8G5 antibody.
Adapted from Gregor et al. (2011).
Additional computational studies suggested the presence of a putative
hydrogen clasp between Asp77 and Val79 in hCG—66-80 may be crucial to
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stabilise the —-turn observed over the P-R-G-V residues in hCG—66-80. The
presence of deprotonated carboxyl group in Asp97 of LH—86-100 may undermine
the hydrogen clasp.
A.1.2 Project Aims.
These data implied that 8G5 was able to distinguish between hCG and LH
—3-loops due to the existence of well characterised structural di erence between
the hCG—66-80 and LH—86-100 peptides. The goal was to improve the
understanding of antibody recognition of the —3-loop epitope hCG—66-80 by
studying the peptides shown in Table A.1, provided by Mologic and
representing the various —3-loops, using solution-state NMR spectroscopy. This
could enable the development of more selective immunoassay methods for
cancer detection and prognosis. New structural information suggested from
NMR data, in combination with other techniques, could then be used to
improve immunoassay methods, which is a valuable tool for cancer.
Table A.1: Sequence of peptides derived from hCG—3-loop.
Name Residue Number Sequence Origin
MOL174 66-80 SIRLPGCPRGVNPVV hCG
MOL179 86-100 SIRLPGCPRGVDPVV LH
MOL180 66-80 SIRLPGCPRGVHPVV hCG with N77H mutation
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A.2 Materials and Methods.
All NMR spectra were recorded on Bruker Avance 700 MHz NMR spectrometer
using a 5-mm triple-resonance probe with 3-axis gradients at a temperature of
25¶C. Spectra were calibrated with respect to residual water (4.719 ppm). Other
spectrometer characteristics are reported in Section 2.2.10. All NMR spectra
were processed using TOPSPIN 3.1 by Bruker (Coventry, UK) and analysed with
NMRFAM-SPARKY (Lee et al. 2015).
A.2.1 Sample Preparation.
Sequences of the peptides used for the present studies are shown in Table A.1 of
Chapter 7 on page 216. All peptides were synthesised using
9-fluorenylmethyloxycarbonyl (FMOC ) solid phase peptide synthesis, purified
by high performance liquid chromatography, and confirmed by mass
spectrometry by Mologic1 (Bedford, UK).
For NMR experiments, the samples were prepared in 10% D2O using 10 mM
phosphate bu er and 1 mM DTT at pH 6.8. The peptide concentration was ¥ 1.3
mM. In contrast with CPG2, these peptides are small and isotopic labelling was
not required as they yield well-resolved homonuclear proton 2D-NMR spectra.
1Dr James Schouten and Dr Joannah Towler (Mologic Ltd., Bedford, UK) produced the
hCG—3-loop peptides (MOL174, MOL179 and MOL180).
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A.2.2 TOCSY.
TOCSY is the abbreviation for TOtal Correlation SpectroscopY. It is also
called HOHAHA (HOmonuclear HArtmann HAhn) (Braunschweiler and Ernst
1983; Bax and Davis 1985). The TOCSY experiment provides through bond
proton-proton correlations due to scalar (i.e. through bond) couplings (Figure
A.3-A). It provides through bond correlations between all the atoms in a single
spin-system, i.e. all the protons in a single amino acid (Figure A.3-B). Each
amino acid has a characteristic pattern of chemical shifts from which the amino
acid can be identified (Figure A.3-C). However, some amino acids have identical
spin systems and therefore identical signal patterns. They are: cysteine,
aspartate, phenylalanine, histidine, asparagine, tryptophan and tyrosine (’AMX
systems’) on the one hand and glutamate, glutamine and methionine
(’AM(PT)X systems’) on the other hand. More or less, TOCSY constitutes a
very e cient transfer element for the assignment of proteins, nucleic acids and
small molecules (Wuthrich 1986).
A range of TOCSY experiments exist. In this work, TOCSY with a
DIPSI-2 mixing sequence was used (dipsi2esgpph pulse sequence in Figure A.4)
(Shaka et al. 1988; Hwang and Shaka 1995). After frequency labelling during t1,
magnetisation is returned to the z-axis for isotropic mixing using the mixing
sequence DIPSI-2, and then returned to the transverse plane for detection
(Rance 1987). The TOCSY sequence works by putting in use a strong RF field,
called a "spin-lock", along one axis. Under its influence the magnetisation is
218
Chapter A
Figure A.3: Information provided by TOCSY experiment. A) TOCSY cross-peaks
arise from scalar coupling. B) The number of transfer steps can be adjusted by changing the
mixing time. Magnetisation can be transferred successively over up to 5 or 6 bonds as long
as successive protons are coupled. C) TOCSY only allows identification of all protons within
the same spin system, i.e. amino acid, because the presence of carbonyl groups disrupts the
TOCSY transfer. Adapted from Roberts and Lian (2011).
transferred from on spin to another through the scalar coupling interactions.
The e ciency of the magnetisation transfer depends on the J-coupling constant
(Figure A.3-B), i.e. magnetisation is transferred more e ciently through large
couplings, and is a ected by the rate of relaxation during the isotropic mixing
pulse. The presence of a cross-peak in TOCSY does not mean that the two
spins are directly linked; instead, it suggests that the magnetisation can be
transferred between the two spins through two or more bonds via scalar
coupling between coupled spins (Figure A.3-B) (Cavanagh et al. 1995).
TOCSY spectra were recorded at 25¶C, using a mixing time range of 50-
130 ms. Data were acquired with 256 increments in the t1 dimension and 2k
increments in the t2 dimension with 64 scans. The sweep width in both dimensions
was 9803.92 Hz. Qsine window functions were used for processing in the F1 and
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Figure A.4: General pulse sequence for TOCSY. In this sequence the isotropic mixing
is carried out by mean of DIPSI. Adapted from Roberts and Lian (2011).
F2 dimensions, respectively.
A.2.3 NOESY.
NOESY stands for Nuclear Overhauser Enhancement SpectroscopY (Kumar
et al. 1980). The NOESY experiment is crucial for the determination of peptide
structure. It uses the dipolar interaction of spins (the nuclear Overhauser e ect,
NOE) for correlation of protons (Figure A.5-A). It identifies the chemical shifts
of pairs of protons that are close together in space within the peptide structure.
These protons may or may not be within the same amino acid. The correlation
between two protons depends on the distance between them, but normally a
signal is only observed if their distance is smaller than 5 Å. The NOESY will
have both inter-residue correlations (Figure A.5-B, red arrows) as well as
intra-residue correlations (Figure A.5-B, blue arrows), which allows the
investigator to deduce which residue is next to which in the peptide chain. It
correlates protons which are distant in the amino acid sequence, but also close
in space due to tertiary structure. This is the most important information for
the determination of protein structures.
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Figure A.5: Information provided by NOESY experiment. A) NOESY cross-peaks
arise from dipolar coupling and is distance dependant, NOE cross-peaks only arise for protons
within 5 Å of each other. B). NOESY provides intra-residue correlations (in blue) and also
inter-residue correlations (in red), crucial for sequential assignment.
The NOESY pulse sequence scheme is shown in Figure A.6. The pulse
sequence starts as usual with a 90¶ pulse followed by an evolution time t1. This
delay is changed to provide chemical shift information in the F1 domain. Then
another 90¶ pulse transmits some of the magnetisation to the z axis and during
the following mixing period, the non-equilibria z components will exchange
magnetisation through the Nuclear Overhauser E ect (NOE). After some time
(shorter than the relaxation time T1), the transverse magnetisation is restored
by the third pulse and detected. If relaxation exchange (or chemical exchange)
has taken place during the mixing time, cross-peaks will be observed in the
spectra.
Figure A.6: General pulse sequence for NOESY. Adapted from Roberts and Lian (2011).
In this work, NOESY spectra using the noesyesgpph pulse sequence were
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recorded at 15¶C, 25¶C and 37¶C at 600 MHz and 700 MHz (Hwang and Shaka
1995). The mixing time for peptide was varied from 60 to 500 ms. Typical
two-dimensional data were acquired with 256 increments in the t1 dimension
and 2k increments in the t2 dimension with 64 scans. The sweep width in both
dimensions was 9803.92 Hz. Qsine window functions were used for processing in
the F1 and F2 dimensions, respectively.
A.2.4 ROESY.
ROESY stands for Rotating frame Overhauser E ect SpectroscopY. The
ROESY experiment is the rotating-frame analogue of NOESY, although there
are a number of di erences between the two experiments. ROESY uses a
spinlock to align spins in the rotating frame. Cross relaxation happens during
the spin lock time and develops at the rate comparable to T1 (Figure A.7). The
duration of the spin lock is set by the mixing time.
Figure A.7: General ROESY pulse sequence. This schematic shows the ROESY pulse
sequence using continuous spin-locking. Adapted from Roberts and Lian (2011).
In this work, ROESY spectra using roesyesgpph pulse sequence were recorded
at 10¶C, 25¶C and 37¶C (Hwang and Shaka 1995; Bax and Davis 1985). The
mixing time for peptide was varied from 10 to 500 ms, similar to NOESY. Typical
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two-dimensional data were acquired with 256 increments in the t1 dimension and
2k increments in the t2 dimension with 64 scans. The sweep width in both
dimensions was 9803.92 Hz.
A.2.5 DQF-COSY.
DQF-Cosy stands for Double Quantum Filtered COSY. It was developed as an
alternative to COSY, which gives information between two protons coupled via
three bonds such as from a proton to its carbon, to the adjacent nitrogen, then
to that nitrogen’s proton (Figure A.8-A) (Rance et al. 1983; Piantini et al. 1982;
Shaka et al. 1983). It contains the same information as does the COSY
experiment. The value of 3J scalar coupling constant can be determined from
the fine structure in the DQF-COSY cross-peak for spins without passive
coupling partners, such as the 3JHNH– . Active couplings (those that lead to the
cross peak) display anti-phase components (components with positive and
negative signal intensity) (Figure A.8-B). The value of a three-bond J-coupling
constant can be related to the intervening torsion angle,  , using the Karplus
relationship (Figure A.8-C) (West et al. 1998; Pardi et al. 1984).
DQF-COSY spectra using the Bruker cosydfesgpph pulse sequence were
recorded at 10¶C, 25¶C and 37¶C (Hwang and Shaka 1995; Derome 2013).
Typical two-dimensional data were acquired with 256 increments in the t1
dimension and 2k increments in the t2 dimension with 64 scans. The sweep
width in both dimensions was 9803.92 Hz. The indirect dimension was zero
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Figure A.8: Information provided by DQF-COSY experiment. A) COSY cross-peaks
arise from scalar coupling. As opposed to TOCSY, magnetisation is only transferred up to 3
bonds. B) Cross-peaks are all antiphase and allow to obtain 3JHNH– . C) Newman projections
of peptide bonds that show how 3JHNH– is related to   backbone dihedral torsion angle via the
Karplus equation.
filled during processing.
A.3 Discussion and Results.
A.3.1 1H NMR Chemical Shift Assignment of —3-loop
Peptides.
The chemical shift assignments of —3-loop peptides were performed using
TOCSY, NOESY and ROESY spectra obtained at 25¶C by the sequential
strategy proposed by Wuthrich (1986). For the purpose of describing the
process, MOL174 has been used as an example (additional data in Appendix).
For short small mixing periods, (e.g. 50 msec), TOCSY spectra gave 1-3 bond
coupling. Correlation of more distant protons was only observable at higher
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mixing time. With the mixing time set at 100 msec, correlations between HN
and protons down the side-chain of each amino acid were detectable. The extent
of correlation depended mainly on the length of the mixing period. The
“fingerprint region” of TOCSY was then used to establish each spin systems
(Figure A.9-A). A single cross peak taken at the shift of one spin should in
principle show the multiplets of all the spins that are part of the network of
coupling to which the spin belongs (Figure A.9-B).
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Many spin systems were determined by identifying as many through bond
connections obtained from TOCSY spectra (Figure A.10). The HN of isoleucine
2 was not observable in some peptides (i.e. MOL174), possibly due to exchange
with the solvent, but the rest of the spin systems were visible in the fingerprint
region (Figure A.10-A). Due to lack of HN spin system in the TOCSY fingerprint
region, proline residues were only identifiable in the aliphatic region (Figure A.10-
B). Some of the proline H– cross-peaks, such as P73 of MOL174, P93 of MOL180
and P70 of MOL179, were not observable because their H– chemical shifts were
very close to the solvent suppression water signal, and therefore were attenuated
by the water pre-saturation scheme used in the pulse sequence. The chemical
shift assignment tables for all three peptides can be found in the Appendix.
Figure A.10: 700 MHz 2D TOCSY spectrum of MOL174. A) Full TOCSY spectrum of
MOL174 a mixing time of 100 ms. A) Fully assigned fingerprint region of the TOCSY spectrum
of MOL174. B) Assigned aliphatic region of the TOCSY spectrum of MOL174.
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A.3.2 Sequential Assignment of MOL174, MOL179 and
MOL180 peptides.
Since there were redundant amino acid types in the sequence of each peptide,
sequential assignment was only possible using the sequential connectivities
observed through NOE or ROEs. All peptides showed very poor NOESY
spectra, despite the fact that a wide range of mixing times were used. The NOE
is created by the relaxation of one spin by a neighbouring spin. This event is
proportional to the internuclear distance r, and the NOE is proportional to r-6
and time dependant. Figure A.11 shows that the NOE first builds-up (at
cross-relaxation rates — relaxation mechanisms involving three spins) and then
decays away, at roughly the spin-lattice relation rate (1/T1) (Williamson 2009).
Hence as the size of the compound studied increases, the cross-relaxation rate
increases, and so does the decay rate (Williamson 2009). Thus, for big proteins,
NOE reaches a maximum at low mixing times (around 300 ms), while for small
peptides the maximum NOE can occur after several seconds.
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Figure A.11: Time dependance of NOE. The graph shows that at low mixing-time, the
NOE quickly builds up, then starts to decay due to relaxation during the mixing time. The
point of maximum NOE is shifted to higher mixing times for small peptides in contrast to huge
proteins. Adapted from Claridge (2008).
Di erent NOE mixing times (60-500 ms) at 700 MHz were tested to check for
the presence of NOE in the spectra. None of the mixing times tested enabled the
observation of NOE peaks in the trio of peptides investigated. Figure A.12 shows
the NOESY spectra at di erent NOESY mixing times ranging from 60 to 500
ms. Some HN-H– peaks were observable, but they corresponded to intra-residue
NOE cross-peaks. We are only showing data for MOL174, but the other peptides
behaved the same.
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There could be two reasons for these results: one is that the tumbling rate
of the peptides generated NOEs with a near zero value intensity; the other
reason may be due to high flexibility exhibited by the peptides in solution, thus
not showing any NOEs. Figure A.13 shows the variation of the proton-proton
NOE as a function of the molecular tumbling rate (Claridge 2008). The sign of
the NOE depends on the magnitude of the correlation time and hence on the
molecular weight. This curve represents the maximum proton-proton NOE as a
function of molecular tumbling rates as defined by Ê0· c, where Ê0 is the
spectrometer observation frequency and · c the correlation time — the time it
takes for the compound to rotate through 1 radian (Wuthrich 1986). The curve
has three distinct regions, which we shall refer to as fast, intermediate and slow
motion regimes. For molecules that tumble rapidly in solution (short · c, hence
low molecular weight molecule) the NOE has a maximum possible value of +0.5
or 50%. At the other end of the spectrum, molecules that tumble very slowly in
solution (e.g. molecules with high molecular weight) experience negative NOE.
In this motion regime, the maximum NOE of -1 or 100% can be obtained.
Unfortunately, between these two extremes, at certain combinations of Ê and · c
the NOE changes sign and even becomes zero (at Ê0· c ¥ 1). The tumbling time
is such that the NOE intensity approaches zero. Unfortunately, the ¥ 1,500 Da
size peptides fell into this troublesome regime. To stay away from this regime,
one could use a di erent magnetic field strength (Ê0), or alter the correlation
time (· c) and the overall molecular tumbling rate by changing the temperature.
Hence temperatures as low as 10¶C and as high as 37¶C were investigated, but
no NOEs were observed. A lower magnetic field of 600 MHz was also tested and
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was unsuccessful.
Figure A.13: NOE as a function of molecular tumbling rate. Adapted from Claridge
(2008).
The only alternative left was to record a ROESY experiment instead of a
NOESY (Bothner-By et al. 1984, Bax and Davis 1985). During the mixing time
in NOESY, the magnetisation is aligned along the transverse plane of the static
magnetic field, but in ROESY the magnetisation is aligned with a much smaller
magnetic field, one that is created by a train of spinlock pulses and is oriented
perpendicular to the static magnetic field. The result is that ROEs (NOEs in a
rotating frame) in a ROESY experiment are always positive regardless of the
correlation time, which is especially useful for intermediate molecular weight
molecules, such as the peptides, where NOESY does not work (Keeler 2011)
(Figure A.14-A). Unfortunately, the ROESY pulse sequence is almost identical
to that used for TOCSY (Cavanagh et al. 1995). A possible complication is the
relay of ROE through TOCSY resulting in false ROESY cross peak, as the
opposite is also possible (Figure A.14-B,C,D). So care has to be taken when
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running and analysing a ROESY experiment.
Figure A.14: Variation of the NOE sign in the NOESY and ROESY experiments,
and ROE artifacts. A) The ROE is always positive, whereas the NOE goes through zero at
a certain tumbling rate and becomes negative. B) Normal transfer pathway for an ROE. C-D)
ROE artifacts due to the presence of spinlock pulses in the ROESY pulse sequence. Adapted
from Claridge 2008.
These experiments resulted in the presence of ROE peaks for all three
peptides at a mixing time of 200 ms (Figure A.15). Analysis of ROESY data
revealed that MOL179 (D77) displayed very few ROEs compared to MOL174
(N77) and MOL180 (H77), which was indicative of a greater flexibility of
MOL179 peptide. Moreover, only MOL174 featured long-range ROEs. This
ROE was seen between NH‘ of Arg74 and H– of Val79. One of the residues is
involved in the potential —-turn observed over the P-R-G-V sequence featured
in the X-ray crystallographic structure of hCG—. On the other hand, the lack of
these long-range ROEs within this region of the sequence for MOL179 and
MOL180 may suggest the lack of stability of this turn in that part of the
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peptide sequence.
Figure A.15: Overlay of 2D 1H ROESY and 2D 1H TOCSY spectra in the amide
region. TOCSY positive cross-peaks are coloured in red, while positive ROESY cross-peaks
are coloured in blue. The ROESY spectra display the ROEs present in A) MOL174 (hCG—3-
loop with N77) B) MOL179 (LH—3-loop with D77) and C) MOL180 (hCG—3-loop with N77H
mutation).
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A.3.3 Secondary Structure Prediction using Chemical
Shift Index.
The assignment of H– allows the prediction of the secondary structure components
present in the di erent peptides to be created utilising the chemical shift index
(CSI) method introduced by Wishart (Wishart et al. 1991; Wishart et al. 1995).
This is based on comparing the experimentally-obtained chemical shift values to
a set of averaged random coil chemical shift values based on an array of seventy
proteins whose structures are known (Wishart et al. 1991; Wishart et al. 1995).
There is a strong correlation between H– chemical shift and secondary structure
as it can provide information about the local structure of a peptide. It has been
shown that an upfield shift (e.g. towards lower ppm) from random coil values is
observed with H– chemical shift in –-helical like (and —-turn like) environment,
while a downfield shift (e.g. towards higher ppm) is experienced when H– is
located in a —-sheet like region (Wishart et al. 1991). In this method three
indicators are assigned, -1, 0 and 1, depending on the deviation from the random
coil values. When an upfield shift is observed, -1 is attributed, reciprocally a
downfield shift is tagged with a 1 index, while a shift close to random coil value is
allocated a 0 indicator. Any sequence displaying a group of 4 or more -1 indices,
not necessarily consecutive, and not disrupted by a +1 describes a helical (or
—-turn) region, while any set of three or more successive +1 indices is recognised
as —-sheet. The calculated chemical shift index for all peptides are displayed
in Figure A.16. By the rules described above, MOL179 (D77) displayed a fairly
unstructured secondary structure. MOL174 (N77) displayed —-turn like structure
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in the R-L-P-R span, while MOL180 (H77) displayed a —-turn along a longer
sequence span of P-G-C-P-R-G. MOL174 and MOL180 were the only peptides
displaying a secondary structure and a binding a nity to 8G5, but with di erent
strength (Figure A.2). Hence, these data show that a single point mutation
seem to indeed disrupt the local structure of the peptide. Although the CSI
showed di erent patterns for MOL174 and MOL180, the mutation from Asn to
His at position 77 seemed to conserve the initial —-turn like conformation, while
a mutation to Asp exposed a totally di erent CSI signature characteristic of an
unstructured peptide conformation in solution.
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Figure A.16: CSI values of H–. Calculated CSI values of C– protons of A) MOL174, B)
MOL179 and C) MOL180 peptides.
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A.3.4 Secondary Structure Prediction using 3JHNH–
Coupling Constants.
In addition to NOEs, 3JHNH– coupling constants were used to investigate the
presence of a —-turn in all 3 peptides (Pardi et al. 1984). The 3JHNH– coupling
constants were measured from the DQF-COSY spectra using the method
described by Wüthrich, where the coupling constants were estimated from the
1D 1H NMR spectrum as described in Figure A.17 (Pardi et al. 1984).
Figure A.17: HN-H– cross-peaks and cross sections parallel to F2 frequency axis
from the DQF-COSY spectrum of MOL174. A) Cross-peaks of residues G71, V76, V79
and V80 in the DQF-COSY spectrum. B) Cross sections through the cross-peaks are shown.
Measurement of the distance between the two peaks in each cross section (arrow) yielded to
3JHNH– .
However, the 3JHNH–-coupling constants should only be used in a qualitative
manner and relative way in NMR analysis of peptides. This is because not only of
the di culty in measuring and interpreting 3JHNH–-coupling constants from DQF-
238
Chapter A
COSY data and conformational averaging. The Karplus curve derived from the
Karplus relation (A.1) can be used to obtain the torsion angles of any 3JH-H-
coupling constant between vicinal protons present in the peptide (Pardi et al.
1984).
3JHNH– = (6.4 cos2 ◊ ≠ 1.4 cos ◊ + 1.9)Hz, ◊ = | ≠ 60¶| (A.1)
The three-bond coupling constant between the intra-residual alpha and amide
protons (3JHNH–) is the most useful for secondary structure determination as it
can be directly related to the backbone dihedral angle   using Equation (A.1).
For protons, three-bond J -couplings (3J) are typically around 7 Hz (Pardi et al.
1984). This number will vary immensely, depending on the local molecular
structure of the peptide such as bond angles and torsional angles. Helical and
extended conformations have very di erent values for   (-60¶ and -180¶,
respectively) which result in di erences in 3JHNH– (Richardson 1981). The
calculated 3JHNH– values shown in Table A.2 were used to investigate the
secondary structure. The corresponding   dihedral angle values were extracted
using Equation (A.1) (Pardi et al. 1984). Equation (A.1) predicts a maximum
of 9.7 Hz. The presence of 3JHNH– values above 9.7 Hz were observed, hence a  
dihedral angle could not be generated from the Karplus equation for these
coupling constants. These high 3JHNH–-coupling constants values were observed
in protein NMR possibly due to non-planar amide bonds (Demarco et al. 1978).
The high values obtained for glycine residues suggested that peptides were quite
flexible. Between Val76/96 and Val79/89 residues, the values started to range
between 4.2 and 9.8 Hz. Experimental   values for 3JHNH– of 4.2 observed in
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MOL179 is -120¶, which is typical of a helix structure. On the other hand
3JHNH– of ¥ 8 Hz (  = -151¶) in MOL174 and MOL180 indicated the presence
of —-sheet secondary structure (Pardi et al. 1984). These results suggested that
there is a structural di erence between the MOL174 and MOL180 peptide pair
and MOL179 peptide in the region close to the P-R-G-V sequence, where the
indispensable —-turn for 8G5 recognition is located.
Table A.2: 3J-couplings between N and C– protons, and their respective   dihedral
angle in all three peptides. All the 3J-coupling constants that are not present in an amino
acid (i.e. proline) are left blank and missing with a "-". The dihedral angles that could not be
calculated when 3J-coupling constants were above 9.8 Hz and were marked with a "-".
Residue 3JHNH–(Hz)/ (¶) 3JHNH–(Hz)/ (¶) 3JHNH–(Hz)/  (¶)
MOL174 MOL179 MOL180
Ser66/86 7.7/-148 9.8/-180 10.5/-
Ile66/87 -/- -/- -/-
Arg68/88 -/- -/- 11.2/-
Leu69/89 9.1/-163 7/-142 9.1/-163
Pro70/90
Gly71/91 15.4/- 7.7 25.9
Cys72/92 6.3/-137 -/- 7.7/-148
Pro73/93
Arg74/94 - 16.1/- 9.8/-180
Gly75/95 15.4/- 16.1/- 13.3/-
Val76/96 9.1/-163 4.2/-120 9.8/-180
Asn/Asp/His 7.7/-148 6.3/-137 7/-142
Pro78/98
Val79/99 9.1/-163 9.1/-163 8.4/-155
Val80/100 9.8/-180 9.1/-163 11.9/-
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A.4 Conclusion.
Instead of obtaining a time-consuming full three-dimensional NMR structure of
the protein of interest, the chapter showed that there are alternative and faster
approaches to investigate structural features. Although the information obtained
from three-dimensional protein structure is undeniable, the investigation of NMR
chemical shift allowed to collect information about the structure of the —3-loop,
especially the structural di erences between the hCG—3-loop and LH—3-loop that
are making the 8G5 antibody able to discriminate between these two di erent
epitopes.
The results presented above indicated the presence of structural di erences
between the three di erent peptides of peptides. In order to be able to
investigate these peptides via NMR spectroscopy, it was crucial to assign their
respective TOCSY spectra. The side-chain assignments using 1D 1H were fairly
straightforward for all three peptides. In the present study it was crucial to
study NOE connectivities due to the presence of amino acid redundancy, but
also to determine the di erences in structure in all three peptides.
Unfortunately, this was the hardest task during this project. NOESY
experiments would not lead to any sequence-specific NOE at 700 MHz (Figure
A.12). This was possibly due to the molecular size of these peptides (¥ 1,500
Da) that made them fall in the inconvenient regime where the NOE goes
through a null (Figure A.13). Several attempts at getting out of this
troublesome regime were considered. Changes in temperatures and magnetic
field were investigated. A 600 MHz magnetic field, instead of the usual 700 MHz
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field, was tested. It did not lead to any NOEs. As Ê0 was lowered, the tumbling
rate must have been reduced too. Since, the NOEs were not visible, the initial
tumbling rate at 700 MHz must have been very close to the zero point and
dropping the field by 100 MHz must have not had a huge impact on the NOE
intensity. Temperature rise (i.e. 37¶), or drop (i.e. 15¶C), did not resolve the
problematic. Hence, ROESY experiment was used to solve this complication.
The preliminary data revealed that MOL179 was highly unstructured, as
very little ROEs were observed compared to MOL174 and MOL180 (Figure
A.15). If there was a hydrogen clasp between Asp77 and Val77 of hCG—3 loop,
we should have been able to observe NOEs or ROEs between these two residues.
Among all three proteins, only MOL174 featured a long-range NOE between
amino acids Arg74 and Val79. Between the few observed NOEs, one of them
were consistent with the presence of —-turns described by Wuthrich (1986). In
an ideal case the segment P-R-G-V, where the —-turn was expected, should
manifest strong HN-HN NOE between residues R74-V76, and G75-V76, and
H–-HN NOE between residue R74-G75 (Wuthrich 1986). Only H–-HN NOE
between R74-H– and G75-HN was observed in MOL174, MOL179 and MOL180.
Moreover, additional NOEs were only observed for MOL174 and MOL179.
These two were also the only peptides showing binding to 8G5 (Gregor et al.
2011) (Figure A.2). In this respect, the NMR data does reflect Gregor et al.
(2011)’s postulate that the —3-loop might have an intrinsic self-contained
secondary structure regardless of the rest of the protein, and that its local
structure could provide the basis for 8G5 recognition and binding. Deviations of
observed chemical shifts from random coil values were indicative of the presence
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of secondary structure (Figure A.16). The result suggested the existence of a
—-turn like structure in MOL174 and MOL180, and the presence of unordered
structure in MOL179 (Figure A.16). The only di erence between MOL174 and
MOL180 is that the —-turn seems to be defined by di erent sequences (i.e.
MOL174 —-turn seems to span over R-L-P-G residues, while MOL179 —-turn
seems to span over P-G-C-P-R-G residues). The di erent CD data obtained by
(Gregor et al. 2011) were indicative of a more disordered structure, thus if turns
were present they would exist in an outnumbered group of open conformation
(Gregor et al. 2011). In fact this problem was also noticed in the conformational
studies of these peptides via NMR. Small numbers of NOEs observed (Figure
A.15) and the high 3JHNH–-coupling constant values (Table A.2) were observed,
and appeared to also corroborate the results obtained with CD. This is due to
NMR data reflecting a population-weighted average over all structures present
in an ensemble of peptide conformers in solution.
Figure A.18: Data summary. NOEs between two di erent residues (brackets) and potential
—-turn sequences (highlighted in orange) are mapped onto the primary structure of the peptides.
To conclude, this NMR study showed that the interpretation of NMR data
to give some insight on peptide conformations was di cult due to flexibility of
these polypeptides. However, in view of the above data, the study was able
to deliver some light on the structural features associated with —3-loop epitopic
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peptides, which might contribute to 8G5 recognition and binding. Still, we did not
observe NOEs between Arg77 and Val7 suggesting the formation of a hydrogen
clasp between these two residues, hence the presence of a —-turn like structure
in hCG—3 loop. Despite the fact that we could not prove the direct impact of
one-point mutation of residue 77 in 8G5 recognition and binding, the di erence
in structural features between the hCG and LH —3-loops are important.
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Chemical shift assignment of
hCG peptides
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